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Abstract
The most insidious pandemic of modern life does not arise from an infectious agent but rather from
malnutrition. With its global incidence tripling over the past three decades, obesity is a major public health
concern. Obesity’s rising prevalence has also illuminated its impact on communicable diseases.
Following the 2009 H1N1 influenza A virus pandemic, obesity was identified as a risk factor for increased
disease severity and mortality in infected individuals. Obesity causes a chronic state of metainflammation with systemic implications for immunity, including delayed antiviral responses to influenza
virus infection, poor recovery, and impaired immunological memory. However, the majority of past work
neglected the innate responses, especially the impact on the epithelium. To better understand the innate
response to influenza infection, obese animal models and human respiratory epithelial cells were
inoculated with influenza viruses to quantify the innate responses. In obese hosts, antiviral effector
production, including type I and type III interferons, was consistently blunted across all model systems
and linked to a highly oxidative, pro-inflammatory environment. This interferon-deficient state altered the
host microenvironment in which influenza replicated, spread, and caused disease. Due to the inherent
mutability and segmented nature of influenza virus, this altered microenvironment also had implications
for the genetic drift and shift of the viral population. Compared to infection of lean hosts, minor variants
rapidly emerged within the viral population in obese hosts which exhibited increased viral replication,
enhanced virulence, and antiviral resistance. The delayed action of interferon also permitted greater rates
of reassortment. Together, this suggested obesity permitted the emergence of novel, and potentially
pathogenic, viral variants. Influenza viruses pose constant seasonal and pandemic threats with high
morbidity and mortality suffered by overweight and obese patients. If current trends continue, nearly half
of the worldwide population will be obese by 2050. This population will have growing impacts on both
non-communicable and communicable diseases and may affect global evolutionary trends of influenza
virus.
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Abstract

Rebekah Reed Honce
Attenuation of Interferon Responses in the Obese Host and
Ramifications for Influenza Virus Evolution
The most insidious pandemic of modern life does not arise from an infectious agent
but rather from malnutrition. With its global incidence tripling over the past three decades,
obesity is a major public health concern. Obesity’s rising prevalence has also illuminated
its impact on communicable diseases. Following the 2009 H1N1 influenza A virus pandemic, obesity was identified as a risk factor for increased disease severity and mortality
in infected individuals. Obesity causes a chronic state of meta-inflammation with systemic
implications for immunity, including delayed antiviral responses to influenza virus infection, poor recovery, and impaired immunological memory. However, the majority of past
work neglected the innate responses, especially the impact on the epithelium. To better
understand the innate response to influenza infection, obese animal models and human
respiratory epithelial cells were inoculated with influenza viruses to quantify the innate
responses. In obese hosts, antiviral effector production, including type I and type III interferons, was consistently blunted across all model systems and linked to a highly oxidative,
pro-inflammatory environment. This interferon-deficient state altered the host microenvironment in which influenza replicated, spread, and caused disease. Due to the inherent mutability and segmented nature of influenza virus, this altered microenvironment
also had implications for the genetic drift and shift of the viral population. Compared
to infection of lean hosts, minor variants rapidly emerged within the viral population in
obese hosts which exhibited increased viral replication, enhanced virulence, and antiviral resistance. The delayed action of interferon also permitted greater rates of reassortment. Together, this suggested obesity permitted the emergence of novel, and potentially
pathogenic, viral variants. Influenza viruses pose constant seasonal and pandemic threats
with high morbidity and mortality suffered by overweight and obese patients. If current
trends continue, nearly half of the worldwide population will be obese by 2050. This population will have growing impacts on both non-communicable and communicable diseases
and may affect global evolutionary trends of influenza virus.
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Chapter 1
Introduction1

1.1

Rationale

With the rising prevalence of obesity has come an increasing awareness of its impact on
communicable disease. Following the 2009 H1N1 influenza A virus pandemic, obesity
was first identified a risk factor for influenza infection, disease severity and mortality (Van
Kerkhove et al., 2011). Over a decade later, the epidemiological and empirical studies done
in the context of influenza have been mirrored in the COVID-19 pandemic (Popkin et al.,
2020). Over-nutrition that results in obesity causes a chronic state of meta-inflammation
with systemic implications for immunity (Andersen, K. E. Murphy, and Fernandez, 2016).
Obese hosts exhibit diminished antiviral responses and poor recovery from viral infections. Furthermore, the efficacy of antivirals and vaccines is reduced in obese hosts, complementing the already weakened immune response and leading to severe, uncontrolled
pathogenesis (CDC, 2019; D. L. Thompson et al., 2011; Vaillant et al., 2009). Due to the
rapid genomic evolution of influenza viruses, there is also concern that the increasingly
obese population with impact the transmission and spread of novel viral strains and variants. Continuation of today’s trends will yield half of the worldwide population considered obese by 2050, undoubtedly having drastic implications for global health.

1.2

Consequences of Obesity on Host Immunity

The respiratory epithelium is the first line of defense against inhaled pathogens. Unfortunately, the obese host is plagued by suppressed immune responses upon infection with
respiratory viruses (Evans et al., 2010; Newton, Cardani, and Braciale, 2016). Once infected, the epithelial cells must correctly sense the pathogen to initiate all downstream
1 Modified:

From final submission with permission from Cold Spring Harbor Laboratory Press. Honce, R.,
N. Wohlgemuth, et al. (Dec. 2019). “Influenza in High-Risk Hosts-Lessons Learned from Animal Models”.
In: Cold Spring Harb Perspect Med. ISSN: 2157-1422 (Electronic) 2157-1422 (Linking). DOI: 10.1101/cshperspect.a038604. Modified: From final submission with permission from Oxford University Press. Honce,
R. and S. Schultz-Cherry. (May2019b). “Influenza in obese travellers: increased risk and complications, decreased vaccine effectiveness”. In: J Travel Med 26.3. ISSN: 1708-8305 (Electronic) 1195-1982 (Linking). DOI:
10.1093/jtm/taz020.
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immune responses. This response relies on a carefully coordinated immune cascade beginning with the recognition of a viral invader, production of interferon (IFN) and IFN
stimulated genes (ISGs), and an induction of a broadly antiviral state (Evans et al., 2010;
Newton, Cardani, and Braciale, 2016). Pattern-recognition receptors (PRRs), the cellular
sensors for foreign RNA and DNA, identify single stranded RNA, double-stranded RNA
or viral replication intermediates to initiate a signal transduction cascade ultimately resulting in the production of type I and type III interferons (IFNs) (Jensen and Thomsen, 2012;
Kawai and Akira, 2010). Type I (IFN-α/β) and type III IFNs (IFN-λ) act in an autocrine
and paracrine manner to produce a protective antiviral state (Whitsett and Alenghat, 2015;
R. K. Durbin, Kotenko, and J. E. Durbin, 2013). IFN signaling induces synthesis of interferon stimulated genes (ISGs) which have both direct and indirect antiviral activities
(Crosse et al., 2018). Without a robust action of IFN and innate responses, downstream
adaptive and memory responses are delayed or even diminished in their effect (McNab
et al., 2015; Crouse, Kalinke, and Oxenius, 2015). As obesity has proven implications for
these downstream effectors of the immune response, earlier perturbations in immunity
due to the obese pulmonary microenvironment may be to blame.

1.3

Consequences of Obesity on Viral Evolution

The altered obese pulmonary microenvironment characterized by a diminished IFN state
not only has implications for disease severity, but can possibly directly modulate the influenza viral population as well. RNA viruses like influenza virus are notable for their
extreme adaptability due to their inherent mutable nature (Wille and Holmes, 2020). This
adaptability lies in influenza’s amazing ability to generate novel viral variants through
mutation but also through the swapping of whole genomic segments upon co-infection.
This viral drift and shift continuously changes the makeup of the global influenza quasispecies, and together with zoonotic spillovers, places influenza virus as a constant seasonal
and pandemic threat to human health (Yoon, Webby, and Webster, 2014). Recently, scientists have begun to appreciate the evolutionary processes that drive diversification of the
influenza viral population within- and between its human hosts (Poon et al., 2016; Xue
and Bloom, 2020; Xue, Moncla, et al., 2018; Tao, Steel, and Lowen, 2014). However, most
of this work neglects the influence altered host microenvironments can have on influenza
evolution (Beck, Handy, and Levander, 2004).

1.4

Specific Aims

It is well understood that obese hosts lack a robust adaptive immune response. Crucially,
a robust adaptive response to infection relies on a cascade that begins as soon as a viral invader is sensed within a cells. It follows that, due to the dampened adaptive and memory
responses observed in hosts with obesity, earlier impairments in immunity also exist. Further, the blunted induction of an antiviral state and the obesogenic environment alters the
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respiratory microenvironment and the immune pressures in which influenza virus faces
as it replicates and spreads. From this, my aims with this work are as follows:
• Obesity will dampen the sensing of viral invaders and blunt antiviral immunity,
namely the initial antiviral response, in the cells of the respiratory epithelium.
• The blunted immune pressures will promote the diversification of the viral species
at the single-nucleotide and whole segment level.
• The collective failures of immunity and altered viral evolution combine to reduce
antiviral and vaccine efficacy in obese hosts.
Together, the hyper-inflammatory state due to obesity dampens the recognition of
the viral invaders, thus delaying and blunting the initial interferon responses. This dulled
antiviral state promotes greater influenza replication, stalls the recruitment of adaptive
immune mediators, and predisposes the obese host to severe disease, poor recovery, and
ultimately, reduced survival post-infection. Distinct from its influence on disease severity,
obesity may also shape the viral population at both the single nucleotide and whole segment level. The resulting viral population, harboring novel viral variants and reassortant
progeny, will have implications for pathogen virulence, antiviral resistance, and vaccine
efficacy.

1.5

Implications

Obesity has systemic implications for immunity that have been attributed to a chronic,
low-grade inflammatory state. With adult and childhood obesity rates on the rise, it is crucial that the scientific community investigates how this population responds to infection
and its impact to the viral population upon infection. The work presented within conveys the deficient viral sensing in the obese epithelium results in increased viral spread
and affords increased diversification of the influenza virus population. This research aids
in understanding the molecular basis of the resulting dampened antiviral responses upon
influenza virus infection of the respiratory epithelium. Further, it advances the collective
knowledge on the impact of obesity on the within-host evolution of influenza viruses.
Many of the ideas and findings presented within this work have been previously
published under my name and are appropriately cited in footnotes and the list of references (Honce, Wohlgemuth, et al., 2019; Honce and Schultz-Cherry, 2019a; Honce and
Schultz-Cherry, 2019b; Honce, Karlsson, et al., 2020; Honce and Schultz-Cherry, 2020c;
Honce and Schultz-Cherry, 2020a; Honce and Schultz-Cherry, 2020b).
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Chapter 2
Influenza Pathogenesis and Immunity in the Obese
Host1

2.1

Introduction

Infectious diseases continue to be a scourge on society. While modern life has brought
about the life-saving invention of vaccines and antimicrobials, leading to a bump in life
expectancy and reduced rates of communicable disease, the number of deaths from infectious diseases continues to number in the tens of millions globally and hundreds of
thousands in the United States each year (Disease Causes of Death Collaborators, 2017;
El Bcheraoui et al., 2018). A yearly threat to global health is the seasonal—and sometimes
epidemic or pandemic—emergence of influenza virus. The burden of influenza disease is
staggering, with models estimating up to one-fifth of the global population infected each
influenza season (Disease: Influenza Collaborators, 2019; Disease Causes of Death Collaborators, 2017). This translates to at least 1 billion infections and up to 500,000 deaths
worldwide as well as economic depression through direct and indirect costs estimated
at 87 billion USD each year just for the United States (Krammer et al., 2018; Molinari et
al., 2007). While all are susceptible to infection and severe disease, the bulk of infections
disproportionally target specific high-risk populations. Both viral strain and host characteristics impact influenza disease susceptibility and severity. High-risk hosts often have
1 Portions of chapter from previously published articles. Modified: From final submission with permission from Cold Spring Harbor Laboratory Press. Honce, R., N. Wohlgemuth, et al. (Dec. 2019). “Influenza in
High-Risk Hosts-Lessons Learned from Animal Models”. In: Cold Spring Harb Perspect Med. ISSN: 21571422 (Electronic) 2157-1422 (Linking). DOI: 10.1101/cshperspect.a038604. Modified: From final submission
with open access permission. Honce, R. and S. Schultz-Cherry (2019a). “Impact of Obesity on Influenza A
Virus Pathogenesis, Immune Response, and Evolution”. eng. In: Front Immunol 10, p. 1071. ISSN: 16643224 (Electronic) 1664-3224 (Linking). DOI: 10.3389/fimmu.2019.01071. Modified: From final submission with
permission from Oxford University Press. Honce, R. and S. Schultz-Cherry. (May2019b). “Influenza in obese
travellers: increased risk and complications, decreased vaccine effectiveness”. In: J Travel Med 26.3. ISSN:
1708-8305 (Electronic) 1195-1982 (Linking). DOI: 10.1093/jtm/taz020. Modified: From final submission with
permission from Oxford University Press. Honce, R. and S. Schultz-Cherry. (Aug. 2020). “A tale of two pandemics: obesity and COVID-19”. In: J Travel Med 27.5. ISSN: 1708-8305 (Electronic) 1195-1982 (Linking). DOI:
10.1093/jtm/taaa097.
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Figure 2.1: High-risk states for influenza infection.

aberrant immune responses and baseline characteristics than impact susceptibility to infection with various influenza viral strains, as well as the antiviral response upon infection.
Classically, the very young, very old, and pregnant women have been identified as susceptible populations; however, recent evidence points to several other states which may
lead to severe infection, including nutritional status. Studying influenza pathogenesis in
the context of these hosts is of paramount importance as those living with one or more
comorbitidies continues to increase (Figure 2.1).
Global rates of overweight and obesity, defined as a body mass index (BMI) of 25
to 30 and greater than 30, respectively, have nearly tripled since 1975. Approximately 1.9
billion people are overweight and over 650 million are obese, translating as nearly half
of the worldwide adult population (Aguilar et al., 2015; WHO, 2020). Obesity is a wellidentified risk for increased mortality due to heightened rates of heart disease, certain
cancers, and musculoskeletal disorders (Andersen, K. E. Murphy, and Fernandez, 2016).
However, obesity has systemic implications. Adipose tissue is a rich immunological organ that can influence wide-ranging bodily functions through release of immunological
mediators including cytokines, chemokines, and specialized adipokines, all of which are
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influenced by the obesogenic environment (Ouchi et al., 2011; Cummins et al., 2014).
As obesity has now reached epidemic status, the scientific community has garnered
greater knowledge of the widespread effects over-nutrition has on immunity and begun to
appreciate how obesity shapes the body’s response to communicable diseases. For centuries, clinicians have recognized under-nutrition as an important factor in the body’s
response to infection (Underwood, 1849; Flanigan and Sprunt, 1956; Webb et al., 1976;
Moser et al., 2019), yet now with overweight and obesity rates reaching epidemic status,
over-nutrition has become an urgent public health concern. A plethora of epidemiological
studies revealed obesity as an independent risk factor for severe disease, as it increased
the risk of hospitalization, intensive care, and mortality upon infection during the 2009 influenza A virus (IAV) H1N1 pandemic (Vaillant et al., 2009; Venkata, Sampathkumar, and
Afessa, 2010; D. L. Thompson et al., 2011; Van Kerkhove et al., 2011; Y. Sun, Q. Wang, et al.,
2016).
Influenza is a potentially severe respiratory viral infection caused by the influenza
virus. Influenza viruses include A, B, C, and D strains; most human cases are caused
by the H1N1 and H3N2 strains of IAV or Yamagata and Victoria lineages of influenza B
virus (IBV), although sporadic infections with influenza C virus (ICV) as well as zoonotic
strains of IAV do occur (WHO, 2018). Influenza typically presents with fever, myalgia,
rhinorrhea, sore throat and sneezing with infections often limited to the upper respiratory
tract, including the nasal, tracheal and often bronchial epithelium. Viral shedding peaks by
day 3 post-infection (p.i.) and peak symptoms follow at days 3-5 p.i. (Carrat et al., 2008).
In more severe cases, infection of the lower respiratory tract including the lung occurs and
is often followed by severe sequelae requiring hospitalization, protracted and worsening
symptoms, extensive viral shedding, and weeks of recovery (Taubenberger and Morens,
2008). Development of viral pneumonia and secondary bacterial infections can lead to
acute lung injury (ALI), acute respiratory distress syndrome (ARDS), need for intensive
mechanical ventilation (IMV), and eventual death (Taubenberger and Morens, 2008).
Several case studies of fatal IAV infections during the 2009 pandemic and retrospective analyses of seasonal influenza have identified obesity as a potential risk factor for
severe disease. However, they neglect to determine the causality between obesity and IAV
pathogenesis. Studies in mouse models of obesity, including leptin-deficient (OB) and leptin receptor-deficient (DB) genetically obese models as well as the high-fat diet-inducedobese (DIO) model (Table 2.1) have identified several immunological mechanisms for the
increased pathogenesis and mortality that mirrors what has been seen in humans (A. G.
Smith, Sheridan, Harp, et al., 2007; O’Brien et al., 2012; Mancuso, 2013; Paich et al., 2013).
Advances in obese ferret models and human primary cell culture are enabling better translational studies of the mechanisms behind the increased disease severity due to the obesogenic environment (Albrecht et al., 2018). Below is a discussion of case reports that
followed the 2009 pandemic which gave researchers the first hints of how obesity alters
influenza pathogenesis. Following is a synthesis of the studies done to understand viral
pathogenesis in obese animal models and parallels to findings in other viral systems.
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Table 2.1: Model systems for the study of viral infections in obese hosts.
Model
Genetic leptin knockout
mouse

ID
OB

Genetics
Most commonly on C57BL/6 background; spontaneous recessive, homozygous Lepob nonsense mutation

Characteristics1
50 g+ weight on normal chow; hyperphagic due to loss of appetite
control and satiety

Genetic leptin
receptor
knockout
mouse

DB

Commonly on C57BL/Ks or
C57BL/6J backgrounds;
spontaneous mutant in Leprdb allele
causing abnormal splicing

40 g on normal chow; hyperphagic
due to loss of leptin receptor signal
transduction

Diet-induced
obese mouse

DIO

Any background, commonly on
C57BL/6J; some strains more susceptible than others

35 g on high-fat purified diet; exhibits typical eating patterns

Control mice

LN/WT

Any matched genetic background

25 g on either low-fat diet (LN) or
regular chow; diet choice may alter
results

Obese ferret

DIO ferret

High genetic diversity

Fed high-calorie, high-fat, highcarbohydrate diet to mimic human
obesity

Ex vivo epithelial cells

mTECs
mNECs
fTECs
fNECs
hNECs
HBECs

Genetic diversity from donor; commonly isolated from the nasal
(NEC), tracheal (TEC) or bronchial
epithelium (BE) of human (h)
donors, ferrets (f), and mouse (m)
lines

Broad range of BMI dependent on
mouse, ferret, or human donor

1 Weight

2.2

of 12-week-old male mouse.

Clinical Case Reports

Case studies of severe and fatal IAV infections with obesity as a comorbidity have identified obesity’s possible influence on disease progression, including extensive viral replication in the deep lung, rapid progression to viral pneumonia, and prolonged and increased
viral shed (Gerberding et al., 2004; Fleury et al., 2009; Nakajima et al., 2010). As obesity
is a relatively modern phenomenon due to the Western lifestyle, the epidemiological link
between over-nutrition and influenza was not widely appreciated until the 2009 H1N1
pandemic.
An early autopsy case from the 2009 pandemic reported the death of an obese (BMI
of 38) 33-year-old male at day 8 post-admission to the hospital (Nakajima et al., 2010). He
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presented with high fever, cough, dyspnea, and diarrhea. Cause of death was identified
as respiratory failure. Upon autopsy, abundant viral replication was detected in type I
and type II pneumocytes within the lower lung, with less viral replication detected in the
bronchial region and none in the trachea. The extensive viral spread joined with severe
pulmonary edema and desquamation of the respiratory epithelial cells (Nakajima et al.,
2010). This severe pathology is reflective of other case reports, pointing to severe alveolar
hemorrhaging and ALI upon infection in the obese patient (Yokoyama et al., 2010).
Other facets of infection dynamics, including host susceptibility and viral shed, may
be associated with obesity. Reports of avian-origin H7N9 infection in Shanghai, China
revealed all three infected patients were obese, middle-aged men, suggesting heightened
susceptibility to zoonotic infections due to obesity. Extended viral shed—at least 19 days—
was detected in a woman with a BMI of greater than 40 treated with oseltamivir for H1N1
virus during the 2009 pandemic (Fleury et al., 2009) Further epidemiological and surveillance studies have strengthened the association between obesity and IAV pathogenesis,
host response, and viral shed (Van Kerkhove et al., 2011; Maier, Lopez, et al., 2018). Studies of IBV infection in obese humans have shown a weaker association between infection
and obese status, with no association between obesity and IBV severity and length of viral
shed (Gutierrez-Pizarraya et al., 2012; Maier, Lopez, et al., 2018). Mechanistic studies in
mouse models, cell culture, and human ex vivo samples below offer potential explanations
for these clinical presentations.

2.3

Laboratory Models to Study Obesity and Influenza

Obese adults are classified as high risk for IAV infection by the United States Centers for
Disease Control (Vaillant et al., 2009; Van Kerkhove et al., 2011; CDC, 2019; CDC, 2020). To
understand the molecular consequences of obesity for the immune response to infection,
researchers have turned to two main mouse models (Table 2.1). One, the leptin deficient
(OB) mouse, displays morbid obesity weighing upwards of 45 grams (g) at maturity. Although not recapitulating the etiology of obesity, the OB mouse provides a genetic understanding of increased adiposity and its effects on the immune system. However, it must
be noted that the leptin knockout has drastic implications for more than just obesity (Lindstrom, 2007; Wauman, Zabeau, and Tavernier, 2017). Attempts to mitigate these impacts
have yielded the leptin receptor knockout model (DB); however, this is largely unused in
viral pathogenesis studies aside from isolating the effect of leptin on the immune response.
The second murine model of obesity, the diet-induced obese mouse (DIO) better recapitulates the progression of human obesity resulting from poor diet and overeating. DIO mice
typically weigh at 35-40 g at the time of experimentation, compared to 25 g for a lean,
wild-type (WT) mouse. Again, caution must be exerted in relying on the DIO model, as
diet composition (high-fat, Western, or high-carbohydrate) and appropriate control diets
must be chosen to ensure proper experimental design (Hariri and Thibault, 2010; Zeeni
et al., 2015).
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The use of obese mouse models has revealed increased viral spread, decreased
wound repair, and delayed and blunted immune responses compared to IAV infection in
lean hosts, leading to poorer infection outcomes due to the obese state. Mouse models are
invaluable tools but do not accurately mimic true human influenza infection or pathogenesis. Reserachers are now turning to the use of ex vivo human respiratory epithelial cells as
well as novel obese animal models to gain a greater understanding of the body’s response
to infection in the context of obesity and diverse genetic backgrounds (Table 2.1). Developing a diet-induced model of obesity in the ferrets enables study of how obesity modulates
other facets of influenza pathogenesis, including susceptibility and transmission (JohnsonDelaney and Orosz, 2011). Finally, the use of obese- and lean-derived primary respiratory
epithelial cells (NHBE cells) can enable the translation of the findings observed in animal
models to an ex vivo model of the human respiratory tract at varied sex, age, and BMI to
help translate findings from these studies to a diverse human population (C. G. Huang
et al., 2018).

2.4

Pathogenesis and Resolution of Influenza Infection

The respiratory epithelium of obese hosts suffers increased damage upon IAV infection
compared to lean, healthy hosts. This increased damage has multiple etiologies. Damage
to the epithelial surface may be due to elevated viral loads recovered from obese mice.
In comparison to lean, wild-type (WT) mice, DIO mice inoculated with a lethal dose of
A/Puerto Rico/8/1934 (PR8) mouse-adapted H1N1 virus showed higher viral titers at
days 6 and 10 p.i.; however, no difference in peak titer at day 3 p.i was recovered from OB
or DIO mice inoculated with CA/09 H1N1 virus (Moorthy et al., 2016; Karlsson, V. A. Meliopoulos, Velde, et al., 2017; V. Meliopoulos et al., 2019). Independent of viral titer, by day
3 p.i., extensive viral spread is evident in OB mice (V. Meliopoulos et al., 2019). Heightened
viral spread triggers increased lung damage, permeability and edema as well as heightened oxidative stress in obese compared to WT mice (A. G. Smith, Sheridan, Harp, et al.,
2007; Y. H. Kim et al., 2012; O’Brien et al., 2012; Karlsson, V. A. Meliopoulos, Velde, et al.,
2017; Milner, Rebeles, et al., 2015; Moorthy et al., 2016). This phenotype persists through
infection, as histological analysis of lungs from one week p.i. show a greater proportion
of the lung still in active infection and decreased area in active repair at days 7 and 8 p.i.
(O’Brien et al., 2012). The breakdown in epithelial integrity due to extensive lung injury
predisposes OB mice to secondary bacterial infections, which also show increased bacterial spread through both the upper and lower respiratory tracts in OB compared to WT
mice (O’Brien et al., 2012; Karlsson, V. A. Meliopoulos, Velde, et al., 2017). Finally, a dysregulated immune system sets up the obese host for increased risk of immunopathological
damage, as discussed more in depth below (O’Brien et al., 2012; Ramos Muniz et al., 2018).
The constellation of increased susceptibility, worsened pulmonary damage, secondary infection risk, and delayed immunity combine to decrease survival p.i. in obese mice (A. G.
Smith, Sheridan, Harp, et al., 2007; O’Brien et al., 2012).
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Lung pathology and infection outcomes

Obesity is comorbid with severe influenza in nearly one-third of hospitalized patients and
fatal cases (Bassetti et al., 2011; Balanzat et al., 2012; Wieching et al., 2012). In both pandemic and non-pandemic influenza seasons, obesity increases the risk of infection, hospitalization, length of hospital stay, and need for mechanical ventilation (E. T. Martin et al.,
2013; Cocoros et al., 2014; V. Martin et al., 2016; Maier, Kuan, et al., 2020). Most strikingly,
obesity class II (BMI > 35 kg/m2 ) resulted in a two-times greater risk of death upon IAV
infection and hospitalization due to the infection, with obesity class I (BMI = 30-35 kg/m2 )
also increasing risks (Fezeu et al., 2011; Louie et al., 2011; Riquelme et al., 2011; Okubo, Nochioka, and Testa, 2018). In other high-risk populations such as pregnant and post-partum
women, obesity also compounded IAV infection risks (He et al., 2017).
Upon infection with IAV, damage to the respiratory epithelium results from both the
viral replication process in addition to the pro-inflammatory immune response. Complete
recovery requires proper clearance and remodeling of viral-induced and immune-induced
damage. Increased lung damage, pulmonary edema, cellularity, inflammatory response,
and immunopathology is present in DIO and OB mice as compared to WT mice inoculated
with IAV in both naïve and vaccine challenge experiments (A. G. Smith, Sheridan, Harp, et
al., 2007; Y. H. Kim et al., 2012; O’Brien et al., 2012; Milner, Sheridan, et al., 2013; Karlsson,
Hertz, et al., 2016; Karlsson, V. A. Meliopoulos, Velde, et al., 2017). The few comparative studies for which no difference in lung pathology was reported used relatively high
lethal doses, underscoring the importance of accounting for viral stock preparation and
the means of administration when comparing host responses and pathogenesis (Moorthy
et al., 2016).
In severe cases, IAV infection denudes the respiratory epithelium, leading to a fluid
influx in the airway space (Taubenberger and Morens, 2008). Obese mice are more likely
than are lean (LN) mice to have increased lung permeability during infection. Using Evan’s
blue dye, Karlsson et al. found that by day 7 p.i., OB mice showed a significantly greater
increase in permeability when compared to LN (Karlsson, V. A. Meliopoulos, Velde, et al.,
2017). This finding was confirmed by increased albumin levels in bronchoalveolar lavage
fluid (BALF) at days 5 to 8 p.i. in both OB and DIO mice, evidence of increased protein
leakage from the lung into the BALF (O’Brien et al., 2012; Milner, Sheridan, et al., 2013;
Karlsson, V. A. Meliopoulos, Velde, et al., 2017). The increased lung permeability upon
IAV infection is coupled with an increase in lung edema and oxidative stress, emphasizing
the multiple etiologies of lung pathology in the obese host (O’Brien et al., 2012; Milner,
Rebeles, et al., 2015; Tan et al., 2017). Infection resolution requires the repair of the damaged epithelial surface, but again OB and DIO hosts are deficient (O’Brien et al., 2012).
Reduced cellular proliferation as determined through KI-67 staining is evident in OB and
DIO mouse lung sections at days 6 and 14 p.i, leaving the lung susceptible to secondary
infections and eventual ARDS (O’Brien et al., 2012).

Chapter 2. Influenza Pathogenesis and Immunity in the Obese Host

11

Heightened immunopathology and poor wound recovery in OB and DIO mice result in increased mortality. IAV strains H3N2 and H1N1 induce greater mortality in OB
and DIO mice than in WT C57BL/6 mice, regardless of their respective vaccine histories
(A. G. Smith, Sheridan, Harp, et al., 2007; O’Brien et al., 2012; Milner, Sheridan, et al., 2013;
Karlsson, Hertz, et al., 2016). This is also true for a viral-bacterial coinfection model. DIO
and OB mice inoculated with PR8 IAV, CA/09 IAV, seasonal H3N2 virus, or influenza B
virus (IBV) and challenged with Streptococcus pneumoniae at day 7 p.i. with influenza virus
had increased mortality when compared to controls (Karlsson, V. A. Meliopoulos, Velde,
et al., 2017).

2.4.2

Viral load and spread in respiratory epithelia

Severe influenza disease results from viral spread and immunopathology in the lower
respiratory tract (LRT). Limited case studies that list obesity as a comorbidity reference
heightened viral replication and extensive hemorrhage in the alveoli leading to increased
disease severity (Nakajima et al., 2010; Yokoyama et al., 2010). The increased incidence
of ALI and ARDS in hospitalized obese patients may result from impaired lung function and gas exchange due to increased alveolar involvement in infection (Riquelme et al.,
2011). Continued investigation using ex vivo human systems and with cohorts of obese and
lean naturally infected patients can help determine how data gleaned from mouse models
translates to human infection, as well as how other comorbidities such as metabolic syndrome, chronic disease, age, and sex will affect the pathogenesis of IAV (P. L. Huang, 2009;
Andersen, K. E. Murphy, and Fernandez, 2016; Perez et al., 2016).
There are conflicting reports of elevated viral load in obese compared to non-obese
mice (Y. H. Kim et al., 2012; O’Brien et al., 2012). In a viral-bacterial coinfection model,
there was no difference in the influenza viral load between obese and WT mice at peak
disease. However, delayed viral clearance was evident in obese mice (Karlsson, V. A. Meliopoulos, Velde, et al., 2017). Similarly, at peak infection, the viral titers in OB and DIO
mice infected with H1N1 viruses were no different to viral load in WT mice, but the obese
mice had prolonged infections. WT mice clear the virus by day 10 p.i. yet OB mice show
no discernible decrease in viral load from peak infection (O’Brien et al., 2012; V. Meliopoulos et al., 2019). Conversely, some reports have suggested that DIO mice have higher viral
titers early in infection with no change at later timepoints p.i. (Y. H. Kim et al., 2012; Moorthy et al., 2016). The disparities between these reports may be due to differences in the
inoculation method, dose, heterogeneity of influenza viral strains, or viral stock preparations. Nevertheless, OB mice experience worse outcomes after infection independent of
increased viral titers.
Paralleling the findings in human autopsy analyses, obese mice exhibit increased
viral spread to the LRT. More viral antigen was present in the bronchiolar and alveolar
regions in DIO mice inoculated with H1N1 virus than in the corresponding regions of
infected control animals (Easterbrook et al., 2011). In a viral-bacterial coinfection model,
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OB mice inoculated with a fluorescent reporter virus showed increased viral spread in the
nasopharynx, trachea, and lung at day 8 and 9 p.i. along with more areas of active viral
infection at days 7 and 9 p.i. (Karlsson, V. A. Meliopoulos, Velde, et al., 2017). Excised
lungs from OB mice showed this increased viral spread to be present as early as day 3 p.i.
(V. Meliopoulos et al., 2019). The culmination of severe lung pathology and increased viral
spread leads to increased mortality in obese mice due to influenza infection and severe
sequelae (O’Brien et al., 2012).
Obesity has clear physical and molecular consequences for pulmonary mechanics
and immunity. Together, these contribute to the observed increased susceptibility of obese
hosts to IAV (Dixon and Peters, 2018); however, ex vivo studies with primary human respiratory epithelial cells have revealed intrinsic cellular differences in viral replication in
obese and lean subjects (Travanty et al., 2015; C. G. Huang et al., 2018). In limited studies
with alveolar epithelial cells (AECs), Huang et al showed that H7N9 infection of obesederived cells resulted in a greater increase in viral RNA production from hours 24 to 72
p.i. than was seen in infected of lean-derived cells (C. G. Huang et al., 2018). These results
support the limited data demonstrating that obese AECs are more susceptible to infection
(Travanty et al., 2015). Further studies are warranted to elucidate the mechanism behind
this increased susceptibility at the epithelial cell level.

2.5

Host Antiviral Responses in Obesity

Poor infection outcomes in obese hosts stem from dampened immune responses (D. C.
Nieman et al., 1999; Mancuso, 2013; Andersen, K. E. Murphy, and Fernandez, 2016). Systemic alterations to antiviral immunity have been described for the baseline obesogenic
lung as well as infection responses to influenza and other respiratory viruses, leaving the
lung susceptible to heightened viral spread, secondary infections, and reduced recovery
(Figure 2.2). In obese hosts, IAV-specific antiviral responses are either delayed or blunted
upon infection (K. Takahashi et al., 2003; A. G. Smith, Sheridan, Harp, et al., 2007; Ouchi
et al., 2011; O’Brien et al., 2012; Chen et al., 2014; Andersen, K. E. Murphy, and Fernandez,
2016). A delayed onset of immune responses is pathogenic; correct timing of the antiviral
cascade is crucial to not only clearing and controlling the infection, but also for maintaining respiratory barrier integrity. The pulmonary environment eventually reaches a “tipping point” of rampant viral spread without opposing control from host immunity. As is
evident by the severe lung damage seen in obese mice p.i., heightened immunopathology
is common (Y. H. Kim et al., 2012; O’Brien et al., 2012; A. J. Zhang et al., 2013; Milner,
Rebeles, et al., 2015; Y. Sun, Q. Wang, et al., 2016). This immunopathology stems from
uncontrolled inflammation triggered by extensive viral spread and poor early responses
to the infection. In studies with other pathogens, obesity also exacerbates the so-called
“cytokine storm” and predisposes the host to fatal outcomes (Ramos Muniz et al., 2018).
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Figure 2.2: Obesity’s effects on immune responses in the pulmonary
environment.
Alterations to the host response to influenza virus infection in the lung
epithelium due to the obese state. Summarizes the intrinsic epithelial,
innate immune, and adaptive immune responses in the obese lung
microenvironment. The effects of obesity on antiviral processes are
indicated by a green + symbol indicating and increased number or process;
a red – sign indicating a decreased number or process; a blue ellipses (. . . )
indicating a delayed response; and a yellow interrogation mark (?)
indicating conflicting or scarce literature. IFN = interferon, ISGs =
interferon-stimulated genes, Ab = antibody, Ag = antigen.

13

Chapter 2. Influenza Pathogenesis and Immunity in the Obese Host

2.5.1

14

Innate immunity

The initial response to IAV is the non-specific and early-acting innate immune defenses of
the nasal, bronchial, and lung epithelium (Agrawal, Kern, and Nikolajczyk, 2017). An altered chemokine and cytokine milieu is characteristic of obese hosts and contributes to the
baseline meta-inflammation seen in this population (Johnson, Milner, and Makowski, 2012;
Lumeng, 2013; Kuroda et al., 2020). Increased visceral and omental adiposity results in
an efflux of pro-inflammatory cytokines that influence systemic cellular processes. These
metabolic changes are seen in the initially infected epithelial cells, migratory immune cells,
and other players in pulmonary tissues needed for appropriate cellular crosstalk and infection control (K. Takahashi et al., 2003; Fain, Tichansky, and Madan, 2005; Teijaro et al., 2011;
Chen et al., 2014; Dixon and Peters, 2018). The baseline and post-IAV infection chemokine
and cytokine alterations in mouse models of obesity are outlined in Table 2.2.
The adipose tissue of obese mice produces high levels of several adipokines including MCP-1, TNFα, and IL-6, as well as the cytokine transforming growth factor-β (TGFβ),
all of which have systemic impacts (K. Takahashi et al., 2003; Chen et al., 2014; Shah et al.,
2015). Two key adipokines that are intimately tied to obesity are leptin and adiponectin
(Hamilton et al., 1995; Lonnqvist et al., 1995; Ouchi et al., 2011). Higher serum leptin
and lower adiponectin levels may contribute to both the heightened pro-inflammatory
cytokine production at baseline and the poor response to infectious stimuli in DIO mice
(Karlsson and Beck, 2010). Early in IAV infection of DIO mice, IL-6, TNFα, and type I
interferon (IFN) upregulation is slowed compared to LN mice (Namkoong et al., 2019).
Differential regulation of IL-2 and IL-12 is also detected in the lung. However, at later
timepoints in infection, there is increased inflammation in DIO mice whereas LN mice
begin to ramp down their inflammatory processes and begin rebuilding the damaged epithelium (K. Takahashi et al., 2003; A. G. Smith, Sheridan, Harp, et al., 2007; Easterbrook
et al., 2011; Y. H. Kim et al., 2012). Differential regulation of the antiviral cytokines and IFN
response upon infection may contribute to the poor adaptive responses in obese mice as
discussed below (A. G. Smith, Sheridan, Harp, et al., 2007; A. G. Smith, Sheridan, Tseng,
et al., 2009; Easterbrook et al., 2011).
Obese adult humans share many of the pro-inflammatory signatures of obese mouse
models at baseline and the systemic leptin-resistance resulting from increased adiposity
(Considine et al., 1996; C. Richard et al., 2017). Fewer studies have interrogated the intrinsic antiviral response of obese-derived human respiratory epithelial cells. In one such
study, obese-derived cells displayed a smaller increase in the levels of IL-8, IL-1β and IP10 levels at hour 72 p.i. in comparison to lean-derived cells, which is consistent with the
delayed and blunted cytokine response in obese rodent models (C. G. Huang et al., 2018).
Systemic alterations in cytokine levels upon infection may be due to greater expression of suppressor of cytokine signaling (SOCS) proteins. SOCS proteins are involved in
the negative regulation of JAK-STAT signaling. The induction of type I and III IFNs as well
as many pro-inflammatory cytokines rely on the JAK-STAT signal transduction cascade
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Table 2.2: Alterations to chemokine and cytokine responses at baseline
and post-infection in obese mice.
Analyte
TGFβ

Model
DIO

Baseline
↓ lung concentration; ↑
lung mRNA expression; ↑
BALF1 concentration

Post-infection
↓ lung concentration

TNFα

DIO

↑ plasma concentration; ↑
lung mRNA expression; ↑
BALF concentration

↑ BALF concentration at 8
dpi1 ; delayed lung mRNA
expression ↑ at 3 and 6
dpi; delayed BALF concentration 3 and 8 dpi;
↓ lung concentration fold
increase at 1 and 3 dpi;
↑ circulating concentration
fold increase at 3 dpi
↑ BALF concentration at 4
dpi

↑ lung concentration

↓ lung concentration at 3
dpi; delayed BALF concentration ↑ at 3 and 8 dpi

DB

G-CSF

DIO

IL-1β

DIO

↓ lung mRNA expression
at 3 dpi; ↓ BALF concentration at 3 dpi; ↓ lung concentration fold increase at
1 and 3 dpi; ↑ lung concentration at 4 dpi; ↑ circulating concentration from
baseline at 3 dpi

IL-2

DIO

↓ LN1 mRNA expression
at 3 and 7 dpi

IL-5

DIO

↓ BALF concentration at 3
dpi
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Table 2.2 : Continued.
Analyte
IL-6

Model
DIO

IL-12

DIO

↓ LN mRNA expression at
3 and 7 dpi

IL-12p70

DIO

↓ BALF concentration at 3
dpi

IL-13

DIO

Delayed BALF concentration at 3 and 8 dpi

Leptin

DIO

↑ serum concentration; ↑
lung mRNA expression

↑ serum concentration ↑ at
2, 4, and 6 dpi; ↓ circulating concentration fold increase at 3 dpi

Adiponectin

DIO

↓ serum concentration; ↓
lung mRNA expression

↓ serum concentration at 2
and 6 dpi

CXCL1/KC

DIO

↑ plasma concentration

↑ BALF concentration at 8
dpi
↑ BALF concentration at 8
dpi

OB

Baseline

Post-infection
Fewer macrophages producing ↑ at 3 dpi; delayed
lung mRNA expression at
3 and 6 dpi, delayed BALF
concentration ↑ at 3 and 8
dpi, ↑ lung and serum concentration at 4 dpi

CXCL2/MIP2α

DIO

↑ lung concentration at 4
dpi

CXCL10/IP-10

DIO

↓ lung mRNA expression
at 1 dpi; delayed BALF ↑
concentration at 3 and 8
dpi
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Table 2.2 : Continued.
Analyte
CCL2/MCP-1

Model
DIO

Baseline

Post-infection
↑ BALF concentration at 8
dpi; ↓ lung mRNA expression at 3 dpi

CCL3/MIP1α

DIO

CCL5/RANTES

DIO

↑ plasma concentration

CCL7/MCP3

DIO

↑ plasma concentrations

CCL11/Eotaxin

DIO

Delayed BALF concentration 3 and at 8 dpi

IFNα

DIO

↓ lung mRNA expression
at 2 dpi

IFNβ

DIO

↓ lung mRNA expression
at 2 and 3 dpi

IFNγ

DIO

↑ circulating concentration
fold increase at 3 dpi

Irf7

OB

Oas1a

DIO

Oas1g

OB

↓ BALF concentration at 3
dpi; ↑ lung concentration
at 4 dpi

↓ alveolar macrophage
mRNA expression

Delayed lung mRNA expression at 3 and 6 dpi;
↓ BALF concentration at 3
and 8 dpi

↓ alveolar macrophage
mRNA expression at 1
dpi; ↓ lung mRNA expression fold-increase at 1
dpi
↓ lung mRNA expression
fold-increase at 1 dpi

↓ alveolar macrophage
and epithelial cell mRNA
expression

↓ alveolar macrophage
mRNA expression at 1 dpi
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Table 2.2 : Continued.
Analyte
Ifit1

Model
OB

Mx2

DIO

Nos2

DIO

Baseline
↓ alveolar macrophage
mRNA expression

Post-infection
↓ alveolar macrophage
mRNA expression at 1 dpi

↓ lung mRNA expression
fold-increase at 1 dpi
↑ pulmonary macrophage
expression

↑ indicates increased, ↓ indicates decreased, ∆ indicates no change
node, BALF=bronchioalveolar lavage fluid, dpi=days post infection
2 DN DC=double negative dendritic cell; pDC=plasmacytoid dendritic cell
1 LN=lymph

(Pothlichet, Chignard, and Si-Tahar, 2008; Wei et al., 2014; Blumer et al., 2017). In DIO
mice, upregulated pulmonary expression of SOCS1 and SOCS3 mRNA is implicated in
blunting IFN responses and is similar to SOCS expression signatures in PBMCs isolated
from obese humans (Karlsson, Sheridan, and Beck, 2010b). Reduced type I IFN production from toll-like receptor (TLR)-stimulated PBMCs was concordant with SOCS3 overexpression in cells derived from obese subjects, possibly providing a mechanism for how
the inflamed obese environment blunts immunity (Teran-Cabanillas et al., 2014). These
alterations may be tied to leptin resistance, as overstimulation with excess leptin could
exhaust the downstream signal transduction pathways and transcription factors similar to
those for antiviral chemokines and cytokines (Vaisse et al., 1996; Wauman, Zabeau, and
Tavernier, 2017). Changes in lipids and lipid-derived mediators also affect the response
to IAV in obese hosts and is an active area of research. The impact of obesity on the lung
metabolome contributes to the increased severity of IAV disease in DIO mice, which may
be ameliorated through exogenous administration of statins and acetaminophen (Karlsson, Schultz-Cherry, and Rosch, 2018; A. J. X. Zhang et al., 2019).

2.5.2

Antigen presentation and phagocytosis

Innate immunity may be the first, non-specific response to viral invaders but it is not the
only mediator of immunity. Crucially, it also acts as stimuli for the adaptive immune
response that specifically targets and destroys invaders. The bridge between non-specific
innate immunity and antigen-specific adaptive immunity relies on appropriate actions of
immune cells from the lymphoid and myeloid lineages (Braciale, J. Sun, and T. S. Kim,
2012). There are more leukocytes in the lungs of DIO mice than in those of WT mice
(Manicone et al., 2016), and the reported effects of obesity on these cells are varied and
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often contradictory. Below follows a focused delineation of the functional changes in these
immune cells in the context of influenza infection and the respiratory system (Table 2.3).
Monocytes and macrophages
Bone marrow-derived and pulmonary macrophages in OB and DIO mice are polarized
toward an M1 pro-inflammatory phenotype (F. Y. Lee et al., 1999; Manicone et al., 2016;
Namkoong et al., 2019). Reduced numbers of lung resident alveolar macrophages are
characteristic of infected DIO and OB lungs, and those that remain show a reduction in
the expression of type I IFN receptor and in IFN-stimulated gene expression when compared to WT mice (A. G. Smith, Sheridan, Harp, et al., 2007; V. Meliopoulos et al., 2019).
These changes may be partly due to meta-inflammation, as a chronically inflamed mouse
model shows similarly reduced macrophage activation and blunted pro-inflammatory cytokine production upon stimulation (Ahn et al., 2015). This is compounded by the impaired marcophage migration to lung alveoli during infection, leading to poor clearance
of the invading pathogen (Milner, Rebeles, et al., 2015; Manicone et al., 2016).
As discussed below, these macrophage phenotypes may partially explain the poor
vaccine response characteristic of the obese host. Although phagocytosis is increased in
peritoneal macrophages isolated from DIO mice, macrophages derived from obese individuals show reduced activation markers, impairing their ability to stimulate effector cells
of the immune system (Cho et al., 2016). This finding is further supported by the increased
presence of immature monocytes but equal presence of effector alveolar and interstitial
macrophages in BALF collected from DB mice at day 4 p.i. (Radigan et al., 2014).
Dendritic cells
Dendritic cells (DCs) prime the T cell response through presentation of phagocytosed antigens. Several studies have shown that the phagocytotic function and activation of DCs
and other antigen presenting cells remain sufficient in the obese host (Paich et al., 2013;
Costanzo et al., 2015), yet there is evidence that antigen presentation is impaired in DCs
from lungs of DIO mice (A. G. Smith, Sheridan, Tseng, et al., 2009). The authors of the
latter study argue that the reduction in antigen presentation by DCs fails to instruct the
T cell response and is related to the elevated IL-6-driven pro-inflammatory status of the
DIO lung (A. G. Smith, Sheridan, Tseng, et al., 2009). Further studies have shown that in
OB and DIO mice, poorly activated DCs fail to induce T cell proliferation, possibly due to
blunted maturation via similar pro-inflammatory signals (Macia et al., 2006; Chen et al.,
2014; Pizzolla et al., 2016). In human cohorts, obese patients have reduced numbers of
circulating DCs and those remaining are less responsive to ex vivo stimulation with TLR
agonists than are those of non-obese patients (O’Shea, Corrigan, et al., 2013).
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Table 2.3: Alterations to immune cell subsets in obese mice at baseline
and post-infection.
Cell type
Monocytes

Model
DIO

Baseline

Post-infection
↑ BALF1 infiltration at
3, 4, 6 and 14 dpi1
↑ BALF infiltration at 3,
6 and 14 dpi
↑ BALF infiltration at 4
dpi

OB
DB

Macrophages

DIO

↑ M1 polarization; ↓
CD86+ and activation;
↓ migration to lung

↓ BALF at 4 dpi

Alveolar macrophages

OB

↓ type I IFN receptor
signaling

↓ IFN mRNA expression, ↓ IFNAR
signaling; ∆ numbers
in BALF at 4 dpi; ↓
numbers in BALF at 7
dpi

↑ BALF number
∆ in BALF at 4 dpi

Interstitial macrophages

DIO

Natural killer cells

DIO

∆ lung number

OB

↑ lung number

DB

Dendritic cells

DIO

↓ lung pDC2 number

↑ BALF infiltration at 6
and 14 dpi; ↓ cytotoxicity; ↓ lung number at 3
dpi
↑ BALF infiltration at 6
and 14 dpi; ↓ BALF infiltration at 4 dpi
↓ BALF infiltration at 4
dpi
↓ antigen presentation,
↓ induction of T cell
proliferation; ↓ lung
DN DC2 and pDC
number at 3 dpi; ↑ LN
migration

Chapter 2. Influenza Pathogenesis and Immunity in the Obese Host

21

Table 2.3 : Continued.
Cell type
Neutrophils

Model
DIO

Baseline
↑ N1 polarization

OB

DB

B cells

T cells

↑ circulating IgG; ↓
bone marrow B cells;
↓ cross-reactive H1N1
and PR8-specific antibodies at 5, 8 and 14 dpi

DIO

CD8+

DIO

Post-infection
↑ NET production, ↑
BALF infiltration at 6
and 14 dpi
↑ BALF infiltration at 3,
6, and 14 dpi; ↓ BALF
infiltration at 7 dpi
↑ BALF infiltration 4
dpi

↑ OCR:ECAR ratios

CD4+

↑ OCR:ECAR ratios

TREG 3
T MEM 3

↓ lung numbers

↓ lung 7 dpi; ↑ crossreactive CD8+ cells 5
dpi
↑ lung at 5 dpi in heterologous challenge; ↓
lung at 3, 4 dpi and 84
dpi; ↓ BALF at 8 dpi
∆ primary T MEM at 30
dpi; ↑ and TCM 3 at 5 dpi
in heterologous challenge; ↓ lung T MEM at 3
and 7 dpi; ↓ TREG suppression of lean TEM 3

↑ indicates increased, ↓ indicates decreased, ∆ indicates no change
lavage fluid; dpi=days post infection
2 DN DC=double negative dendritic cell; pDC=plasmacytoid dendritic cell
3T
REG =regulatory; T MEM =memory; TCM =central memory; TEM =effector memory.
1 BALF=bronchioalveolar
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Neutrophils
As with macrophages, neutrophils also show a pro-inflammatory N1 phenotype in DIO
mice and those isolated from obese humans show increased production of inflammatory free radicals upon stimulation ex vivo (Manicone et al., 2016; C. Richard et al., 2017).
Lethally challenging obese mice with mouse-adapted PR8 H1N1 virus results in increased
neutrophil migration to the lung and production of more neutrophil extracellular traps
than are seen in LN mice (O’Brien et al., 2012; Radigan et al., 2014; Moorthy et al., 2016). As
this persists from day 3 to at least day 6 p.i., it may compound the severity of the observed
lung pathology due to release of cytotoxic proteins and development of ALI (Narasaraju
et al., 2011; O’Brien et al., 2012; Milner, Rebeles, et al., 2015).
Natural killer and other cell subsets
Natural killer cells also are impacted by the obese environment (O’Shea and Hogan, 2019).
Unlike macrophages, NK cells are decreased in DIO mice and in overweight and obese humans; however, they are increased in OB mice highlighting the disparities between murine
models of obesity (Chandra, 1980; A. G. Smith, Sheridan, Harp, et al., 2007; Lynch et al.,
2012; O’Shea, Corrigan, et al., 2013). Malnutrition has been empirically shown to increase
the severity of IAV disease and impair NK cell function in WT mice, yet DIO and OB mice
show increased NK cell infiltration of the lung (Ritz et al., 2008; O’Brien et al., 2012; Radigan et al., 2014). No studies have investigated the impact of obesity on the response of
basophils, eosinophils, and other leukocytes during IAV infection. However, as obesity
causes perturbation in the circulating leptin and adiponectin levels and leptin can interact
with signal transduction pathways critical to the aforementioned leukocytes and other immune cells, the impact of the obesogenic environment undoubtedly extends beyond our
current knowledge (Wauman, Zabeau, and Tavernier, 2017).

2.5.3

Adaptive immunity

Complete resolution of viral infection relies on the actions of the adaptive immune system. Primed by the initial innate response, B- and T-lymphocytes control and clear the
remaining infection; however, obesity dampens these efforts and poorly positions the host
for optimal lung repair (Mancuso, 2013; Inzaugarat et al., 2014).
Cell-mediated immunity
Cell mediated adaptive immunity depends on effector, helper, memory, and other subsets
of T cells. Recent studies have aimed to clarify the literature and to elucidate the molecular mechanism behind the reduced T cell response seen in both obese mice and humans,
as well as how specific T cell subsets respond to the obese environment and IAV infection. T cell lymphopenia as well as a pro-inflammatory skew and reduced proliferation,
activation, and function of T cells has been described in DIO, leptin receptor and leptindeficient (Kimura et al., 1998; Macia et al., 2006; Karlsson, Sheridan, and Beck, 2010a; Cho

Chapter 2. Influenza Pathogenesis and Immunity in the Obese Host

23

et al., 2016; Toubal et al., 2020), with the mechanistic differences p.i. with influenza virus
outlined below.
Deficiencies in the activation and function of CD4+ and CD8+ T cells were found
in studies performed with PBMCs isolated from healthy weight, overweight, and obese
humans (O’Rourke et al., 2005; Paich et al., 2013). Compared to cells isolated from healthy
weight subjects, stimulated CD8+ and CD4+ T cells derived from obese subjects produced
significantly more IL-5, whereas IFNγ and granzyme-B production trended lower (Sheridan, Paich, Handy, Karlsson, Hudgens, et al., 2012; Paich et al., 2013). Significantly lower
fold increases in TNFα and trends toward lower fold increases in IL-6 were also described
in these participants (Paich et al., 2013). The poor T cell responses to influenza could also
be due to reduced T cell diversity, as in DIO mice obesity accelerated the reduction in T
cell receptor excision circles, leading to the reduction of T cell Vβ repertoire diversity which
parallels what is seen in the aged host (H. Yang et al., 2009).These findings are commensurate with the “adipaging” hypothesis, whereby obese status acerbates the aging of the
immune system to mirror the immune deficits seen in the elderly (Perez et al., 2016). This
inflammatory T cell phenotype is even maintained after weight loss, suggesting the effects
of obesity are highly durable (Surendar et al., 2020).
Interrogations of specific T cell subsets found no difference in the levels of αβ T cells
due to obesity; however, γδ T cells were reduced in number, and those remaining showed
increased differentiation that impaired their antiviral functionality and response to antigen
presentation (Costanzo et al., 2015). Decreasing levels of γδ T cells correlates with increasing obesity status, and the remaining γδ T cells possess an immature phenotype characterized by poor IFNγ production concordant with γδ T cells from an aged host (Paich et al.,
2013; Costanzo et al., 2015). It has been suggested that the differential cytokine milieu and
growth factor deficiency blunt the maturation of antigen presenting cells, thereby extending the poor innate response seen in obese hosts to later adaptive responses. The antiviral
function of γδ T cells is regulated by type I IFNs, and the lack of an IFN response in the
OB host could explain their poor functionality (A. G. Smith, Sheridan, Harp, et al., 2007;
A. G. Smith, Sheridan, Tseng, et al., 2009; Costanzo et al., 2015; Tsai et al., 2015). Interestingly, increases in total numbers of memory T cells were discovered in the visceral adipose
tissue of DIO mice, but these high amounts led to immunopathology upon viral infection
(Misumi et al., 2019).
Obesity-related metabolic dysregulation has also been proposed as the driver of
poor effector, helper and memory T cell responses through effects of T cell immunometabolism (H. L. Park et al., 2014; Rebeles et al., 2019). In their study, Rebeles et al initially inoculated DIO or LN mice with X-31 virus, then challenged DIO, lean, or weight loss dietswitched DIO mice with PR8 virus (Rebeles et al., 2019). T cells isolated from DIO and
LN mice were tested for glycolysis as measured by their extracellular acidification rate
(ECAR) as well as mitochondrial respiration as measured via their oxygen consumption
rate (OCR). A high OCR:ECAR ratio suggests a greater relative magnitude of oxidative
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phosphorylation versus glycolysis, which is an indicator of a naïve or memory T cell phenotype. Conversely, a low OCR:ECAR ratio is suggestive of effector T cells (Loftus and
Finlay, 2016; O’Neill, Kishton, and Rathmell, 2016; Rebeles et al., 2019). DIO mice, even
after weight loss, showed elevated OCR:ECAR ratios for both CD4+ and CD8+ T cells
post-viral challenge, showing that obesity alters the metabolic programming of memory T
cells and this phenotype persists after weight loss (Rebeles et al., 2019).
Antibody-mediated immunity
Few studies have investigated how the obesogenic state affects humoral responses to IAV
infection. Increased visceral adiposity attracts B cell numbers, which interact with T cells
and contribute to the systemic, chronic inflammation characteristic of obese hosts (DeFuria
et al., 2013; Shaikh et al., 2015; Frasca, Diaz, Romero, and Blomberg, 2020). However, the
literature on how these baseline alterations affect the IAV-specific response is sparse and a
needed area for future study.
Lower levels of H1N1 virus-specific antibodies during IAV infection or upon vaccination reduce the neutralizing response to infection in DIO compared to LN mice (Y. H.
Kim et al., 2012; Milner, Sheridan, et al., 2013). Hemagglutination inhibition (HAI) titers
measured at days 7 and 21 p.i. with H1N1 virus in DIO mice were less than those in LN
mice. This reduction in titer was related to a decrease in B cells in the bone marrow of
DIO mice as well as to diminished specific B cell subsets, including regulatory and follicular B cells (Frasca, Diaz, Romero, Vazquez, et al., 2017; Kosaraju et al., 2017; GarciaHernandez et al., 2018; Crouch et al., 2019). However, not all B cell subsets are reduced
in number; inflammatory double-negative B cells are increased in obese hosts, as well as
elderly hosts, but also require higher amounts of glucose to produce antibodies compared
double-negative B cells derived from young humans (Frasca, Diaz, Romero, Thaller, et al.,
2019). A single report has suggested that suggests antibody-dependent-cellular cytotoxicity (ADCC) is slightly increased in OB mice; however, no further studies have defined
ADCC in the context of IAV infection (Chandra, 1980).
To date, no studies have determined how obesity affects the response of other facets
of humoral immunity—including germinal center formation, antibody class-switching,
and the Fc receptor repertoire—to IAV infection. In other infection models, reduced immunoglobulin G (IgG) class switching but elevated IgM levels followed bacterial infection
of obese hosts (Farnsworth et al., 2018). DIO mice showed reduced formation of lymph
node associated germinal centers and reduced recruitment of T cells and B cells to these
germinal centers at day 14 p.i. (Farnsworth et al., 2018). As leptin is a major regulator
of B cell development, maturation, and activity, alterations to the adipokine balance due
to obesity may directly affect B cell function, B cell interactions with other lymphoid cell
types such as T-follicular helper cells, and antibody class-switching (A. J. Zhang et al.,
2013; Wauman, Zabeau, and Tavernier, 2017). Indeed, leptin induces immunosenescence
in obese-derived B cells concordant with effects of aging on B cell function (Frasca, Diaz,
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Romero, and Blomberg, 2020). Continued studies on the B cell and antibody-mediated response to influenza virus must also consider how obesity alters these responses (Krammer,
2019).

2.6

Prevention and Control of Infection

Keys to controlling influenza infection and spread are preemptive vaccination before seasonal outbreaks and early antiviral administration p.i.. In obese hosts, poor innate and
adaptive responses to natural infection and vaccination also impair immunization efficacy
(Frasca and Blomberg, 2020).

2.6.1

Vaccine efficacy in the obese host

Comparisons of vaccine efficacy among healthy-weight, overweight and obese adults preand post-vaccination found that obese adults had a greater decline in influenza-specific
antibody titers 1-year post-vaccination even though initial serological responses showed
no significant differences (Sheridan, Paich, Handy, Karlsson, Hudgens, et al., 2012; Neidich et al., 2017). In one study of elementary school-age children, obesity was linked to
increased symptoms and more school days being missed. However, vaccination with a
live attenuated vaccine was equally protective for obese and non-obese children (Smit et
al., 2016). In adults vaccinated with an inactivated, trivalent influenza vaccine found that
BMI was negatively associated with protective immune responses over time (Sheridan,
Paich, Handy, Karlsson, Hudgens, et al., 2012). Although individuals with a high BMI had
an initially higher fold increase in broad levels of IgG antibodies and influenza-specific
HAI titers, by 12 months post-vaccination there was a greater decline in antibody titers
in obese participants than in non-obese participants (Sheridan, Paich, Handy, Karlsson,
Hudgens, et al., 2012; Callahan et al., 2014; Esposito et al., 2016). These protective levels of
influenza-specific antibodies may not be foolproof indicators of vaccine efficacy (Sheridan,
Paich, Handy, Karlsson, Hudgens, et al., 2012; Sheridan, Paich, Handy, Karlsson, SchultzCherry, et al., 2015). As is noted by Neidich et al, our current correlates of protection may
not be predictive of actual defense from infection and may explain why vaccinated obese
adults display adequate HAI titers but still succumb to IAV infection at higher rates than
healthy-weight adults (Neidich et al., 2017).
Although adjuvanted vaccines outperform non-adjuvanted vaccines in terms of the
neutralizing and non-neutralizing responses elicited, adjuvanted vaccines failed to provide protection against a homologous viral challenge in both OB and DIO mice (H. L.
Park et al., 2014; Karlsson, Hertz, et al., 2016). In a heterologous challenge model with two
strains of H1N1 virus, DIO mice were sub-lethally infected with PR8 virus, then challenged
with a lethal dose of CA/09 virus. The initial PR8 virus infection provided heterologous
protection against CA/09 virus in both LN and DIO mice, but DIO mice had reduced HAI
and microneutralization titers as well as quicker waning of protective antibody levels and
increased lung pathology (Milner, Sheridan, et al., 2013). Quicker waning of protective

Chapter 2. Influenza Pathogenesis and Immunity in the Obese Host

26

immunity in vaccinated obese hosts is not unique to influenza immunization, as it also has
been documented in vaccination against tick-borne encephalitis, hepatitis A and B, and rabies viruses as well as tetanus (Eliakim et al., 2006; Rendi-Wagner et al., 2007; Banga et al.,
2014; Fan et al., 2016; Garner-Spitzer et al., 2020). Analysis of the antibody-based responses
raised in vaccinated obese hosts against influenza virus revealed a reduced breadth and
magnitude of HA and NA-based responses, potentiality explaining the failure to confer
adequate protection (Karlsson, Hertz, et al., 2016). Even after vaccination, DIO challenge
mice had higher MCP-1 and impaired B cell responses, translating to poor infection control
and a damaging inflammatory environment (H. L. Park et al., 2014; Kosaraju et al., 2017).
Protective immunizations should elicit multiple “types” or classes of immune responses (Estrada and Schultz-Cherry, 2019). However, in addition to poor humoral responses, obese hosts exhibit poor memory T cell functions which further weakens vaccine
efficacy. In their study with PBMCs isolated from lean, overweight, and obese vaccinated
donors, Sheridan et al found that obese humans have reduced CD8+ T cell activation 12
months post vaccination (Sheridan, Paich, Handy, Karlsson, Hudgens, et al., 2012). This
persists p.i., as there is an initial reduction in influenza-specific T cells after a heterologous
challenge as well as a reduction in memory T cell numbers several months p.i. in DIO
mice (Karlsson, Sheridan, and Beck, 2010b). However, other studies in the DIO model
have found obesity to have no impact on the maintenance of pre-existing CD8+ memory T
cells or the differentiation and maintenance of newly evoked memory CD8+ T cells (Khan
et al., 2014).
Together, these data translate to an increased risk for influenza in the obese population—even those vaccinated—and mirrors the findings from epidemiological studies. Vaccinated obese and overweight adults had a twofold risk of IAV infection versus healthyweight adults (Neidich et al., 2017). Mechanisms behind impaired vaccine efficacy in
mouse models of obesity have found while serological responses may be equal between
vaccinated obese and lean mice, OB and DIO mice have reduced survival following IAV
challenge which were not improved with repeat vaccination, adjuvanted vaccination, increased vaccine dose, or decreased viral challenge (Y. H. Kim et al., 2012; Karlsson, Hertz,
et al., 2016).
Obesity is often co-morbid with other diseases that raise risks for infection, including metabolic syndrome and diabetes mellitus, further highlighting the need to prevent
infection (Goeijenbier et al., 2017). There are currently no alternative vaccinations recommended for obese individuals, such as the highly immunogenic vaccine recommended
for elderly population (Ng et al., 2019). Since HAI titers wane more quickly in the obese
population, using these high-dose vaccines may boost the antibody response and provide
greater, longer-lasting protection (Sheridan, Paich, Handy, Karlsson, Hudgens, et al., 2012;
Neidich et al., 2017). However, using higher dose and adjuvanted vaccines did not boost
immunity in mouse models (Karlsson, Hertz, et al., 2016). Continued studies on vaccine
dosage and formulation are required to mitigate the increased IAV infection rates seen in
the obese population.
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Antiviral interventions and obesity

Mitigation of influenza infection relies on prompt administration of potent antiviral drugs.
However, due to influenza virus’s inherent mutability, continual development of antivirals
is needed as historically, influenza has rapidly gained resistance to all marketed drugs
(Naesens, Stevaert, and Vanderlinden, 2016; Shin and Seong, 2019). Currently recommended drugs are the neuraminidase inhibitors oseltamivir (Tamiflu), zanamivir (Relenza)
and peramivir (Rapivab) and the endonuclease inhibitor baloxavir marboxil (Xofluza),
with several others in late-phase clinical (Koszalka, Tilmanis, and Hurt, 2017). The amantadines (Rimantadine) are no longer recommended because of the high resistance in contemporary circulating IAV strains (Lehnert et al., 2016; Naesens, Stevaert, and Vanderlinden, 2016). Although these drugs show promise in reducing total influenza symptoms,
few have been empirically tested for efficacy in obese populations.
Interestingly, reports of increased disease severity due to obesity during the 2009
H1N1 pandemic may have spurred clinicians to prescribe antivirals earlier, therefore preventing additional burden of severe disease (Segaloff et al., 2018). However, more studies are warranted to understand how effective our current antivirals are at reaching the
infected tissue and protecting obese populations from severe disease and whether the increasing reports of poor antiviral efficacy are due in part to the increasing obese population
(Jefferson et al., 2014). A comparison of the pharmacokinetics of oseltamivir showed that
obese humans clear the drug more quickly than do non-obese patients, but this increase
in the clearance rate was small with potentially insignificant biological impact (Jittamala
et al., 2014; Chairat et al., 2016). These reports suggest that dose adjustment for obese patients is not necessary from a pharmacokinetic perspective, but the question remains as to
whether the dosage is appropriate to control viral replication (Ariano et al., 2010; Pai and
Lodise, 2011). The protective capacity of early antiviral administration is highlighted in
obese mice. In a study with DIO and OB mice, O’Brien et al preemptively administered
doses of 20 mg or 100 mg of oseltamivir carboxylate to mice 8 h before infection, with
repeat doses administered every 12 hours. for 5 days (O’Brien et al., 2012). The 100 mg
dose completely protected both DIO and OB mice, whereas the 20 mg dose increased survival from 20% to 80% and mitigated lung pathology (O’Brien et al., 2012). However, it is
unknown how p.i. treatment with neuraminidase inhibitors will reduce viral spread and
development of severe sequalae in the obese host.
Conversely, baloxavir marboxil, the novel endonuclease inhibitor FDA-approved
for influenza treatment in 2018, does require dose adjustment based on weight. Those
patients over 80 kg receive double the dose as those under 80 kg (T. Yang, 2019). Due to
its long half-life, only a single dose is warranted, unlike prescribed course of oseltamivir
(Koshimichi et al., 2018). However, like the other classes of drugs, antiviral resistant variants have quickly emerged upon treatment in late-phase clinical trials (Hayden et al., 2018;
Omoto et al., 2018). No studies have interrogated if baloxavir treatment requires doseadjustment based on BMI and not just weight.
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Obesity and Other Viral Pathogens

Influenza is not unique in its impact on the obese host. Obese adults also suffer disproportionate hospitalizations for other respiratory viruses. Adults with obesity class II had
a 2.78x higher risk of hospitalization upon infection with seasonal coronaviruses, metapneumovirus, parainfluenza virus, and rhinoviruses compared to healthy weight adults
(Moser et al., 2019). This is also true for other viral and bacterial infections, including hepatitis C virus (Lo Iacono et al., 2007; Delgado-Borrego et al., 2010), urinary tract infections
(Semins et al., 2012), plus nosocomial and surgical infections including sepsis (Dowsey
and Choong, 2009; Linam et al., 2009; Waisbren et al., 2010; X. Wang et al., 2019). Even
parasitic infections show a documented increase in severity in obese hosts (Martins et al.,
2020). More recently, the emergence of severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) and the associated disease, COVID-19, has shed new light on the contribution of obesity to susceptibility and severity of infection. As of the 1st of October,
2020, the COVID-19 pandemic has resulted in over 30 million documented infections and
over 1 million lives lost. The clear inequality in infection burden has again brought obesity’s preeminent threat to the forefront of public health. Mirroring findings from the 2009
H1N1 influenza pandemic, obesity is a risk factor for hospitalization, severity of disease,
and mortality upon infection with SARS-CoV-2. The first widespread community acquisition of SARS-CoV-2 in the United States occurred in Washington state and reports quickly
outlined the majority of patients presented with 3 or more comorbidities, with obesity
implicated in nearly half of cases (Buckner et al., 2020). In New York City’s first wave
of SARS-CoV-2 infections, those under 60 with obesity I had a 2.0 times greater odds of
admission to the hospital compared to discharge, with odds even greater for those with
obesity class II or greater (OR=2.2, CI=1.7-2.9) (Lighter et al., 2020). These findings are
echoed in cohorts worldwide. In a retrospective study centered in France, the prevalence
of obesity was 1.35 times higher in hospitalized patients compared to the general public
(CI 1.08–1.66, p=0.0034) (Caussy, Wallet, et al., 2020). Finally, obesity is associated with
a longer median hospital stay of 23 (IQR=17-30) versus 18 (IQR=13-24) days (Gao et al.,
2020).
Upon hospitalization, obese patients are also more likely to need intensive care.
Obesity’s prevalence is significantly higher in severe and critical COVID-19 cases compared to the general public, and also higher compared to non-COVID-19 intensive care
patients (Caussy, Wallet, et al., 2020; Caussy, Pattou, et al., 2020). BMI, albeit an imperfect
measure of health, is also a predictor of disease severity. Obese patients were found to
have a 2.91 greater odds of severe or critical disease severity compared to non-obese cases
in a case-controlled adult cohort centered in three Chinese hospitals (Gao et al., 2020).
The need for IMV is positively associated with BMI. Of those admitted to intensive care
units, less than half of lean patients needed IMV, with percentages moving to 63.5, 59.5,
and 81.8 for those overweight (BMI 25-30), obesity class I, and obesity class II+, respectively (Caussy, Wallet, et al., 2020; Simonnet et al., 2020). Strikingly, patients with obesity
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class II endured a 7.36 greater odds of requiring IMV—itself a strong predictor of mortality—compared to lean counterparts (Simonnet et al., 2020). Preliminary retrospective
analyses suggest class II obesity is a predictor of mortality (OR=3.78, 1.45-9.83), but additional investigation is needed (Palaidiomos et al., 2020). The double threat of a viral and
obesity pandemic is daunting. However, the advances made in understanding the molecular consequences of obesity and other metabolic disorders in the context of influenza will
undoubtedly translate to our new viral foe, SARS-CoV-2. Links between metabolic and
infection response molecular signaling pathways and the generation of ROS have already
been suggested as potential mechanisms behind this increased severity (Codo et al., 2020;
Rebello, Kirwan, and Greenway, 2020). Initial reports also suggest the expression of the
SARS-CoV-2 receptor (angiotensin converting enzyme-2, or ACE-2) is significantly higher
in overweight compared to lean bronchial sections (Highman and Singh, 2020), warranting
further empirical studies on the cellular consequences of obesity and SARS-CoV-2 (Barton
et al., 2020).

2.8

Implications

As the number of people living with one or more co-morbidity continues to increase,
the role of host factors in influenza virus pathogenesis becomes ever more important
(Figure 2.1). Curbing the obesity epidemic will not only improve the quality of life for
those millions of people directly affected; it will also dampen the impact of obesity on
infectious disease (Erbelding et al., 2018; Henry et al., 2018). Differing influenza pathogenesis in comorbid states and across the lifespan highlights the need for a carefully controlled
and appropriately timed immune response in order to clear the virus and maintain airway
integrity. Continued studies of the mechanistic interactions between the lung epithelia,
resident and circulating immune cells, and influenza virus will aid in the understanding
of influenza pathogenesis and, potentially, in the development of novel therapeutics for
obese and other high-risk populations. Interventions such as weight loss programs, diet
change, and exercise are the first-line of defense against the obesity epidemic, yet few studies have examined whether these interventions will improve antiviral outcomes in obese
patients (Warren et al., 2015; Kosaraju et al., 2017; Rebeles et al., 2019). Modeling the collective knowledge assembled from obese mouse models, ex vivo human systems, and studies
conducted in human cohorts may help generate new hypotheses to explain the increased
disease severity and reduced immune response in obese humans. By bridging work done
in virology, immunology, physiology, and metabolism, researchers can gain a holistic view
of how obesity affects everything from the systemic immune response to localized events
in viral life cycle within respiratory epithelial cells.
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Chapter 3
Influence of Nutrition on Viral Evolution1

3.1

Introduction

Humans and our hominid predecessors have co-existed and have co-evolved with viral
pathogens for hundreds of thousands if not millions of years (Sharp and Simmonds, 2011;
Van Blerkom, 2003; Enard and Petrov, 2018). Our actions have directly influenced viral
emergence, evolution, and spread (Findlater and Bogoch, 2018; Voskarides, Christaki, and
Nikolopoulos, 2018). However, contemporary humans exist in a vastly different—and
largely obesogenic—environment than did our ancestors. The pervasiveness of the Western diet and disparities in food access and security have altered how we as hosts interact with our viral pathogens. It is well known the implications of malnutrition on host
immune responses, but can nutrition actively shape how viruses evolve? Globally, both
obesity and nutrient deficiencies are increasing their incidence (Eggersdorfer et al., 2016),
forcing revision of our understanding of how viruses, including the seasonal and pandemic threat of influenza, evolve within their hosts.
Influenza is a significant burden on public health. Yearly, millions of influenza cases
are recorded worldwide, resulting in estimates of up to 600,000 deaths (V. J. Lee et al., 2018;
W. W. Thompson et al., 2009; Nair et al., 2011). The great proportion of the resulting morbidity is suffered by at-risk populations such as the aged, young, immunocompromised,
and malnourished. Comorbidities, sex, and age not only impact the host but can also
1 Portions of chapter from previously published articles. Modified: From final submission with open access
permission. Honce R, Schultz-Cherry S. They are what you eat: Shaping of viral populations through nutrition
and consequences for virulence. PLoS Pathog. 2020 Aug;16(8):e1008711. DOI: 10.1371/journal.ppat.1008711.
Modified: From final submission with open access permission. Honce, R. and S. Schultz-Cherry (2019a).
“Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and Evolution”. eng. In: Front Immunol 10, p. 1071. ISSN: 1664-3224 (Electronic) 1664-3224 (Linking). DOI: 10.3389/fimmu.2019.01071. Modified: From final submission with permission from Oxford University Press. Honce, R. and S. Schultz-Cherry.
(May 2019b). “Influenza in obese travellers: increased risk and complications, decreased vaccine effectiveness”. In: J Travel Med 26.3. ISSN: 1708-8305 (Electronic) 1195-1982 (Linking). DOI: 10.1093/jtm/taz020.
Modified: From final submission with permission from Cold Spring Harbor Laboratory Press. Honce, R., N.
Wohlgemuth, et al. (Dec.2019). “Influenza in High-Risk Hosts-Lessons Learned from Animal Models”. In:
Cold Spring Harb Perspect Med. ISSN: 2157-1422 (Electronic) 2157-1422 (Linking). DOI: 10.1101/cshperspect.a038604.
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impact the virus itself. In review of human-origin influenza sequences deposited to the
Influenza Research Database (FluDB) with host metadata, high-risk groups generally harbored higher numbers of single nucleotide polymorphisms (SNPs) within the influenza
genome (Figure 3.1, Y. Zhang et al., 2017; H. K. Nelson et al., 2001; Engels et al., 2017.
The appearance of IAV minor variants within the individual host is concordant with
the eventual emergence of the same variants in global circulation (Xue, Stevens-Ayers, et
al., 2017). Certain variants may contribute to antiviral resistance, vaccine escape, and/or
enhanced transmission phenotypes. Aside from this constant genetic and antigenic drift,
influenza’s segmented genome allows for rapid antigenic shifts through shuffling of gene
segments in coinfected cells, termed reassortment. The effect of highly susceptible obese
hosts to infection, co-infection, or the generation of novel viral variants within obese is an
urgent need for study, as they will undoubtedly impact influenza evolution and the burden
of disease on the entire population (Xue, Stevens-Ayers, et al., 2017; J. Holland et al., 1982;
A. J. Te Velthuis and Fodor, 2016; Joseph et al., 2017).

Figure 3.1: Increased diversity in viruses derived from high-risk hosts.
Human infection samples with clinical metadata was stratified by various
high-risk groups including (A) comorbid state of obesity or diabetes
mellitus, other comorbidity, or healthy adult with no listed comorbidities,
(B) sex, and (C) age range on presentation of symptoms from 18-34, 35-50,
or 51-65. Data analyzed first for normality using Kolmogorov-Smirnov
test, then for differences in SNPs using a Kruskal-Wallis test in (A, C) and
Mann-Whitney in (B) with *p<0.05. Data curated by Sarah Sidak.
Data source: Zhang, Y. et al. (Jan. 2017). “Influenza Research Database: An
integrated bioinformatics resource for influenza virus research”. In:
Nucleic Acids Res 45.D1, pp. D466–D474.ISSN: 1362-4962 (Electronic)
0305-1048 (Linking). DOI: 10.1093/nar/gkw857. Database accessed on 28
March 2019.
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Influenza Evolution and Population Diversity

Diversity in RNA viruses can stem from the single-nucleotide variants (SNVs) that comprise the quasispecies, but also from minor variants that are selected to fixation and alter
the consensus sequence, segment swaps, and as higher-level changes such as incomplete
virion packaging and generation of defective viral genomes (DVGs) (Figure 3.2, J. Holland
et al., 1982). These multi-level changes in viral diversity are observed in influenza virus.
As a segmented RNA virus, influenza virus can display diversity at the nucleotide and
genome segment levels. Single nucleotide variants contribute to the gradual genetic drift
responsible for outdating vaccines each year, while reassortment of the genome segments
causes genetic shifts that may shepherd a new pandemic strain into human circulation
(Joseph et al., 2017). Further, the generation of DVGs has implications for influenza viral
replication, disease severity, and immune recognition (J. Holland et al., 1982; Vasilijevic
et al., 2017).

3.2.1

Viral drift, quasispecies, and SNVs

First theorized over four decades ago (Epstein and Eigen, 1979), a quasispecies population
structure has been documented in plant, animal, and human pathogens (Duarte et al., 1994;
Kattenbelt et al., 2010; Arenas et al., 2004). A viral quasispecies describes the mutant but
related genomes that collectively infect, replicate, and spread among hosts. Traditionally,
the theory has been applied to RNA viruses. Due to their short generation times, small
genomes, and the inherent lack of proofreading in most RNA replication—with a notable
exception being the Coronaviridae family—single nucleotide variants (SNVs) emerge at a
rate of roughly 103 to 107 more mutations per nucleotide copied compared to DNA viruses
(Domingo and J. J. Holland, 1997). Confusingly, population diversity, quasispecies, and
viral drift are often used interchangeably when discussing RNA viral evolution. Quasispecies dynamics is the evolutionary theory behind a continuous flux of mutations into
and out of the viral population due to processes of mutation and selection. However, quasispecies is often used as a descriptor for the viral population diversity. Here, the term
population diversity is favored when describing the genetic make-up of the viruses discussed and use of quasispecies is for broader, more conceptual arguments on the impacts
of genetic diversity on viral evolution and virulence.
Non-synonymous SNVs are continuously accrued and purged from viral genomes.
This flux generates a related “swarm” of viruses which have little effect on the consensus
sequence but may show phenotypic differences. Mutations with phenotypic consequences
are generally deleterious; very few mutations have any fitness benefit (Visher et al., 2016).
However, if beneficial mutations arise, they may relate to host range, drug resistance or
vaccine escape, and replicative capacity (Domingo, Sheldon, and Perales, 2012; Wasik et
al., 2016). Both beneficial and the common deleterious mutations balance the structure of
the viral swarm through complementation, interference, and cooperation (Garcia-Arriaza
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Figure 3.2: Variation in segmented RNA viruses.
Host effects on viral evolution could relate to individual SNVs and
antigenic drift, segment-level reassortments and antigenic shift, or to
packaging differences and generation of defective viral genomes. (A)
Influenza virus, thanks to its error-prone RNA-dependent RNA
polymerase, generates “mistakes” during replication that may accumulate
in the genome and gradually causes antigenic drift of the virus. (B) As a
segmented virus, co-infection of a single organism may lead to segment
swapping and the generation of a reassortant virus. (C) Incomplete
packaging or polymerase “skipping” during replication can lead to
defective viral genomes.

et al., 2004; Vignuzzi et al., 2006; Koelle and Rasmussen, 2015). Within a single host, tissuespecific subpopulations may vary in virulence without affecting consensus sequence or
phenotype (Sanz-Ramos et al., 2008; Pfeiffer and Kirkegaard, 2006). Importantly, the consensus sequence should not be considered the “fittest sequence,” as selection, competition,
and genetic drift act upon the entire viral swarm. Therefore, fitness of the swarm often
exceeds clonal sequence fitness, highlighted by work in vesicular stomatitis virus (Duarte
et al., 1994) and bacteriophage systems (Domingo, Sabo, et al., 1978).
Viruses are obligate intracellular parasites and require a host cell to complete their
life cycle. Barriers to replication exist within and between susceptible hosts which restrict viral population diversity to quell infections (Pfeiffer and Kirkegaard, 2006). In
these wide-ranging environments, a heterogeneous viral swarm containing with differing abilities to infect, transmit, and survive environmental and immunological onslaughts
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may safeguard viral existence. However, this genetic plasticity has bounds with a middle
ground between high- and low-fidelity replication evolutionarily beneficial (Braun et al.,
2019; Delgado-Eckert, Ojosnegros, and Beerenwinkel, 2011). The “goldilocks” approach
maximizes fitness by avoiding lethal mutagenesis while ensuring amenability to selective
pressures (Lancaster and Pfeiffer, 2012). Too low fidelity leads to error catastrophe and collapse of the viral population; conversely, a highly clonal population may be extinguished
by host defenses (Ruiz-Jarabo et al., 2003; Zeng et al., 2014; Fitzsimmons et al., 2018; Pfeiffer and Kirkegaard, 2005)).
Numerous theories have questioned the biological relevance of a quasispecies and
challenge its significance in describing the evolution of RNA viruses (Lancaster and Pfeiffer, 2012; Holmes and Moya, 2002). However, boosting genetic diversity—to a point—is
theorized to increase virulence for a viral population. A viral swarm is hypothesized to be
better equipped in facing bottlenecks imposed by infecting hosts, environmental persistence, and transmission. Even within a single host, blockades due to infection barriers and
the immune response diminish sequence variation, leaving a relatively homogenous population until replicative errors replenish the mutant pool (Pfeiffer and Kirkegaard, 2006). In
studies with classical swine fever virus, higher genetic diversity correlated with virulence
(Topfer et al., 2013); however, this conclusion has been challenged (Jenckel et al., 2017). In
other animal viruses, diversity increases precede the selection of virulent genomes (Kattenbelt et al., 2010). Parallel conclusions have been made for human pathogens. In hepatitis C
virus (HCV)-positive patients, high viral diversity prior to transplantation correlated with
higher liver fibrotic scoring 1-year post-transplantation (Arenas et al., 2004). Continued
genetic evolution of HCV correlated with progressing hepatitis, whereas resolution was
associated with genetic stasis of HCV population (Farci et al., 2000; Honda et al., 1994). A
model low-fidelity RNA-dependent RNA polymerase (RdRp) poliovirus variant demonstrates increasing genetic diversity may not always yield fit populations (Vignuzzi et al.,
2006; Korboukh et al., 2014), yet high-fidelity RdRp mutants producing nearly clonal populations display reduced fitness in vivo (Pfeiffer and Kirkegaard, 2005).
Conversely, other viruses have shown a discordant trend between replication fidelity and population diversity. Chikungunya viruses (CHIKV) engineered with highfidelity polymerases produce a more genetically diverse and more virulent quasispecies
compared to wild-type and low-fidelity variants (Riemersma et al., 2019). However, increases in CHIKV genetic diversity through in vitro experimental evolution through vertebrate or invertebrate cell types correlated with greater viral adaptability and replicative
fitness. suggesting the correlation between population diversity and viral virulence is context dependent and diversification of the population can easily manipulate other facets of
viral pathogenesis (Coffey, Beeharry, et al., 2011; Coffey and Vignuzzi, 2011).
Influenza is notoriously a highly diverse pathogen on the genetic and antigenic
scale—a major reason why our yearly vaccines are quickly outdated. When comparing
genetic diversity among the human influenza species, subtypes and strains, IAV harbors
greater within-host diversity than IBV, and within IAV, contemporary H3N2 strains show
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higher genetic entropy than for pdmH1N1/2009 isolates (Figure 3.3, Valesano et al., 2020;
Poon et al., 2016; Neher and Bedford, 2015; Hadfield et al., 2018). Adaptation of influenza
viruses to distinct host species, as modeled through in vitro infections in various speciesdistinct cell lines, can alter both genetic composition and glycosylation patterns, most notable in their impacts on vaccine production (Roedig et al., 2011; Nakamura et al., 2019;
Geoghegan, Senior, and Holmes, 2016).
The genetic plasticity of influenza viruses renders our yearly vaccines ineffective,
can lead to antiviral resistance, and may be associated with more severe disease, leaving our population at risk of severe influenza disease (T. C. Li, Chan, and N. Lee, 2015;
McKimm-Breschkin, 2013; Vries et al., 2013). Within- and between-host estimates of genetic diversity are dependent on the often-narrow bottlenecks imposed upon the “stick,
spread, stick again” life history of respiratory-transmitted viruses. Estimates range from a

Figure 3.3: Antigenic advances in influenza viral strain sequences over
one decade.
Radial phylogenies of influenza A viral strains H1N1 and H3N2 as well as
influenza B viral lineages Victoria and Yamagata were created. Color
variation indicates antigenically distinct isolates with cooler shades being
more ancestral. Estimates of mutation frequency are as follows: H1N1,
3.45x10-3 substitutions/year; H3N2 3.37x10-3 substitutions/year;
B/Victoria 1.5x10-3 substitutions/year; and B/Yamagata 1.98x10-3
substitutions/year.
Data source: Individual “Seasonal Influenza Radial Trees” by nextstrain
and used under CC BY 4.0 with labels added and composite constructed by
the author. Neher, R. A. and T. Bedford (Nov. 2015). “nextflu: real-time
tracking of seasonal influenzavirus evolution in humans”. In:
Bioinformatics. 31.21, pp. 3546–8.ISSN: 1367-4811 (Electronic) 1367-4803
(Linking). DOI: 10.1093/bioinformatics/btv381. Database accessed 14
February 2020.
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median of 3 to 250 variants per viral genome and are constantly refined as newer sequencing and bioinformatics tools become available (Poon et al., 2016; Xue, Moncla, et al., 2018;
Xue and Bloom, 2019). Stochastic processes are hypothesized to be the predominant evolutionary process at work within the human host infected with influenza virus, typically
yielding few novel variants within a single host (McCrone et al., 2018). While only a few
novel variants at varying frequencies may arise, they can be transmitted dependent on the
bottleneck size (Zwart and Elena, 2015). Larger bottlenecks may transmit greater variants
and lead to the spread of novel variants through a population (Xue, Stevens-Ayers, et al.,
2017; Xue and Bloom, 2020). Importantly, the route of transmission as well as the host have
impacts on this bottleneck and can thus influence the variants transmitted (Varble et al.,
2014).

3.2.2

Reassortment and viral shift

As a segmented virus, genetic shift also occurs in influenza and often introduces an antigenically distinct virus with pandemic potential into human circulation (G. J. Smith, Bahl,
et al., 2009; G. J. Smith, Vijaykrishna, et al., 2009). In humans, IAV and IBV cause most seasonal infections, with IAV the cause of regular pandemics often due to zoonotic spillover.
Influenza C virus sporadically causes infections in children, while influenza D virus has
only been documented in cattle (Krammer et al., 2018; Yoon, Webby, and Webster, 2014).
For IAV, there 16 hemagglutinin (HA) and 9 neuraminidase (NA) subtypes have been documented in wild avian species, two each HA and NA in bats, but only 3 HA and 2 NA subtypes have been documented to spread human to human with H5N1, H7N9, and H9N2
viruses also causing sporadic zoonotic infections (Wille and Holmes, 2020).
Aside from the antigenic HA and NA surface proteins and the structural matrix proteins (gene segments M1 and M2), internal proteins including the polymerase (encoded by
the PB1, PB2, and PA gene segments), nucleoprotein (NP), and non-structural proteins
(NS1, NEP) are also able to reassort and generate a novel influenza strain. These reassortments can occur within- and across species (Wille and Holmes, 2020). For example,
the 2009 H1N1 “swine flu” pandemic was caused by a novel H1N1 strain comprised of
reassortment among the “triple reassortant” virus and a Eurasian swine virus (Garten et
al., 2009). The pandemic virus comprised Eurasian avian-like swine NA and M segments,
North American avian-origin PB2 and PA segments, human H3N2 origin PB1 segment,
and classical swine origin HA, NP and NS segments (Neumann, Noda, and Kawaoka,
2009).
Viral reassortment is first and foremost constrained by co-infection. Two or more influenza viruses must not only infect the same host at near the same time, but also coinfect
the same cell within that host as to allow packaging of a reassortant progeny virus. The
likelihood of either two independent transmission events with distinct viruses or a single
transmission event from an already co-infected host is quite low, as empirical studies in
guinea pigs and ferrets have shown very few variants are transmitted between wild-type
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hosts and the inherent mutation rate within wild-type hosts is accordingly low as well
(Xue, Moncla, et al., 2018; Tao, Steel, and Lowen, 2014; Sobel Leonard et al., 2016). However, upon co-transmission of distinct viral strains, co-infection of individual cells within
a host is fairly common (Tao, Steel, and Lowen, 2014).
Cellular co-infection is also constrained by the host immune response. Upon infection, host cells release antiviral proteins, namely interferon (IFN), that induces an antiviral
state which seeks to quell the primary infection and often effectively blocks a secondary
infection. Pre-existing immunity to seasonal influenza viruses limits co-infection. Importantly, this centers timing as a constraint to co-infection as well. If secondary infection
occurs too soon after primary infection, the co-infection rate may be low because of the
few cells initially infected and the subsequent induction of the immune response prohibiting further assault. After the primary infection, allowing for a single round of replication
and spread in vitro allows for a greater number of cells to be infected with the primary
virus through viral spread as well as the newly infected cells still being non-refractory
to further infection with a secondary virus as their IFN-based defenses had not yet been
engaged (Marshall et al., 2013). The timing of co-infection is also important to ensure viral life cycles “link up” and progeny virions package genomes and proteins from both
parental viruses, leading to an estimated “window of reassortment” of about 18 hours
post-primary infection in animal models (Marshall et al., 2013). Just as with the majority
of SNVs and amino acid mutations, reassortment often imposes a fitness cost on the resulting viral progeny but can give fitness benefits (Phipps et al., 2017; Muller et al., 2020;
Villa and Lassig, 2017). This further constrains the reassorted progeny virus, especially
those from antigenically distinct parental viruses, as often times it is less fit and is less
efficient in replication than the parental strains leading to extinction (Phipps et al., 2017;
Hause et al., 2012). Differences in packaging signal sequences can restrict the reassortment
between distinct influenza viruses but can even enable experimental intertypic reassortment between IAV and IBV (Essere et al., 2013; Baker et al., 2014). Other characteristics
of influenza viruses, such as polymerase subunit compatibility, balance of HA and NA on
the surface, and segment mismatches all also play a role in the production of reassortant
progeny (Naffakh et al., 2000; Wagner, Matrosovich, and Klenk, 2002; Cline, Karlsson, Freiden, et al., 2011; Jackson et al., 2009). Finally, an active area of study is the contribution of
incomplete viral genomes on reassortment (Fonville et al., 2015).
Host effects on reassortment are an emerging field. Current in vivo models of transmission and reassortment rely on “wild-type” animals with limited host status diversity,
such as guinea pig and ferrets. However, surveillance data has shown that limited host immunity and host ecology can modulate the rate of viral reassortment (Fabrizio et al., 2016).
A lack of pre-existing immunity and its effects on reassortment is modeled in surveillance
of swine in North America. Since most farmed swine are slaughtered early in life, they do
not have a robust infection history and thus, are more susceptible to co-transmission and
co-infection of distinct influenza strains, leading to the high genetic diversification through
reassortment in swine-origin influenza viruses (M. I. Nelson et al., 2012; Vijaykrishna et al.,
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2011). While co-transmission events may be somewhat rare in humans, hosts with compromised immunity or a dearth of pre-existing immunity may be particularly vulnerable
to generating a novel reassortant virus.

3.2.3

Defective viral genomes and interfering particles

Finally, differences in viral replication may alter the characteristics and even the pathogenesis of a within-host viral population. The description of “defective” particles, also known
as DVGs and defective interfering particles (DIPs) in the context of influenza virus, are
virions incapable of replication on their own due to large internal deletions in one or more
of their required gene segments.
In the context of Sendai virus (SeV) and respiratory syncytial virus (RSV), copy-back
DVGs are potent stimulators of the type I IFN response by activating crucial transcription
factors (Tapia et al., 2013; Y. Sun, Jain, et al., 2015). Influenza virus also commonly produces DVGs in human infections (M. A. Martin et al., 2019). Importantly, this has real
impacts on disease severity, as reduced accumulation of these defective viruses has been
associated with severe or fatal in patients infected with influenza virus, as compared to
patients with mild pathogenesis, possibly as these non-replicating RNAs can still agonize
innate immune responses and contribute to immunity (A. J. W. Te Velthuis et al., 2018;
Vasilijevic et al., 2017).
Little is known of how the host may influence DVG and DIP formation or if their
formation is beneficial to the viral population. DIPs are sensitive to the multiplicity of infection (MOI); at higher MOIs, they readily are produced as their “defects” can be complemented by intact virions (Garcia-Arriaza et al., 2004). This process may be an unavoidable
“side effect” of rapid, error-prone RNA-dependent replication, or actually be of benefit
to the virus (Fitzsimmons et al., 2018; Xu et al., 2017). In paramyxoviruses, it is suggested
that DVGs can enhance viral persistence, so there may be more viral benefits to this process
than we currently know (Xu et al., 2017).

3.3

Nutritional Status and Viral Evolution

The immunological status of the host has been implicated in shaping the viral quasispecies
of dengue virus (Parameswaran et al., 2017), norovirus (Vega et al., 2014), influenza virus
(Chaudhry et al., 2016), and coronavirus (Kleine-Weber et al., 2019) infections, among others. Classic examples of host characteristics that attenuate the immune response are also
implicated in shaping the quasispecies and influencing virulence, including aging (Gay
et al., 2006) and immunocompromised status (Vries et al., 2013; Chaudhry et al., 2016;
Roosenhoff et al., 2018). However, we must take a step back to question if host characteristics that alter the immune response can also shape the viral quasispecies. Nutritional
status has been implicated in altering within-host viral evolution and has been shown
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to increase susceptibility to infection, extend infection duration, delay clearance, and increase shedding, all of which potentially increase viral transmission and may prolong the
effects of within-host pressures on the viral population (H. K. Nelson et al., 2001; Domingo
and J. J. Holland, 1997; Maier, Lopez, et al., 2018). Interestingly, host nutritional status
has also been linked to the emergence of novel viral variants and vaccine escape mutants
in influenza, coxsackievirus, and hepatitis C virus populations (Zhu, X. Liu, et al., 2016;
Zhu, Y. Wang, et al., 2016; Beck, Shi, et al., 1996; H. K. Nelson et al., 2001). However, few
studies have specifically interrogated how the obesogenic environment may modulate the
influenza viral population.
The analysis of infections with multiple variants, the rate of reassortment, and the
within-host evolutionary dynamics are areas in which the impact of obesity is poorly understood. Identifying not only the mechanisms by which influenza affects the obese host,
but also how the obesogenic state may directly affect influenza itself must be defined. The
increased viral spread but similar viral load observed in obese hosts as compared to lean
hosts may highlight how infection of different cell types or the individual viral load within
single cells can impact the cooperative and competitive dynamics within the quasispecies
(Xue, Stevens-Ayers, et al., 2017; A. B. Russell, Trapnell, and Bloom, 2018).

3.3.1

Prolonged infections and within-host evolution

Varying pathogenesis can also alter the within-host evolutionary pressures on a pathogen.
Extended infections provide additional rounds of replication wherein potentially more
mutations can be accrued. Further, protracted infections also draw out the pressures of
host immunity and may lead to novel antigenic variants. While it is argued that prolonged infections are seldom the source of variants that go on to dominate global circulation (Eden et al., 2017), there is evidence that extended infections in immunocompromised
hosts can generate novel variants that may be resistant to treatment options. Extended
infections in immunocompromised hosts have even been hypothesized as reservoirs for
novel norovirus variants (Vega et al., 2014; Steyer et al., 2018).
Ferrets that were experimentally treated with a cocktail of immunosuppressants
prior to infection with H3N2 virus showed greater and extended viral shed (Vries et al.,
2013; Roosenhoff et al., 2018). Upon treatment with the neuraminidase inhibitor oseltamivir,
viral shed was slightly reduced but did coincide with the emergence of a NAI-resistant
substitution (Vries et al., 2013). This same phenotype was uncovered in human epidemiological data, wherein patients with extended viral shed, even upon antiviral treatment,
continued to shed virus and eventually shed antiviral resistant isolates (Vries et al., 2013;
Chaudhry et al., 2016; Roosenhoff et al., 2018).
The infectious period of influenza is prolonged in hosts with obesity, which potentially leads to greater transmission events as well as an extended time in which influenza
virus is subjected to host immune pressures. Obese patients hospitalized with severe influenza disease are burdened with higher peak viral loads and delayed viral clearance
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when compared to non-obese patients (B. Wang et al., 2017; To et al., 2010). In mouse models, several studies have shown that wild-type animals clear IAV infection earlier than do
obese (Karlsson, V. A. Meliopoulos, Velde, et al., 2017; V. Meliopoulos et al., 2019). In the
DB model, clearance of IAV was impaired in global leptin receptor knockout mice but not
in animals in which leptin was conditionally knocked out of lung epithelial cells, suggesting that immune-epithelial cell interactions are required for swift viral clearance and are
impaired in the obese host (Radigan et al., 2014).
Two studies have extended the findings in obese mouse models to humans by identifying high BMI as increasing the duration and quantity viral shedding. Maier et al found
that viral shedding is prolonged in obese adults. In their cohort of adults in Managua,
Nicaragua, IAV shedding in symptomatic obese adults lasted nearly 50% as long than in
symptomatic lean counterparts. In obese adults with no symptoms or only a single symptom of active IAV infection, virus shedding lasted over 104% longer than in lean adults
with similar symptoms (Maier, Lopez, et al., 2018). No association between BMI and duration of viral shed was found for children or adolescents, or with IBV (Maier, Lopez, et al.,
2018). In a study of college-aged adults in Maryland, USA, Yan et al. found viral RNA in
exhaled breath correlated positively with BMI, suggesting increased viral load and viral
shedding in humans with obesity (Yan et al., 2018). These hypotheses are corroborated by
mouse studies. While at peak infection there may be no difference in viral titer, at later
timepoints OB mice show higher viral loads versus WT mice (Karlsson, V. A. Meliopoulos,
Velde, et al., 2017; V. Meliopoulos et al., 2019). With a potential increased length of disease, due largely to the blunted immune responses, there may also be an increased time
for emergence of virulent mutations.

3.3.2

Viral evolution in malnourished hosts

Globally, 1 in 9 people are undernourished and 1 in 3 are overweight or obese, with innumerable others suffering from micronutrient deficiencies (2020 Global Nutrtion Report:
Action on equity to end malnutrition 2020). Consequently, it is of utmost importance to understand if host nutrition actively shapes how viruses evolve as many hosts do not mirror
the actively studied “wild-type” condition. Not only do nutritional deficiencies or nutritional excesses increase the risk of infection and of serious adverse events (Flanigan and
Sprunt, 1956; A. K. Taylor et al., 2013; Weger-Lucarelli, Auerswald, et al., 2018; Karlsson
and Beck, 2010), but can also drive increased virulence of the infecting pathogen (Domingo
and J. J. Holland, 1997). Previous work has identified micronutrient deficiencies which
may increase pathogen virulence through acquisition of minor variants. In mineral- and
vitamin-deficient mice, genetic mutations arise in coxsackie B and influenza virus populations that promote virulence even in well-nourished hosts (H. K. Nelson et al., 2001; Beck,
H. K. Nelson, et al., 2001; Beck, Shi, et al., 1996; Beck, Handy, and Levander, 2004).
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Interestingly, arbovirus-infected obese or protein-deficient mice showed higher morbidity but lower viral diversity, and both malnourished models transmitted virus less efficiently. While both under- and over-nourished mice suffered greater morbidity upon infection with CHIKV, Mayaro virus (MAYV), and Ross River virus akin to many arboviruses
(Weger-Lucarelli, Auerswald, et al., 2018; Weger-Lucarelli, Carrau, et al., 2019), MAYV
isolated from obese and protein-deficient mice had reduced diversity measured through
Shannon’s entropy and did not display changes in virulence or replicative fitness in vivo.
Interestingly, both obese and undernourished mice were less efficient in transmitting virus
during mosquito feeding (Weger-Lucarelli, Carrau, et al., 2019). These findings further
strengthen that the impacts of viral diversity on virulence and viral fitness is largely context dependent, as host-viral interactions can be unique to vertebrate or invertebrate host
species (Lancaster and Pfeiffer, 2012).
Undernourishment and obesity are two sides of the same coin, implicated in blunting immune responses and increasing susceptibility to infection (Maier, Kuan, et al., 2020;
Flanigan and Sprunt, 1956; A. K. Taylor et al., 2013). The dearth of host responses to
infection—particularly innate immunity—and the baseline malnourished state facilitates
greater viral replication, permits the diversification of the viral swarm, and potentially
allows for the emergence of advantageous mutations and may increase the likelihood of
cellular co-infection and thus generation of reassortant progeny viruses. Robust innate
immune responses restrict subsequent infection severity, possibly through reduced viral
replication and acquisition of a genetically diverse viral population (Wasik et al., 2016;
Fitzsimmons et al., 2018). Dietary metabolites also influence cellular metabolism and can
push the body to a state of meta-inflammation; this pro-oxidant environment may also directly influence the genetic composition of the viral population (A. D. Smith, Botero, and
Levander, 2008).
Nutritional excess or deficiency may dampen the host immune responses and alter cellular metabolism, indirectly fostering an advantageous environment for viruses to
explore the sequence space (Figure 3.4). Other indirect consequences of poor nutrition
may also be involved. Blunted immune responses may alter viral tropism and viral- or
immune-induced pathology, thus remodeling the microenvironment in which the virus
attacks the host. Also, nutrition is increasingly appreciated as an influence on the gut microbiome (Maruvada et al., 2017). Interestingly, perturbations to the microbiome—both
respiratory and gut—dampen IFN responses to respiratory virus infection (Steed et al.,
2017; Tomosada et al., 2013; Ichinohe et al., 2011). However, no empirical studies have yet
connected the obese microbiome to modulating enteric or respiratory viral populations.

3.3.3

Influenza evolution in obese hosts

Host nutritional status, akin to other forms of compromised immunity, has long been
known to impact viral pathogenesis and more recently, to impact the viral population,
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Figure 3.4: Facets of malnutrition that shape the viral population.
Nutritional status can alter the baseline state of host cells and the antiviral
response post-infection. These departures to healthy metabolism and
robust immunity may cultivate a pro-viral environment for increased
replication and perhaps permit acquisition of beneficial mutations due to
reduced selective pressures on the viral population. Other indirect effects
of malnutrition could also alter viral interactions with resident microbiota.
Finally, the ripple effects of over- and under-nutrition are systemic for the
host; however, nutrition status may have differing impacts for the virus
based on tissue tropism, route of transmission, and mode of pathology.

through reduced immune pressures and an altered cellular microenvironment (WegerLucarelli, Auerswald, et al., 2018; H. K. Nelson et al., 2001). However, evolutionary dynamics of influenza infection within a single host, whether human, animal models, or
reservoirs, is an emerging field and often neglects host variability (Xue, Stevens-Ayers, et
al., 2017). The extended infections and increased shed seen in obese human cohorts provides ample reason to investigate how the obese host may alter influenza evolution and
population dynamics, at the SNV, segment, and virion level (Maier, Lopez, et al., 2018; Yan
et al., 2018). The altered immune pressures and enhanced pathogenesis seen in hosts with
obesity undoubtedly has effects on the viral population. Increased viral spread, reduced
innate and adaptive pressures, altered cellular metabolism, and the potential for higher
MOI infections or spread outside the respiratory tract all could influence the composition
of the viral swarm either through increasing the likelihood of a novel variant being maintained in the population, increasing the rate of co-infection and therefore reassortment, or
even by modulating bottleneck sizes at transmission. The outcome of this needed research
may raise concerns that even a single infection of an obese host may alter the viral population, leading to heightened virulence or transmission properties that can affect the global
evolutionary patterns of influenza virus (Xue, Stevens-Ayers, et al., 2017).
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Discussion

Pathogen virulence and evolutionary dynamics are both complex interplays of host and
pathogen properties. Host nutritional status has long been considered a risk for infection susceptibility and severity and is now implicated in shaping viral evolution. Continued studies on the molecular consequences of obesity and malnutrition at the macro- and
micro-nutrient levels will reveal which host defenses are impaired through malnutrition
and how they control quasispecies development, antigenic drift, reassortment and viral
pathogenesis. Similarly, as we gain insight into how host status influences these processes,
we too can exploit these features as for host benefit (Moratorio et al., 2017; Ruiz-Jarabo
et al., 2003).
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Chapter 4
Materials and Methodology1

4.1

Rationale

This work builds upon previous knowledge using influenza viruses and mouse models
of obesity while extending the findings with the use of novel obese ferret and human primary epithelial cells. As outlined in Chapter 2, obesity has implications for the immune
response to infection, starting from the moment the virus is recognized by the host to the
generated memory responses upon viral clearance. Through use of the diet-induced and
genetically obese mouse models, the novel obese ferret model, and ex vivo models of the
human respiratory system, the effects of obesity on the early responses to infection, as
well as how the obesogenic environment may impact the invading pathogen itself, can be
quantified.
Influenza, a notoriously highly mutable and ever-present viral threat, serves as the
key virus of interest in this work. Here, most of the work is done using the 2009 H1N1
pandemic virus isolate, A/California/04/2009 (CA/09) virus, with other seasonal, pandemic, and zoonotic viruses serving to extend the findings. Influenza serves as a useful
model for both major arms of this research. First, influenza has been implicated in multiple epidemiological studies as a particular scourge on certain high-risk host populations,
including those with obesity (Van Kerkhove et al., 2011; Moser et al., 2019). This suggests
that empirical study of influenza in laboratory models of obesity could potentially illuminate a molecular mechanism behind this increased susceptibility to infection and severity
to disease. To accomplish this, animal models of obesity as well as ev vivo models of the
human respiratory epithelial are used to interrogate questions regarding attenuation of the
host immune response to influenza infection in obese hosts. Here, the use of diet-induced
and genetically obese mice strengthen the conclusion made, as both are valuable tools
in delineating the effects of adiposity on host antiviral responses and within-host evolution. Further, this work is extended to the novel obese ferret model developed within
1 Portions of chapter from previously published article. Modified: From final submission with open access
permission from American Society for Microbiology. Honce, R., E. A. Karlsson, et al. (Mar. 2020). “ObesityRelated Microenvironment Promotes Emergence of Virulent Influenza Virus Strains”. In: Mbio 11.2. ISSN:
2150-7511 (Electronic). DOI: 10.1128/mBio.03341-19.
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the Schultz-Cherry laboratory (Appendix A) and translated to humans through culture of
primary respiratory epithelial cells from donors at a variety of body mass indices.
Mouse models of obesity have been widely used in immunological and microbiological research. Here, I utilized both diet-induced and genetically obese models. Each
has their benefits and caveats. First, the diet-induced model better recapitulates the etiology of human obesity as it develops increased adiposity through "poor diet." Importantly,
diet composition can have drastic impacts on the metabolic state of the mouse (Lutz and
Woods, 2012). However, this is a time-intensive model. A minimum of 16 weeks is needed
to develop the obese phenotype. Different mouse strains display varying levels of susceptibility, and even complete resistance, to developing obesity. Second, the genetically obese
model is an attractive option as it develops obesity through ablation of the transduction
pathway that stimulates satiety via loss of the leptin hormone. These mice gain weight
rapidly through hyperphagia of rodent chow, reaching sizes of greater than 50 g at maturity. Weight gain continues for the life of the mouse, with weights of 80-90 g reached in
some studies. However, ablating the leptin signalling pathways has implications beyond
the feeding response. Leptin is a major player in the maturation of immune cell responses,
particularly important for macrophage and B cell development (Carbone, La Rocca, and
Matarese, 2012; Frasca, Diaz, Romero, and Blomberg, 2020).Thus, relying solely on the genetically obese model can confound the conclusions made. Using both the OB and DIO
model and comparing the experimental results can increase the robustness of the conclusions drawn.
The gold-standard model for influenza pathogenesis and transmission studies is
the ferret. Due to macro- and micro-anatomical similarities between the human and ferret respiratory tract, laboratory use of the ferret model has enabled greater understanding
of influenza, and other respiratory viral disease, pathogenesis, transmission, and vaccination responses. Crucially, ferrets are the best model for estimating viral transmission,
as they show similar vulnerability to the viral strains and subtypes that cause disease in
humans. However, using ferrets as a laboratory model does come with roadblocks. Very
few reagents exist, although the Schultz-Cherry laboratory and others are filling out the
ferret tool box, but also, very few high-risk states can be replicated in ferrets. However,
since high-risk states are, as the name suggests, of the highest concern when studying
the pathogenesis and potential prevention of influenza infection, it is necessary to include
these populations in empirical investigation. The development of the diet-induced obese
ferret model, characterized in Appendix A, will be a valuable tool for pathogenesis, transmission, and vaccination studies going forward.
Finally, primary epithelial cells, namely bronchial epithelial cells, are utilized to enable the translation of the findings using in vivo mouse and ferret models to humans. When
grown ex vivo at the air-liquid interface, NHBE cells form tight-junctions, develop cilia,
and produce mucus just as they would in vivo. These "lung in a dish" enables study of the
barrier that separates outside from in, a crucial interface in understanding viral pathogenesis. Further, primary cultures of epithelial cells show great variability in their antiviral
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responses, which can then be linked to donor characteristics (C. G. Huang et al., 2018).
Through use of this model, the host characteristics that influence viral uptake, epithelialbased antiviral responses, and even some recovery responses, can be approximated in a
cell culture dish. Crucially, a diverse batch of donors can be tested, with different ages,
sexes, and body-mass-indices, increasing the significance of the findings.
Influenza viruses pose seasonal and pandemic threats to animal and human health
worldwide. The sheer diversity of influenza subtypes and strains is worrisome enough,
yet influenza also undergoes constant genetic shift and drift. This generation and purging
of minor genetic variants in the viral quasispecies coupled with the swapping of whole
segments affords influenza viruses an extraordinarily high level of adaptability and ability
to escape host immune pressures (Krammer et al., 2018). These evolutionary dynamics
have been shown to be sensitive to host immune pressures and other characteristics (Plant
et al., 2017; D. Park et al., 2016), yet few if any studies have interrogated the contribution of
distinct host states on viral evolution. As obesity is poised to remain as one of the largest
health threats to humanity, it is imperative that the unique immune and metabolic pressures within the host with obesity are surveyed for their effects on within-host evolution
of influenza viruses.

4.2

Materials and Methods

Together, this work seeks to understand the early immune consequences of obesity on
the antiviral response and the implications for this altered microenvironment on the viral
population. Below is delineation of the specific methods that underlie the findings present
within this dissertation.

4.2.1

Viral Stocks, Purification and Titration

Viral propagation and titration
CA/09 (pH1N1), A/Switzerland/9715293/2013 (H3N2), A/Memphis/257/ 2019 (H3N2),
A/Swine/Texas/4119-2/1998 (cH3N2), Victortia-lineage B/Brisbane/60/2008 and Yamagata-lineage B/Massachusetts/2/2012 were obtained from Dr. Robert Webster and Dr.
Richard Webby (St. Jude, Memphis, TN). A/Yellow-billed pintail/Chile/11/2011 (H7N3),
and A/Canine/Florida/ 14/2006 (H3N8) were isolated by our laboratory. A/Puerto Rico/8/1934 HA-mRuby2 and HA-mNeon reporter viruses were generously supplied from Dr.
Nicholas Heaton (Duke, Durham, NC). An NS1 deleted A/Puerto Rico/8/1934 (∆NS1)
was obtained from Dr. Adolfo Garcia-Sastre (Mt. Sinai, New York, NY, Haye et al.,
2009). Reverse-genetics Netherlands/602/2009 (pH1N1) wild-type (NL/09 WT) and variant virus which contains single silent mutations per segment compared to WT (NL/09
VAR) were obtained from Dr. Anice Lowen (Emory, Atlanta, GA) for use in reassortment
studies and propagated in Madin-Darby canine kidney (MDCK) cells (M. Richard et al.,
2018; Sutherland et al., 2010). A stable reverse-genetics reporter virus encoding NanoLuc
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on the PA segment, rg-CA/09 PA-nLuc pH1N1 virus was also previously developed in our
lab with Dr. Andrew Mehle (University of Wisconsin, Madison, WI) (Tran et al., 2013). This
virus shows no attenuation in vitro and recapitulates parental virus dynamics in mouse and
ferret models (Tran et al., 2013; Karlsson, V. A. Meliopoulos, Savage, et al., 2015), with the
advantage of 24-hour turn around for viral titer determination. Viruses were propagated
in the allantoic cavity of 10-day-old specific pathogen free embryonated chicken eggs unless otherwise indicated (Cline, Karlsson, Seufzer, et al., 2013).
Viral titer was determined through quantifying the tissue culture infectious dose-50
(TCID50 ) unless otherwise noted. Briefly, confluent Madin-Darby canine kidney (MDCK)
cells were inoculated in triplicate with serial 10-fold dilutions of homogenized indicated
samples in 100 µL of MEM plus 0.75% bovine serum albumin (BSA) and modified, L(tosylamido-2-phenyl) ethyl chloromethyl ketone trypsin (TPCK-trypsin). After 3 days of
incubation at 37◦ C, 50 µL of supernatant was mixed with 50 µL of 0.5% packed turkey red
blood cells diluted in phosphate buffered saline (PBS) for 45 minutes (min) at room temperature. Observance of hemagglutination indicated a positive result. For rg-CA/09 PANluc pH1N1 virus, 10-fold serial dilutions of samples and negative controls were plated
in triplicate onto confluent MDCK cells seeded in a flat-bottomed 96 well tissue-culture
treated opaque white plate. Plates were incubated overnight at 37◦ C. After 16 hours, 75
µL of media removed from each well and plates wrapped in foil then placed at -80◦ C for a
minimum of 1 hour to lyse cells. After thawing plates, the addition of 25 µL of NanoGlo
substrate per well was added to measure luminescence. Wells were considered positive at
3X luminescence of negative control wells. Quantitative TCID50 was determined via the
method of Reed and Meunch (Reed and Muench, 1938).
Generation of inactivated influenza vaccine
CA/09 (pH1N1) virus was inactivated using β-propiolactone (BPL, Sigma cat:P5648). Egggrown CA/09 virus was clarified by centrifuging at 4000 rpm for 20 min, after which a
1:2000 (vol/vol) dilution of BPL was added to the allantoic fluid. Fluid was mixed thoroughly and left at 4◦ C for 72 hours after which an hemagglutination assay (HA) was performed. Following, two safety tests were performed to ensure inactivation. Undiluted,
inactivated virus (100 µL) was injected into 5 eggs. After 3 days of incubation at 37◦ C,
allantoic fluid was removed and assays for HA activity. Allantoic fluid from HA-negative
eggs was pooled, and the safety test was repeated. Allantoic fluid from HA-positive eggs
were diluted 1/100 in PBS with antibiotics and safety test repeated. If after both safety
tests the virus still shows HA, further inactivation is required. Fully inactivated virus was
stored at 4◦ C until use.
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Cell Culture

Cell Lines
Madin-Darby canine kindey (MDCK) cells were cultured in modified Eagle’s medium
(MEM, Corning) supplemented with 2 mM glutamine (Gibco) and 10% fetal bovine serum
(FBS, Atlanta Biologicals) and incubated at 37◦ C in 5% CO2 . Antibiotics (penicillin and
streptomycin) were added to MDCK media when assays involving animal tissues or samples were performed. Vero cells were obtained from ATCC and cultured in Dulbecco’s
modification of Eagle medium (DMEM), supplemented with 10% heat-inactivated FBS.
Hep2 cells (ATCC CCL-23) were maintained in EMEM (Corning) with 10% FBS and incubated at 37°C in 5% CO2 .
Primary respiratory epithelial cells
Normal human bronchial epithelial cells (NHBE cells; cat:CC-2540S) were obtained commercially (Lonza) or from a procurement protocol with the National Disease Research Interchange (NDRI, Table 4.1). Passage 1 or 2 cells were expanded and cultured in bronchial
epithelial cell growth basal medium (BEBM) supplemented with the bronchial epithelial
cell growth SingleQuots (BEGM). NHBE cells were seeded onto human placental collagen
coated 12mm permeable transwell inserts at a concentration of 2.5 x 104 cells per well.
After reaching confluence, apical media was aspirated, and basal media replaced with airliquid interface media containing half Dulbecco’s modfied essential media (DMEM), half
bronchial epithelial cell growth basal media (BEBM), plus the bronchial epithelium SingleQuots, to complete differentiation. Media was changed every two to three days. NHBE
cells were inoculated with indicated influenza viruses at 4 weeks post-ALI. The apical surface of NHBE cells were washed twice with PBS containing magnesium and calcium to
remove interfering mucins. Cells were then apically inoculated with diluted virus at the
indicated multiplicity of infection (MOI). Virus adsorbed for 2 hours at 37◦ C, then was
aspirated and cells washed 2X with PBS to remove unbound virus. Apical wash was collected at hour 48 p.i. by adding 200 µL BEGM to apical surface and incubating at 37◦ C
for 1 hour. Washes were immediately aliquoted and stored at -80◦ C for downstream applications. Sampling from the basolateral chamber included collected all basal media and
replacing with fresh at the indicated timepoints.
Replication kinetics
MDCK cells were infected at the indicated MOI for one hour with indicated viruses or biological samples. After adsorption period at either 4◦ C or 37◦ C depending on experimental
conditions, cells were washed three times with PBS to remove unbound virus. Infected
cells were cultured in MEM containing 0.075% BSA and 1 µg/mL TPCK-trypsin. Aliquots
of culture supernatants were collected at noted timepoints and immediately stored at -80◦ C
for determination of virus titers as described previously.
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Table 4.1: Characteristics of human
primary respiratory epithelial cells.
Lot
628080
560120
619260
366559
ND18579
543643
ND18505
310206
548314
302899
408030
470899
321139
626776
627466
340483
544414
646466
ND18305
ND18444
613375
619261
343489

BMI1
19
20
20
21
22
23
23
24
25
25
26
27
30
32
32
32
32
33
34
35
35
38
41

1 BMI=Body

Age
42
59
65
6
16
57
66
64
52
70
57
37
56
19
24
44
48
38
67
7
65
53
24

Sex2
M
F
F
M
F
F
M
M
M
M
F
M
M
F
F
F
M
M
M
F
F
M
F

Source
Lonza3
Lonza
Lonza
Lonza
NDRI4
Lonza
NDRI
Lonza
Lonza
Lonza
Lonza
Lonza
Lonza
Lonza
Lonza
Lonza
Lonza
Lonza
NDRI
NDRI
Lonza
Lonza
Lonza

mass index. For donors under 12 years of age, BMI-for-age is calculated.
2 M=male, F=female
3 Lonza cat:CC-2540.
4 National
Disease Research Interchange. Cells isolated in house.
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Drug susceptibility assays
MDCK cells were maintained in minimum essential medium (MEM; Lonza) supplemented
with 2 mM GlutaMAX (Gibco) and 10% fetal bovine sera (FBS; Atlanta Biologicals) and
grown at 37◦ C under 5% CO2 . MDCK cells were seeded in 12-well or 96-well cell culture
treated plate. Upon confluency, MDCK cells in 96-well plates were inoculated in triplicate
with 10-fold serial dilutions of indicated viruses in infection media (MEM, 2 mM GlutaMAX (Gibco), 1% BSA, and 1 µg/mL TPCK-treated trypsin) containing increasing concentration of oseltamivir (OSE) carboxylate (0, 0.1, 0.5, 1, 10, 50, 100, 500, 1000, and 10,000 nM)
or dimethyl sulfoxide (DMSO). Plates were maintained at 37◦ C under 5% CO2 for three
days, at which time viral titer determined through hemagglutination of 0.5% turkey red
blood cells in PBS. Infectious viral titers were calculated using the Reed-Muench method
(Reed and Muench, 1938). The dose-response curve was fitted to determine the necessary
concentration of oseltamivir (OSE) to reduce viral titers by 50% (half maximal inhibitory
concentration, IC50 ). Assays were repeated three times with average IC50 reported.
Stimulation of NHBE cells with TLR agonists
A panel of NHBE cells (n=3 per BMI) were seeded onto human placental collaged coated
transwells and differentiated at the air-liquid interface. Once at full differentiation, cells
were apically washed 3X with PBS and apically stimulated with 10 ug/mL of Poly I:C
HMW (InvivoGen cat:tlrl-pic) or 10 ug/mL R848 (InvivoGen, cat:tlrl-r848) in 100 µL PBS
for 6 hours or CA/09 virus at MOI=0.01 in 100 µL of PBS for 2 hours. Post-stimulation,
the apical surface was washed 3X with PBS. Apical supernatants were collected by the
addition of 200 µL PBS to the apical chamber, incubating at 37◦ C for 30 min, then collecting
and storing at -80◦ C. Total basal supernatants (500 µL) were also collected and replaced
with fresh media. Supernatants were collected at 2, 8, 12, and 24 hours post-stimulation.
Type I and Type III interferon production was measured using commercially available
enzyme-linked immunosorbent assays (ELISAs, pbl Assay Science cat:41100, cat:61830).
Quantifying reactive oxygen species production
BMI-discordant, age-, race- and sex-matched NHBE cells were seeded in a 96-well clear
bottom, black wall plate and allowed to reach confluency. Cells were inoculated at a
MOI=1 with CA/09 virus or PBS control in 100 µL. After a 1-hour adsorption, the virus
was aspirated, and cells washed with PBS. For cells undergoing treatment with the ROS
inhibitor N-acetyl-l-cysteine (NAC, Abcam, cat:ab143032), media containing 1 mM NAC
was added. At hour 24 post-inoculated and treatment, cells were washed twice with PBS
and the reactive oxygen species (ROS) assay substrate added (Abcam, cat:186028). After
incubation for 30 min, ROS production was quantified through excitation and emission
at wavelengths of 540/570 nm. For positive control, cells were stimulated with 10% hydrogen peroxide 30 min prior to addition of substrate. Negative control cells remained in
complete BEGM for the duration of the experiment.
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In vivo Experiments

Statement of ethics
All procedures were approved by the St. Jude Children’s Research Hospital Institutional
Animal Care and Use Committee (IACUC) and followed the Guide for the Care and Use
of Laboratory Animals. These guidelines were established by the Institute of Laboratory
Animal Resources and approved by the Governing Board of the U.S. National Research
Council. Designated diet and food were provided ad libitum unless otherwise indicated
for the duration of the experiments
Studies in mice
Husbandry and diets. The majority of experiments utilized 8 to 12-week old w
C57BL/6 male (WT) (JAX:000664) and B6.C-Lepob/ob /J genetically obese (OB) (JAX:000632)
male mice were obtained from Jackson Laboratory. Genetically obese, Lep−/− Itgb6−/−
mice (OBIFN) were bred at St. Jude as previously described with the original Itgb6 mice
(Hood and Cheresh, 2002) obtained from Dr. Dean Sheppard (University of California,
San Francisco, CA) and backcrossed for 10 generations onto the C57BL/6 background and
bred in-house. IFNAR KO mice were originally obtained from Dr. Laura Knoll (University
of Wisconsin, Madison, WI) and then bred in-house. Knockouts were confirmed by PCR
using primer sets (Ifnar−/− ) reported on the Jackson Laboratories website, or as previously
described (β6) (Morris et al., 2003). The diet-induced obesity murine model was also utilized. Here, 3-week-old male or female C57BL/6 mice were randomized to receive either
control chow diet (Research Diets) or high-fat diet (HFD, Research Diets cat:D12492) ad libitum. Weights were measured biweekly to monitor growth curves. Mice were maintained
at 12 h light-dark cycles at ambient temperature (18-23◦ C) and humidity (40-60%)
Viral inoculation and post-infection monitoring. Mice were lightly anesthetized
with isoflurane (2.5-3%) prior to intranasal inoculation of indicated viruses. Viruses were
diluted in 25 µL PBS and administered drop-wise to each nare, taking care to allow complete inhalation. Mice were monitored as they regained consciousness after which they
were returned to their caging for the remainder of the study period.
Weights and clinical scores were recorded every day for 14 days. Moribund mice
that had lost more than 30% body weight or reached clinical scores of greater than 3 were
humanely euthanized. Clinical signs were scored as follows: 0=no observable signs, 1=active, squinting, hunching or scruffy appearance; 2=squinting and hunching, active only
when stimulated; 3=excessive hunching, squinting, not active when stimulated; 4=hindlimb paralysis, shivering, rapid breathing, moribund (Irwin, 1968; Irwin, 1962). At indicated days p.i., mice were euthanized via CO2 asphyxiation with necessary samples harvest and processed immediately or stored at -80◦ C for future analysis. Secondary measures
of euthanasia include cervical dislocation or pneumothorax.
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Bioluminescent imaging. Mice were deeply anesthetized with isoflurane and retroorbitally injected with 0.3 µL/g Nano-Glo substrate (Promega) diluted in 100 µL of PBS
and immediately sacrificed. Whole lungs were removed and imaged for 3 min using a
Xenogen IVIS200 system with Living Image software (PerkinElmer). Living Image software was used to quantify viral spread. Data are representative of three independent
experiments (V. Meliopoulos et al., 2019).
Experimental evolution of influenza A viruses. Lean (WT or LN), diet-induced
obese (DIO) or leptin-knockout (OB), IFN-deficient (IFNAR) and the obese, interferonsufficient Lep−/− Itbg6−/− (OBIFN) mice (n=3-5/group) were lightly anesthetized under
2.5% isoflurane and intranasally inoculated with p0-H1N1 or H3N2-p0 at 103 TCID50 in
25 µL of PBS. Mice were observed daily or twice daily during the height on infection for
morbidity and weight loss. Morbidity was scored using clinical sign measurements as
follows: 0=normal, 1=ruffled fur, 2=hunched back, slow circular movement, 3=trembling,
4=paralysis and moribund. At day 3 p.i., mice were sacrificed under CO2 asphyxiation and
lungs were collected and homogenized in PBS. Viral titers were determined as described
above, and pooled lung homogenate standardized to a viral dose of 103 TCID50 units was
used to infect a new set of lean or obese mice respectively for a total of 5 or 10 passages.
Parental viruses considered p0 include pH1N1 at egg-passage 2 and H3N2 at egg-passage
3. Quantification of the virulence of indicated mouse-passaged viruses was accomplished
by intranasally infecting n=5/virus/dilution 10-week-old C57BL/6 with passage 5 (p5)
viruses at log10 dilutions from 102 to 105 TCID50 units in 25 µL of PBS to discern the mean
lethal dose 50% (MLD50 ). Mice were euthanized when they reach the human endpoint
of greater than 30% weight loss and clinical scores of 4. To understand the disease progression of the passaged viruses, n=5 recipient WT mice were infected intranasally with
indicated doses of indicated viruses. Mice were monitored for morbidity over 14 days.
On day 3 p.i., lungs were collected from n=3 to 5 mice and homogenized for viral titer
determination as described above.
WT/VAR estimates of reassortment in mice. A/Netherlands/602/2009 (pH1N1)
WT and VAR viruses were used in coinfection studies to determine the baseline rate of reassortment in obese and lean mice. Mice were either coinfected with WT/VAR NL/09 at a
1:1 ratio in 25 µL PBS with a total viral particle count of 104 TCID50 units, or super-infected
with VAR NL/09 given at hour 4, 12 or 24 p.i. with WT NL/09. Lungs of mice were harvested at hour 48 p.i. with WT NL/09 and homogenized in 500 µL PBS for downstream
plaque isolation and melt curve analysis.
Antiviral resistance in vivo. Oseltamivir (OSE) was administered by oral gavage as
described below at 10 mg/kg free base equivalencies twice daily for 5 days. At 12 hours
after the initial dose, mice were lightly anesthetized with isoflurane and inoculated with
103 TCID50 units of CA/09 (pH1N1) virus in 25 µL PBS. Control mice received a PBS oral
gavage at the same timepoints. At 0.5- 1-, 3-, 5- and 7- days p.i., lungs were collected,
homogenized in 1 mL PBS and stored at -80◦ C for downstream viral titer determination
and deep sequencing. For deep sequencing statistical analysis, days 1 and 3 and days 5
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and 7 are grouped as early and late points in infection, respectively, due to low copies of
viral RNA at very early and very late periods in infection.
Vaccination and monitoring. After anesthesia with 4% isofluroane, blood was collected via retroorbital bleed. Next, mice were immunized with 50 µL of BPL-inactivated
CA/09 virus, standardized to 1 µg HA per mouse in PBS, in the right quadriceps femoris
muscle. Mock-vaccinated mice received 50 µL of PBS. Following a two-week period to
generate a vaccination response, retroorbital blood was again collected from all mice (utilizing the opposing eye) to determine seroconversion following immunization.
Administration of treatments via oral gavage. Oseltamivir phosphate (MedChemExpress, cat:HY-17016) was dissolved in PBS at 5 mg/mL. Oseltamivir was administered
by oral gavage at 10 mg/kg free base equivalencies once 12 hours pre-infection and continuing twice daily for 5 days beginning at hour 12 p.i.. For treatment with recombinant
interferon, 8-week-old male OB and C57BL/6 WT mice were intranasally infected with
103 TCID50 units of the indicated virus as previously described. 8 hours pre-infection,
mice were primed with a 100 µL oral gavage of either 1,000 units recombinant murine
IFNα2 (Thermo Fisher; cat:14831262) or vehicle control (PBS + 0.1% BSA). At hour 8 p.i.,
mice were lightly anesthetized with isoflurane and intranasally treated with 1,000 units
recombinant murine IFNα or vehicle control in 25 µL.
Studies in ferrets
Infections and sample collection. Index ferrets (I) were lightly sedated with 4%
isoflurane and inoculated intranasally with 104 to 106 TCID50 units of the indicated viruses
in 1 mL or 500 µL PBS (Figure 4.1). Depending on experimental design, ferrets were either co-housed for severity studies or initially singly housed for transmission studies. For
transmission studies, twenty-four hours after inoculation of index ferrets, naïve ferrets
were placed either in direct contact (D) with the donor group or housed in adjacent cages 4
to 6 inches from the inoculated group to mimic respiratory transmission (R). Body weight
and temperature were assessed every 24 h and the ferrets were monitored for clinical signs
of infection (see Infection symptom score for details) for 14 days (Belser et al., 2020). Nasal
washes were collected every 2 days p.i. for viral titration. To collect nasal washes, the
ferrets were anesthetized intramuscularly with 0.3 mL of ketamine solution (30 mg/kg of
body weight ketamine) with sneezing induced by drop-wise addition of 1 mL sterile PBS
containing antibiotics (100 U/mL penicillin, 100 µ/mL streptomycin) collectively to each
nostril. Nasal washes were collected in a sterile specimen cup, briefly centrifuged to collect, and viral titers determined via TCID50 analysis. Peripheral blood mononuclear cells
and plasma were collected at days 0, 3, 9, and 21 p.i. for downstream flow cytometry,
hemagglutination inhibition assays, and protein analyses.
Infection symptom scoring. To determine infection severity, ferret weight, temperature, and behavior were recorded daily. A temperature above 40◦ C indicates fever
(0=temperature less than 39.9◦ C, 1=temperature greater than or equal to 40.0◦ C). Animal
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Figure 4.1: Ferret infections and sampling.
For influenza pathogenesis and transmission studies in ferrets, ferrets were
(A) lightly anesthetized with isoflurane and intransally inoculated with
indicated viruses. To sample nasal washes, ferrets were (B) sedated with 30
mg/kg ketamine and (C) nasal wash collected in 1 mL PBS.

54

Chapter 4. Materials and Methodology

55

behavior was recorded continuously for 60 min daily to determine the presence and intensity of the following: sneezing (0=none, 1=mild, 2=severe), lethargy (0=active and playful, 1=active when stimulated, 2=not active when stimulated, 3=lethargic), and coughing
(0=absent, 1=present). The following signs of illness were also recorded: nasal discharge
(0=absent, 1=present), conjunctivitis (0=absent, 1=present), and nasal wash color and consistency (0=clear, 1=cloudy, 2=discolored, 3=discolored and thick). Nasal wash color was
recorded every other day. Total symptom score is the sum of each category.
Euthanasia and sample collection. At days indicated, ferrets were deeply anesthetized with isofluorane and were euthanized via injection with Euthasol. Nasal swabs
and turbinates, lungs, and other organs were harvested for titers and downstream assays
or fixed in formalin for histological analysis.

4.2.4

Assays

v/c/mRNA analysis
Total RNA was extracted from MDCK cells inoculated with indicated viruses at a MOI of
0.001 using TRIzol (Ambion) according to manufacturer’s specifications. Complementary
cDNAs to viral, complementary, and messenger RNA were synthesized using primers specific to the viral NP gene as described previously (Kawakami et al., 2011). Real-time PCR
was performed using QuantiFast SYBR Green PCR kit (Qiagen, cat:204054) on a CFX96
real-time system (Bio-Rad) as described previously (Cline, Karlsson, Seufzer, et al., 2013).
RNA extraction
Homogenized samples were subjugated to phenol-chloroform extraction to purify RNA.
For cell culture, an appropriate amount of TRIzol reagents (per manufacturer’s suggestion) was added to the cell culture dish. Cells were scraped off using the pipet tip and
homogenized by mixing, with continued extraction as per manufacturer’s instructions.
For organs, 25 mg of organ was either extracted using TRIzol or with commercial
kits. For the former, organs were bead beat in 600 µL of TRIzol reagent. After centrifugation at 10,000 × g for 30 seconds, RNA in the supernatant was purified using the Zymo
Direct-zol RNA kit (Zymo, cat:R2051). Extraction using a commercial kit began with homogenization using the Qiashredder (Qiagen, cat:79654) following with extraction through
RNeasy Mini Kit (Qiagen, cat:74104) with DNase treatment as per manufacturer’s instructions. RNA was quantified spectrophotometrically (Nanodrop) and stored at -80◦ C for
downstream assays or immediately processed to cDNA.
Synthesis of cDNA and quantitative PCR
cDNA was synthesized using 500 ngs of total RNA using SuperScript VILO IV (Inivtrogen, cat:11754050). Synthesized cDNA was diluted 1:20 in RNase free water prior to use in
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qPCR reactions. PCR was run using 1 µL of diluted cDNA to detect indicated mRNA, using the QuantiTect primer/probe assay system (Qiagen) according to the manufacturer’s
protocol (Table 4.2). Samples were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or actin as an internal control.
Table 4.2: Qiagen primer assays for gene
expression analysis.
Host species
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse

Gene target
GAPDH
IFIT1
IFNA1
IFNB1
IFNL1
IFNL2
IRF1
IRF3
IRF7
IRF9
PRKRA
SOCS1
SOCS3
STAT1
STAT2
STAT3
Gapdh
Ifit1
Ifna2
Ifnl2
Ifnl3
Ifnlr1
Ifnar1
Irf1
Irf7
Socs1
Socs3
Stat1
Stat2
Stat3
Oas1g

Category number
QT00079247
QT00201012
QT00201964
QT00203763
QT00222495
QT00222488
QT00494536
QT00012866
QT00210595
QT00001113
QT00061222
QT01157905
QT00244580
QT00074123
QT00095704
QT00068754
QT01658692
QT01161286
QT00253092
QT02531305
QT00148659
QT00494137
QT00105112
QT02414720
QT00245266
QT01059268
QT02488983
QT00162183
QT00160216
QT00148750
QT00115528
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FLUIDIGM HT-qPCR
Total RNA was extracted from whole-lung homogenate using the Qiashredder (Qiagen,
cat:79654) and RNeasy Mini Kit (Qiagen, cat:74104) with DNase treatment. cDNA was
synthesized using 500 ngs of total RNA using SuperScript VILO (Inivtrogen, cat:11754050).
cDNA (1 µL) and primers were loaded onto a 96x96 well chip for HT-qPCR on the FLUIDIGM platform, with downstream analysis completed in FLUIDIGM Real-Time PCR Analysis software and the HT-qPCR in Bioconductor/R (Dvinge and Bertone, 2009). Resulting
Ct values were normalized to endogenous actin expression and ΔCt values to average expression of target genes of indicated control at baseline, with ΔΔCt values reported as fold
changes over baseline.
Polymerase activity assay
NHBE cells (n=3 donors per BMI) were seeded onto human placental collagen-coated surface and allowed to reach 95% confluency. Lipofectamine-3000 (12 uL) was mixed with
400 µL Opti-MEM media and allowed to complex at room temperature for 15 min with 20
µL P3000 reagent and 3 µg of total plasmids in a 6:6:3:30:5 ratio of pB2:PB1:PA:NP:pol II
Luc on the CA/09 virus backbone. Media was aspirated from NHBE cellss and 1 mL of
fresh Opti-MEM plus transfection reagents were added in a 4:1 ratio. Transfection reagents
were applied for 6 hours, after which media was aspirated and replaced with complete
BEGM plus retinoic acid. At hour 24 post-transfection, luciferase activity was read using the Promega luciferase assay system (cat:E1501, lot:306966) by adding 10 mL of assay
buffer to substrate, with cell lysis buffer added to water in a 1:4 ratio. To each well as
added 150 µL of the prepared lysis buffer. Plate was rocked and cells scraped into tube,
vortexed for 15 seconds, then centrifuged at 12,000 × g for 2 min at 4◦ C. Supernatant was
transferred to a new tube, and cells in the pellet resuspended in 500 µL PBS and counted
using the Cellometer. Supernatant was added in duplicate to wells of an opaque white
plate with 100 µL of prepared luciferase added immediately prior to reading on BioRex
luminometer with gain set to 100. Values were averaged for 3 technical replicates per biological repeat and reported as fold increase in luminiescence over mock transfected cells.
Mock transfected cells were transfected with an incomplete complement of polymerase
plasmids. Ratio of reagents and plasmids was optimized in pilot studies, with efficiency
estimated by transfection of a green fluorescent protein (GFP) plasmid into the NHBE cells
and manual enumeration of GFP positive cells via immunofluorescent microscopy (EVOS).
Immunofluorescent microscopy
At indicated timepoints, supernatant was removed from NHBE cells cultured at the airliquid interface, cells were washed twice with PBS and fixed in 4% paraformaldehyde. To
determine viral protein production, cells were permeabilized in 0.5% Triton X-100 in PBS
for 15 min, blocked in 5% BSA in PBS for 1 hour, and stained using mouse anti-NP (1:10;
ATCC RRID:AB10949071) overnight at 4◦ C. Cells were then washed three times in PBS and
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stained with chicken-anti-mouse IgG Alexa Fluor647 (1:200, Invitrogen RRID:AB2535869)
or donkey-anti-rabbit IgG Alexa Fluor488 secondary antibodies (1:200, Invitrogen RRID:
AB162543). All cells were stained for DNA using daimindino-2-phenylindole (DAPI; 1:1000,
Sigma cat:D9542). Cells were washed twice with PBS and transwell membranes mounted
onto microscope sides in ProLong Gold antifade reagent (Life Technologies). To better visualize the morphology and thickness of differentiated primary respiratory epithelial cell
monolayers, fully differentiated NHBE cells (as determined by transepithelial resistance
measurements) were stained with MemBrite Fix-488 dye according to manufacturer’s instructions (Biotium, cat:30093-T). After dye uptake to the phospholipid membrane, cells
were fixed with 4% paraformaldehyde and nuclei stained with DAPI prior to mounting
onto slides with ProLong Gold antifade reagent (Life Technologies). Fluorescence was
examined on a Nikon C2 laser scanning confocal microscope mounted to Nikon TE2000
inverted microscope or an EVOS live cell imaging system with downstream analysis performed in ImageJ. For a three-dimensional view, z-stacks were captured for a 20 µm crosssection with micrographs captured at 0.5 µm intervals.
Estimates of reassortment using WT/VAR viruses
Plaque assays were performed on indicated samples. Samples were diluted 1:10 in MEM
containing BSA and MDCK cells inoculated with -1 to -6-fold dilutions in duplicate on
a single 12-well plate. After a one-hour adsorption period, MDCK cells were washed
twice with PBS and a 1 mL agarose overlay containing a 1:1 mix of 1.6% SeaKem agarose
and 2X MEM containing 0.0075% BSA (Gibco, cat:15260-037), sodium bicarbonate (Gibco,
cat:25080-094), MEM vitamin solution (Gibco, cat:11120-052), and L-glutamine (Gibco, cat:
35050-061). After 3 days of incubation at 37◦ C, plaques were visualized by holding plates
up to laboratory lights and marked with a pen. 12 plaques were selected per sample and
picked using a wide-bore 1 mL pipette. Plaques were ejected into 160 µL of PBS, with 40
µL of RNA/DNA shield added afterward. Total viral RNA was extracted from plaques
using the Quick Viral DNA/RNA 96 Kit (Zymo, cat:D7023) according to manufacturer’s
directions. RNA was eluted into 40 µL of nuclease-free water and converted to cDNA using the Maxima reverse transcriptase (Fermentas) and influenza A virus-specific primer
(5’-GCGCGCAGCAAAAGCAGG-3’) according to instructions. Synthesized cDNA was
diluted 1:4 with nuclease free water and stored at -20◦ C. Segment-specific primer pairs
were used to amplify the NL/09 WT and VAR regions for high-resolution melt curve analysis as previously described (M. Richard et al., 2018; Phipps et al., 2017; Marshall et al.,
2013). The 8 primer pairs were thawed on ice and combined to a final concentration of 4
µm in Precision Melt Supermix (Bio-Rad) for each forward and reverse segment, thus 8
master mixes were prepared. Each plaque pick was assayed in duplicate for all 8 master
mixes, so 3 µL of each master mix was added to the wells of a 384-well plate, followed
with 2 µL of synthesized cDNA. Each plaque pick therefore used 16 wells and each biological sample a total of 192 wells. Quantitative PCR was then performed on a BioRad CFX
machine with precision melt software and genotypes recorded.
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Pharmacokinetic analysis
Plasma and lung tissue pharmacokinetic (PK) profiles of prodrug OSE and active metabolite OSE carboxylate was evaluated in male C57BL/6 and OB mice (Jackson Labs), approximately 12 weeks in age by the St. Jude Preclinical Pharmacokinetics Shared Resource.
OSE phosphate was dissolved in aqueous at 5 mg/mL for a 10 mL/kg gavage, yielding
at 10 mg/kg dose. Terminal blood samples were obtained at various times up to 16 hours
post-dose and immediately processed to plasma. A 200 µL aliquot of plasma was then
quickly pipetted from each sample and transferred into a separate 2 mL microcentrifuge
tube containing 800 µL of ice cold 15 ng/mL OSE-d3 carboxylate (Toronto Research Chemicals, Lot 14-SBK-47-3, Purity 97%) in methanol, capped, vortexed for 30 seconds and then
centrifuged to pellet the precipitated protein. An 800 to 950 µL aliquot of the supernatant
was then pipetted into an empty pre-labeled microcentrifuge tube, capped and stored at
-80◦ C until analysis. Following terminal bleeds, animals were perfused with PBS to flush
blood from the vasculature. Lungs were then extracted, rinsed with PBS as necessary, and
snap frozen in liquid nitrogen. Lungs were then placed in appropriately labeled microcentrifuge tubes in a cooler on dry ice and transferred to a -80◦ C freezer as soon as possible.
Frozen lung samples were weighed in tared 2 mL Lysing Matrix A (MP Biomedical,
Santa Ana, CA) tubes and diluted with a 5:1 volume of liquid chromatography/mass spectrometry grade methanol. The lungs were then homogenized with a FastPrep-24 system
(MP Biomedicals, Santa Ana, CA). The homogenization consisted of three 6.0 M/S vibratory cycles of 1 min each on the FastPrep-24 system. To prevent over-heating due to friction, samples were placed on wet ice for 5 min between each cycle. The homogenates were
then centrifuged at 14,000 × g and stored at -80 ◦ C until analysis. Plasma and lung homogenate samples were analyzed for OSE (OSE phosphate, Cayman Chemical Co., Batch
0458276-29, purity 98%) and OSE carboxylate (Toronto Research Chemicals, Lot 3-SKC52-1, Purity 98%) with a qualified LC MS/MS assay. Calibration and quality control stock
solutions were prepared in DMSO and serially diluted in DMSO to prepare calibration/QC
spiking solutions. For the analysis of plasma samples, these spiking solutions were then
used to prepare calibration and QC samples in methanol. Methanol calibration and QC
samples, 200 µL each, were then pipetted into glass HPLC vials and evaporated on a CentriVap Console (Labconco) evaporator (40 min at 60◦ C, then 30 min at 70◦ C). The residue
was reconstituted in 800 µL of ice cold 15 ng/mL OSE-d3 carboxylate in methanol as an
internal standard. Blank male C57BL/6 plasma (200 µL) was then pipetted into each vial,
immediately vortexed for 1 minute and centrifuged to pellet the protein.
Since lungs were simultaneously homogenized and protein precipitated in methanol,
the calibration and QC samples were prepared by spiking into blank male C57BL/6 lung
homogenate. Aliquots (25 µL) of the standards, QC solutions and samples were then pipetted into the IS spiking solution and vortexed to mix. A 2 µL aliquot of the extracted supernatant was injected onto a Shimadzu LC-20ADXR high performance liquid chromatography system via a LEAP CTC PAL autosampler. The LC separation was performed using
a Phenomenex Kinetex Polar C18 (2.6 µm, 50 mm x 2.1 mm) column maintained at 50◦ C

Chapter 4. Materials and Methodology

60

with gradient elution at a flow rate of 0.50 mL/min. The binary mobile phase consisted of
water-formic acid (100:0.1 v/v) in reservoir A and acetonitrile-formic acid (100: 0.1 v/v) in
reservoir B. The initial mobile phase consisted of 5% B with a linear increase to 55% B in 3
min. The column was then rinsed for 2 min at 100% B and then equilibrated at the initial
conditions for 2 min for a total run time of 7 min. Under these conditions, OSE carboxylate,
IS and OSE eluted at 1.22, 1.22 and 1.83 min, respectively. Analyte and IS were detected
with tandem mass spectrometry using a SCIEX 5500 QTRAP in the positive ESI mode and
the following mass transitions were monitored: OSE carboxylate 285.18 → 138.10, OSED3 carboxylate 288.20 → 139.20 and OSE 313.20 → 166.20. The method qualification and
bioanalytical runs all passed acceptance criteria for non-GLP assay performance. A linear model (1/X2 weighting) fit the calibrators across the 1.00 to 500 ng/mL range, with
a correlation coefficient (R) of ≥ 0.9973. The lower limit of quantitation (LLOQ), defined
as a peak area signal-to-noise ratio of 5 or greater verses a matrix blank with IS, was 1.00
ng/mL. Sample dilution integrity was confirmed. The plasma intra-run precision and accuracy was ≤ 6.63% CV and 95.8% to 109%, respectively. The lung homogenate intra-run
precision and accuracy was ≤ 4.48% CV and 94.9% to 111%, respectively. OSE plasma Ct
data were grouped by matrix and nominal time point, and the mean Ct values were subjected to noncompartmental analysis (NCA) using Phoenix WinNonlin 8.1 (Certara USA,
Inc., Princeton, NJ). The extravascular model was applied, and area under the Ct curve
(AUC) values were estimated using the “linear-up log-down” method. The terminal phase
was defined as at least three time points at the end of the Ct profile, and the elimination
rate constant (Kel ) was estimated using an unweighted log-linear regression of the terminal
phase. The terminal elimination half-life (T1/2 ) was estimated as 0.693/Kel , and the AUC
from time 0 to infinity (AUCin f ) was estimated as the AUC to the last time point (AUClast )
+ Clast (predicted)/Kel . Other parameters estimated included observed maximum concentration (Cmax ), time of Cmax (Tmax ), concentration at the last observed time point (Clast ), time
of Clast (Tlast ), apparent clearance (CL/F = Dose/AUCin f ), and apparent terminal volume
of distribution (Vz /F). The apparent plasma-to-lung partition coefficient (Kpinf) was estimated as the ratio of the AUCin f in tissue to AUCin f plasma, whereas Kplast was similarly
estimated using AUClast values.
Protein quantification through ELISAs
Total and effector antibody quantifications. Total IgG levels at day 21 p.i. in
both vaccinated and unvaccinated mice was analyzed in banked sera via ELISA according to manufacturer’s instructions (Thermo Fisher, cat:88-50400-88). To quantify influenzaspecific antibodies, hemagglutination inhibition (HAI) assays were performed. Mouse sera
were treated with receptor- destroying enzyme (RDE; Seiken), and HAI assays were performed according to World Health Organization (WHO) guidelines (WHO, 2012). Influenzaspecific antibody quantification was performed on sera pre-vaccination, 21 days postvaccination and pre-infection on all mice as well as 21 days post-influenza infection on
surviving mice.
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Quantification of metabolic biomarkers. Simultaneous detection of metabolic biomarkers of obesity was accomplished using the MesoScale Discovery metabolic assay platform (MSD; cat:K15301K) to quantify protein concentrations of c-peptide, total ghrelin,
total glucagon-like peptide 1 (GLP-1), insulin, leptin, and total peptide tyrosine tyrosine
(PYY) in sera. Whole blood was collected, allowed to clot at room temperature for 15 min,
then spun at 5,000 × g for 15 min to separate sera which was immediately snap frozen and
stored at -80◦ C. Sera was diluted 1:5 in metabolic assay buffer and used per manufacturer’s
protocol. Adiponectin was measured individually using the Adiponectin/Acrp30 DuoSet
ELISA per manufacturer’s protocol at a dilution of 1:10,000 (R&D Systems, cat:DY1119).
Quantification of antiviral response. Cytokines involved in the antiviral response
were quantified using the MesoScale Discovery proinflammatory panel 1 kit which allows
for the detection of IFNγ, IL-1B, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-13, and TNFα in cell
culture conditioned media (MSD, cat:K15049G). Apical washes were collected at indicated
timepoints from NHBE cells (n=3 wells/donor, 2 donors/BMI) inoculated with CA/09
virus at MOI=0.01. Apical wash was diluted 1:2 with assay buffer and assayed in duplicate according to manufacturer’s instructions. Analysis was completed in Discovery
Workbench software (Version 4.0, MSD).
Detection of type I and III interferons. Basolateral media from differentiated NHBE
cells was collected at indicated timepoints and stored at -80◦ C. Conditioned media was
used neat or at a 1:2 dilution with assay buffer in commercial assays for the detection of
IFNα, IFNβ, and IFNλ subtypes (pbl Assay Science, cat:41100, cat:61830). ELISAs were
performed according to manufacturer’s recommendations. Apical washes were initially
assayed in parallel, but no production of either type I or III interferons were detected.
Additionally, levels of IFNα produced by NHBE cells in culture tend to be below the limit
of detection for commercial ELISA kits, except for the VeriKine-HS human interferon-α all
subtype TCM ELISA kit (pbl Assay Science, cat:41135-1).
Circulating leptin levels. Whole blood (5 mL) was collected from 15-week old ferrets on either lean or DIO diet for 12 weeks. Blood was processed to serum by centrifuging
at 5000 × g for 30 min at 4◦ C. Sera was diluted 25-fold and assayed in duplicate for total
leptin levels according to manufacturer’s instructions (Sigma-Aldrich, cat:RAB0333).

4.2.5

Sequencing, Statistics, and Bioinformatics

Deep sequencing preparation
Viral RNA was extracted from 50 µL of whole lung, sneeze material, or other sample as
indicated on a Kingfisher Flex Magnetic Particle Processor (Thermo Fisher) by using the
Ambion MagMAX-96 AI/ND Viral RNA Isolation kit (Applied Biosystems, cat:AM1834).
RNA concentration was measured spectrophotometrically (Nanodrop). Multi-segment
polymerase chain reaction (MS RT-PCR) was performed using SuperScript™ III One-Step
RT-PCR System with Platinum Taq HiFi DNA Polymerase (Thermo Fisher, cat:12574-035)
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Table 4.3: Universal primers for multi-segment
amplification of influenza A viruses.
Primer
Opti-F1
Opti-F2
Opti-R1
1

Sequence1
GTTACGCGCCAGCAAAAGCAGG
GTTACGCGCCAGCGAAAGCAGG
GTTACGCGCCAGTAGAAACAAGG

Primers reported as 5’—3’.

and influenza-specific universal set of primers (Table 4.3, Mena et al., 2016). RNA (5 µL)
was added and placed into a thermocycler paused at 55◦ C. The following cycling parameters were then followed: 1 cycle of 55◦ C/2min; 1 cycle of 42◦ C/60min; 94◦ C/2min; 5 cycles
of 94◦ C/30s, 44◦ C/30s, 68◦ C/3.5min; 26 cycles of 94◦ C/30s, 57◦ C/30s, 68◦ C/3.5min; 1 cycle of 68◦ C/10min; and then held at 4◦ C. 5 µL of the reaction was analyze by 0.8% agarose
gel electrophoresis to verify all genomic segments are present, with PB1 and PB2 migrating
together at 2.3Kb and minimal non-specific amplification below 800 bp The MS RT-PCR
reaction was purified using Agencourt AMPure XP Kit (Beckman Coulter) according to
manufacturer’s instructions. Briefly, 40 µL of the DNA amplicons were transferred to a 96well microplate (Biorad) and mixed with Agencourt AMPure XP beads (Beckman Coulter)
for magnetic separation of the amplicons. The bound beads were washed twice with 100%
ethanol and the purified amplicons suspended in 1x Tris buffer (TE). The concentration of
the purified DNA was measured spectrophotometrically prior to storage at -20◦ C (Nanodrop). DNA amplicons were deep sequenced using Illumina MiSeq technology. Deep
sequencing was performed by the St. Jude Children’s Research Hospital Hartwell Center with DNA libraries prepared using Nextera XT DNA-Seq library prep kits (Illumina,
cat:FC-131-1024) with 96 dual-index bar codes and sequenced on an Illumina MiSeq personal genome sequencer.
Bioinformatics, databases, and analyses
Single nucleotide variants (SNVs) relative to the indicated reference sequence were determined in two independent methods. First, reads were mapped using the breseq pipeline.
Breseq was ran with the –predict-polymorphisms option to detect polymorphic mutations, the –no-junction-prediction option to omit junction prediction, and the –targetedsequencing option to account for uneven coverage due to the linear influenza gene sequences. Mapping results were tabulated using the gdtools utility distributed with breseq (Barrick and Lenski, 2009; Barrick and Lenski, 2009). Second, reads were mapped to
the reference sequence using CLC Genomics Workbench 9 (Qiagen, Denmark) as previously reported (Dinis et al., 2016; Van den Hoecke et al., 2015). Briefly, fastq files were
imported, sequences trimmed to remove low quality (<Q30) bases and reads shorter than
50 bases. Reads were aligned to the A/California/04/2009 virus reference sequence from
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GenBank, then an in silico consensus sequence for p0 was constructed in which all other
viruses were compared to detect minor variants. Sequences of obese- and lean-passaged
viruses were then compared to the parental (p0) strain used as the initial inoculum. Reads
were aligned to the reference genome and the low frequency variant detection tool used to
identify SNVs at greater than 1% relative frequency. Variants were filtered to remove lowquality variants, and results compared with the previous bioinformatics workflow. No
significant difference was detected between the two methods, increasing our confidence in
variant calling. Variants reported within utilize the former method. Within-host diversity
was measured using Shannon’s entropy (H) according to (Eq. 4.1) by using the relative
frequencies, or P(i), of each single nucleotide variant11. Diversity calculations were performed individually across gene segments with absolute values reported.
n

H (X) =

∑ p(i) log2 p(i)

(Eq. 4.1)

i

Mutations were queried in the Influenza Research Database to determine their natural prevalence and their, if known, phenotypic impacts reported in the literature (Y. Zhang
et al., 2017). Protein sequence variance analysis for human viral sequences was performed.
Comparison of the variants discovered were made in reference to the indicated parental
virus and relative variant frequencies calculated by dividing the number of the identified
amino acid minor variant by total sequences queried. The raw sequencing reads have
been deposited in the NCBI Sequence Read Archive (SRA) under BioProject identifier PRJNA589188, with SUB6541476 containing primary infection data and SUB6637573 containing reinfection data.
Statistical analysis
Data were organized in Microsoft Excel and GraphPad Prism 8. Specifics of statistical details for each experiment can be found in the figure legends or results section of specific
chapters. All data are displayed as means ± standard error of the mean unless otherwise indicated with in-text statistical significance designated when appropriate for multiple comparisons and in figure legends for outputs of chosen statistical tests. Outliers are indicated
with “X” and determined using the ROUT test for outliers set at Q=1%. Significance for
all experiments was set a priori to α=0.05 and indicated by *. Bioinformatics analysis was
completed using R statistical packages and CLC genomics.
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Chapter 5
Blunted Interferon Responses and Amplified Influenza
Disease Severity in Obese Hosts1

5.1

Introduction

Obese individuals are at high risk for severe influenza infection and account for most hospitalizations due to influenza virus (Milner and Beck, 2012). Prior studies have demonstrated that post-infection recovery and wound healing fail to reach levels of wild-type
even weeks after initial infection, suggesting that epithelial dysregulation is present in the
obese host (O’Brien et al., 2012). As obesity is an ever-growing epidemic, we must understand how this unique population responds to infection, especially in the initial epithelial
cells infected. To better understand the molecular consequences of obesity on influenza
pathogenesis and the host innate immune response, I utilized two animal models—obese
mice and the novel obese ferret model (Appendix A)—and an ex vivo model of the human
respiratory epithelium. With these varied approaches, I defined the diminished TLR-3 specific signaling in obese epithelial cells resulting from a state of chronic inflammation and
oxidative stress blunts the type I and III interferon (IFN) responses, leading to increased
viral spread, replication, and disease severity.

5.2
5.2.1

Results
H1N1 virus induces greater viral spread and mortality in obese mice compared to wild-type mice

Genetically obese (OB) and C57Bl/6 (WT) mice were inoculated with 104 TCID50 units of
A/Puerto Rico/8/1934 (H1N1) virus (PR8) with weight, clinical signs of infection, and
survival monitored for 14 days. While losing less weight than WT mice p.i. (Figure 5.1,
p=0.0231, comparisons made to day 10 p.i.), OB mice had significantly higher clinical scores
1 Portions of chapter from previously published article. Modified: From final submission with open access
permission from American Society for Microbiology. Honce, R., E. A. Karlsson, et al. (Mar. 2020). “ObesityRelated Microenvironment Promotes Emergence of Virulent Influenza Virus Strains”. In: Mbio 11.2. ISSN:
2150-7511 (Electronic). DOI: 10.1128/mBio.03341-19.
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(p=0.0374) and drastically reduced survival (p=0.0173) in comparison to WT mice. To interrogate this disparity in survival p.i., OB and WT mice were intranasally inoculated with
103 TCID50 units of an A/California/04/2009 (CA/09) H1N1 reporter virus encoding nLuc
on the PA segment to quantify viral spread and titers throughout infection (Karlsson, V. A.
Meliopoulos, Tran, et al., 2018; V. Meliopoulos et al., 2019). Despite statistically similar
viral titers, OB mice have increased viral spread in the lungs at day 3 p.i. as compared to
C57Bl/6 (WT) mice (p<0.0001).

Figure 5.1: H1N1 virus induces greater viral spread and mortality in
obese mice compared to wild-type mice.
(A-C) OB and WT mice were inoculated with PR8 virus. Over 14 days, (A)
weights; analyzed to day 10 pi, mixed effects model p=0.0231, f=7.849; (B)
clinical scores; two=way repeated measures ANOVA, mouse genotype
p=0.0374, f=6.213, dpi x mouse = 0.0315, f 1.918; and (C) survival; log-rank
Mantel-Cox, χ2 = 5.664, df=1, p=0.0173 were monitored. (D-F) OB and WT
mice inoculated with a bioluminescent reporter CA/09 virus (n=5
mice/genotype/timepoint). (D) No difference in viral titers recovered from
day 0 to 3 p.i. (E) Bioluminescent flux measured in excised lungs shows
increased viral spread at day 3 p.i. in OB mice (n=5 mice/timepoint);
two-way ANOVA with mouse genotype as source of Representative
images of viral spread. Data is representative of 3 independent
experiments with n=3-5 mice/experiment. Data represented as means ±
standard error in variation in (A,B,D,E) with *p<0.05.
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5.2.2

Genetically obese mice show blunted interferon responses early in infection

Impaired cellular immune responses are characteristic of obese hosts and may translate
to a reduced control of viral spread and clearance of viral infection (A. G. Smith, Sheridan, Harp, et al., 2007). However, these studies demonstrate increased viral spread occurs
in obese mice by day 3 p.i. At this early timepoint, IFNs are critical for controlling viral
replication and spread (McNab et al., 2015). Thus, a blunted IFN response may be affording greater cell-to-cell spread of virus. Indeed preliminary analysis using high-throughput
qPCR on the Fluidigm platform showed that at day 2 p.i. with CA/09 virus, OB mice
showed reduced expression of genes involved in viral sensing and signaling, IFNs, and
the innate immune response compared to expression in WT mouse lungs (Figure 5.2). To
further interrogate these differential responses, total RNA was extracted from lungs of WT
and OB mice inoculated with 103 TCID50 units of CA/09 virus and probed for type I IFN
signaling. Analysis of qPCR shows IFN induction and signaling genes are blunted in the
obese host. At 8 hours p.i., there is significantly less Irf7 (p=0.0027), leading to reduced expression of Ifna1 (p=0.0001) and Ifnb1 (p=¬0.0066) at hour 24 p.i. By 72 p.i., this translates to
reduced Stat1 (p=0.0903) and significantly reduced Ifit1 (p=0.0313) expression in the lungs
of OB mice compared to WT mice. All gene expression is standardized to levels of WT
mice at baseline.

5.2.3

Greater peak titer, prolonged shed, and severity of disease in obese ferrets
is accompanied by a reduction in interferon gene expression

While mice are a good model organism, every model has its limitations. To better understand the pathogenesis of influenza infection in obese hosts, I utilized a novel diet-induced
ferret model (Appendix A). Ferrets were inoculated intranasally with indicated viruses
and monitored over 14 days for signs and symptoms. Infection with seasonal H3N2 virus
(A/Memphis/257/2019) included significantly extended shed of virus (p=0.0017) and increased viral shed over time (p=0.0238, Figure 5.3). At peak, viral loads were higher in
obese compared to lean ferrets in nasal washes (p=0.0212). Obese ferrets also had elevated signs of infection (p<0.0001). Infection with CA/09 virus included a trend toward
prolonged viral shed, increased viral titers, and significantly elevated clinical sings of infection (Figure 5.3). Obese ferrets, independent of viral strain, suffered increased risk of
a symptomatic influenza infection (Table 5.1). Compared to lean diet, an obese diet increases the risk of displaying clinical signs of influenza infection by over two-fold for all
viruses studied (RR=2.56 ± 0.68), and when broken down by virus strain and subtype,
shows increased risk for H1N1 virus (RR=2.62 ± 1.65), H3N2 virus (RR=2.61 ± 0.94), H9N2
virus (RR=1.90 ± 1.60), and influenza B virus (RR=2.75 ± 4.52, Maier, Kuan, et al., 2020).
At day 2 p.i. with A/Netherlands/602/2009 (pH1N1), lungs from obese ferrets
showed significant signs of extensive viral spread in the lower lobes and evidence of hemorrhaging and necrosis in comparison to focal infections in lung lobes of lean ferrets at
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Figure 5.2: Obesity blunts the interferon response to H1N1 virus
infection.
(A) Male OB and WT mice (n=5/timepoint) were intranasally inoculated
with 103 TCID50 units of CA/09 virus. RNA was extracted, and HT-qPCR
performed on cDNA using the FLUIDIGM platform, with expression
normalized to Actb and average expression of target gene in WT mice at
baseline. (B) DAVID functional gene enrichment analysis was performed
on the genes with negative differential expression relative to responses in
WT mice with the top 5 annotation clusters reported. (C-G) OB and WT
mice (n=3/timepoint) were intranasally inoculated with 103 TCID50 units
of CA/09 virus and lungs probed for expression of genes involved in the
interferon response. Compared to WT mice, OB mice have reduced
expression of (C) Irf7, (D) Ifna1, (E) Ifnb1, (F) Stat1, and (G) Ifit1 at
timepoints indicated. Data analyzed in (C-G) with unpaired t-test and
represented as means ± standard error with *p<0.05.
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Figure 5.3: Influenza A virus replicates to higher titers and for longer in
obese ferrets.
(A-D) Ferrets inoculated with A/Memphis/257/2019 (H3N2) virus and
monitored for 14 days. (A) Higher and prolonged viral titer in nasal
washes determined through TCID50 in obese compared to lean ferrets;
two-way ANOVA with repeated measures, diet p= 0.0958, f=3.110; dpi x
diet p=0.0017, f=3.937. (B) Area under the curve of nasal wash titers;
unpaired t-test, p=0.0238, t=2.846. df=8.141. (C) Viral titers at peak
infection (day 2 p.i.) are higher in obese compared to lean ferrets; unpaired
t-test with Welch’s correction, p=0.0212, t=2.846, df=8.141. (D) Higher
clinical scores across the infection course in obese compared to lean ferrets;
two-way ANOVA with repeated measures, diet p<0.0001, f=57.61; dpi x
diet p<0.0001, f=6.536. (E-H) Ferrets inoculated with A/California/04/2009
(pH1N1) virus and monitored for 12 days. (E) Non-significant increase in
viral titers and prolonged viral shed in obese compared to lean ferrets. (F)
Trend toward increased area under the curve in nasal wash titers for obese
compared to lean ferrets; unpaired t-test, p=0.0510, t=2.134, df=14. (G)
Trend to higher peak viral titers in nasal washes at day 2 p.i. from obese
ferrets; unpaired t-test with Welch’s correction, p=0.0740, t=2.158, df=6.045.
(H) Significantly elevated clinical signs of infection in obese compared to
lean ferrets across the infection time course; two-way ANOVA with
repeated measures, diet = 0.0024 f=44.19, dpi x diet<0.0001 f=6.417. (I)
Representative images of ferret lungs at day 3 p.i. inoculated with
A/Netherlands/602/2009 (pH1N1). (J) Viral titers determined via TCID50
in lung lobes of n=2 ferrets/diet inoculated with A/California/04/2009
(pH1N1) virus. Data represented as means ± SEM in (A-H, J) with *p<0.05.
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Figure 5.3: Influenza A virus replicates to higher titers and for longer in
obese ferrets.

the gross anatomy level (Figure 5.3). These findings are supported by higher viral loads
in the five lung lobes of obese ferrets infected with CA/09 (pH1N1) virus, particularly the
lower lobes, in comparison to lean ferrets (Figure 5.3).
To determine if the novel, diet-induced ferret model also shows this phenotype, n=2
obese and lean ferrets were inoculated with CA/09 virus at 106 TCID50 units and lungs
excised at hour 24 p.i. Analysis of gene expression revels a similar trend to reduced IFN
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Table 5.1: Relative risk of symptomatic influenza infections in
diet-induced obese and lean ferrets.

Obese
Lean

Total
ferrets
8
8

At-risk
days
88
112

Symptomatic
days
37
18

Absolute
risk
0.42
0.16

Relative
risk1
2.62 ± 1.65

A/Memphis/257/2019 (H3N2)

Obese
Lean

14
13

174
160

105
37

0.60
0.23

2.61 ± 0.94

<0.0001*

A/Hong Kong/1073/1999 (H9N2)

Obese
Lean

13
13

122
146

22
15

0.19
0.10

1.90 ± 1.60

0.04*

B/Brisbane/60/2008 (Victoria)

Obese
Lean

3
3

21
21

11
4

0.52
0.19

2.75 ± 4.52

0.04*

Total

Obese
Lean

38
37

405
439

175
74

0.43
0.17

2.56 ± 0.68

<0.0001*

Virus

Diet

A/California/04/2009 (pH1N1)

p-value
0.0001*

1

Relative risk of symptoms if in obese group. Represented as risk ratio ± 95% confidence
interval. * Indicates significant difference in relative risk at α = 0.05.

induction and signaling gene expression, as IRF1, IRF3, and IRF9 show modest reductions
in expression, while IFNA.C has a significant decrease (p=0.0309) and MX1 trends towards
reduced expression (Figure 5.4). Gene expression is standardized to levels of lean ferrets
at baseline and is the average expression across all five lung lobes.

5.2.4

Greater viral replication, viral spread, and cell loss in obese-derived human primary respiratory epithelial cells compared to lean donors

Does the phenotype of higher viral replication and spread translate to ex vivo human epithelial cells? To these ends, obese- and lean-derived normal human bronchial epithelial
cells werecultured at the air-liquid interface and inoculated with indicated viruses at the
indicated MOIs. CA/09 virus replicated to higher titers in obese-derived NHBEs at both
low (p<0.0001) and high MOI (p=0.0033, Figure 5.5) as compared to lean-derived, ageand sex-matched NHBE cells. Indeed, viral titers positively correlated with BMI (p=0.0483,
Figure 5.5). This increased replication is accompanied by greater viral spread throughout
the monolayer. Using a PR8 reporter virus encoding the mRuby2 fluorophore on the HA
segment, NHBE cells were inoculated and visualized via the EVOS live cell imaging system. A greater number of cells expressing the fluorescent HA protein is evident (hour
16 p.i., p=0.0081; hour 24 p.i. p=0.0037, all timepoints p<0.0001; representative images at
hour 24 p.i., Figure 5.5), To better understand how early this increased viral spread is evident, NHBE cells were synchronously inoculated with CA/09 H1N1 virus and fixed with
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Figure 5.4: Blunted interferon responses in lungs of CA/09 virus infected
obese ferrets.
(A) Using the FLUIDIGM HT-qPCR platform, expression of genes across
five lung segments in n=2 obese and lean ferrets was quantitated, with
z-scores reported. (B-F) Expression of genes involved in interferon
induction and response is blunted in the lungs of diet-induced ferrets, as
they show modest reductions in (B) IRF1, (C) IRF3, and (D) IRF9, (E)
significant reduction in IFNA.C (p=0.0309, t=2.639, df=7), and (F) reduced
MX1 expression. Expression standardized to endogenous HRPT levels and
compared to expression at OB or LN baseline, respectively. Data analyzed
in (B-F) with unpaired t-test and represented as means ± standard error
with *p<0.05.

paraformaldehyde at hours 0, 4, 6, 8, and 12 p.i.. Cells were probed via immunocytochemistry for the expression of viral nucleoprotein. In obese-derived cells, NP staining is
evident as early as hour 4 p.i., while first signals are seen in lean-derived cells at hour 6
with extensive staining not present until hour 8 p.i. (Figure 5.5). Strikingly, viral polymerase activity is increased in NHBE cells from obese donors. Using a minigenome assay
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Figure 5.5: Greater viral replication and spread obese-derived primary
respiratory epithelial cells compared to those from lean donors.
Obese-derived NHBE cells (n=12 wells/donor) inoculated with CA/09
virus show increased replication kinetics compared to lean-derived cells.
(A, B) representative age-, race, and sex-matched, BMI-discordant NHBE
cells infected at (A) MOI=0.01 with CA/09 virus and (B) at MOI=10 with
CA/09 virus. (C) Viral titer at hour 24 p.i. from panel of BMI-discordant
NHBE cells (n=3 wells/donor); y=0.139x-0.5889. (D-E) Age, race- and
sex-matched NHBE cells inoculated with PR8 HA-mRuby2 reporter virus.
At timepoints indicated, images captured from live cell microscopy (n=3
images/well) were taken and analyzed in imageJ for mRuby2 fluorescence
as a measure of viral spread (hour 16, p=0.0081; hour 24, p=0.0037). (E)
Representative images of PR8 mRuby2 viral spread at hour 24 p.i. (F)
Nucleoprotein and DAPI staining in NHBE cells synchronously infected
with CA/09 virus and fixed in paraformaldehyde at indicated timepoints.
(G-H) Polymerase activity is increased in NHBE cells from obese donors.
Data analyzed in (A,B, D) with ordinary one-way ANOVA and in (C) with
linear regression. Data represented as means ± standard error with *p<0.05.

on the CA/09 virus background, polymerase activity was increased at hour 24 p.i. in
obese-derived cells versus lean. Similar, albeit low, transfection efficiency was achieved
(Figure 5.5).
The heightened viral spread and replication in obese-derived NHBE cells also leads
to greater cell loss from the monolayer. At hours 0, 6, 24, 48, and 72 p.i. with PR8 virus,
monolayers were fixed with paraformaldehyde and stained to visualize cleaved caspase3 as a correlate of dying cells and DAPI to visualize nuclei. Cells were visualized using
the EVOS imaging system. Mirroring the extensive spread and lung damage in obese
mouse models, obese-derived NHBE cells have greater cleaved caspase-3 staining, leading
to greater to cells lost from the monolayer as calculated by quantifying DAPI signal in
imageJ (Figure 5.6). Visualizing fluorescent dye uptake to the cellular membrane through
confocal microscopy shows this cell loss and the resulting denuded monolayer (Figure 5.6).

5.2.5

Primary respiratory epithelial cells from obese donors show reduced interferon responses upon stimulation

Does the delayed and blunted IFN response observed in obese mice (both genetic and
DIO) translate to humans? Accordingly, a diminished IFN responses is recapitulated in
differentiated normal human bronchial epithelial (NHBE) cells derived from obese donors.
Infecting BMI-discordant NHBE cells at the air-liquid interface with CA/09 virus at MOI
of 10 resulted in reduced expression of IRF7 (p=0.0790) at hour 8 p.i., significantly blunted
IFNA1 (p=0.0017) and IFNB1 (p=0.0001) at hour 16 p.i. and IFNL2 (p=0.0461) at hour 24 p.i.,
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Figure 5.5: Obese-derived primary respiratory epithelial cells show
greater viral replication and spread early in infection.
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Figure 5.6: Greater cell loss upon infection in obese-derived NHBEs
compared to lean.
(A, B) representative age-, race, and sex-matched, BMI-discordant NHBE
cells infected at MOI=0.01 with PR8 HA-mRuby2 virus. (A) Relative signal
of cleaved caspase-3 quantified in imageJ in NHBE cells at times indicated.
Greater signal in obese-derived cells at hours 24 (p=0.0005, t=4.096), 48
(p=0.0004, t=4.181), and 72 p.i. (p<0.0001, t=5.376). (B) Percent-cell loss in
NHBE monolayers p.i. as quantified via number of DAPI-positive cells in
each field of view (average of n=3/images per well). Increased cell loss at
hours 48 (p=0.0018, t=4.321) and 72 p.i. (p=0.0313, t=3.067) in obese-derived
NHBE cells.(C) Representative images of cell monolayers stained for DAPI
and selective dye uptake to the cell membrane at hour 72 p.i. Data
analyzed in (A, B) with ordinary one-way ANOVA with Sidak’s multiple
comparisons test and represented as means ± standard error with *p<0.05.

followed by reduced IFN signaling, as STAT1 (p= 0.0293) and IFIT1 (p=0.0211) expression
at hour 24 p.i. is reduced in obese-derived versus lean-derived NHBE cells (Figure 5.7).
All gene expression is normalized to levels in lean-derived cells at baseline. The observed
impairment IFN responses is accompanied by increased viral replication, as shown above.
These studies provide initial evidence that the epithelial cells from people with obesity
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Figure 5.7: Human primary respiratory epithelial cells from obese
donors show blunted interferon responses.
(A-F) RNA extracted from obese- and lean-derived NHBE cells (n=3
wells/timepoint) infected at MOI=10 with CA/09 virus. Gene expression
normalized to GAPDH and average expression of target gene in lean cells
at baseline. Compared to lean cells, obese-derived NHBE cells have
reduced increased expression of (A) IRF7 at hour 8 p.i., (B) IFNA1 and (C)
IFNB1 at hour 16 p.i. and (D) IFNL2, (E) STAT1 and (F) IFIT1 at hour 24 p.i.
(G-H) NHBE cells (n=2-3 donors/BMI) were stimulated with CA/09 virus
(IAV), or nucleotide analogs Poly I:C and R848, or PBS as control. Total (G)
IFNα and (H) IFNλ in the basolateral chamber was quantified via ELSIA at
hour 12 post stimulation. Data analyzed in (A-F) with unpaired t-test and
in (H) with two-way ANOVA with Sidak’s correction. All data represented
as means ± standard error with *p<0.05.

have blunted antiviral responses leading to increased viral replication kinetics.
To understand a potential mechanism behind this blunted IFN response, differentiated NHBE cells were stimulated with different TLR-agonists, inoculated with CA/09
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virus as a positive control, or treated with PBS as a negative control. High-molecular
weight poly I:C, a synthetic analog of double-stranded RNA, was chosen as a TLR-3 specific agonist, and low-molecular weight R848, or resiquimod, was chosen as a TLR-7/8
agonist. At 16 hours post-stimulation, concentration of IFNα and IFNλ in the basolateral
media was determined via ELISA. While differences were detected in type I IFN levels at
the expression levels, the concentration of IFNα in the basolateral media was too low to
quantify levels (Figure 5.7). However, the type III IFN levels were easily quantitated and
showed a significant difference in IFNλ concertation upon infection with influenza virus
(p=0.0284) or stimulation with Poly I:C (p=0.0004), but no difference in IFNλ concentration upon stimulation with R848 or PBS, suggesting a TLR-3 specific sensing and signaling
deficiency in obese-derived primary respiratory epithelial cells (Figure 5.7).

5.2.6

Greater reactive oxygen species production in obese-derived compared
to lean-derived respiratory epithelial cells contributes to altered cytokine
milieu

Obesity is commonly defined as a state of chronic, meta-inflammation with systemic effects (Andersen, K. E. Murphy, and Fernandez, 2016). What exact effects does obesity
impact in NHBE cells that can contribute to the observed diminished antiviral responses?
This heightened inflammatory state has been contributed to higher levels of reactive oxygen species (ROS), which are also implicated in the aging process (Correia-Costa et al.,
2016; Perez et al., 2016). ROS levels are increased in obese-derived NHBE cells at baseline
(p=0.0158) and upon inoculation with CA/09 virus (p=0.0289). Treatment with the ROSscavenger N-acetyl-l-cysteine ameliorates this difference and reduces the viral load at hour
24 p.i. in obese NHBE cells (p=0.0322, Mata et al., 2011; R.-H. Zhang et al., 2014, Figure 5.8).
The heightened inflammatory environment in the obese state may reduce the interferon response through modulation of suppressor of cytokine signaling (SOCS) proteins.
The interplay among proinflammatory cytokines, interferon induction and signaling, and
the SOCS negative regulators was probed in obese and lean-derived NBHEs. At the RNA
level, increases in SOCS1 and SOCS3 expression was blunted and delayed in obese-derived
cells compared to lean. Interestingly, levels of SOCS genes tended down by hour 24 p.i.
in lean cells, yet in obese, were finally showing their delayed increases over baseline levels (Figure 5.8). SOCS proteins are key negative regulators of the cytokine response, and
too much, too little, or expression at the wrong time can have drastic implications for
pathogenesis and have been implicated in the modulated immune response in obese hosts
(Teran-Cabanillas et al., 2014; S. Liu et al., 2019). The secreted cytokine mileu in obese
and lean NHBE cells was quantified using a multi-analyte proinflamatory cytokine ELISA
platform (MSD). At baseline, obese-derived NHBE cells show reductions in IL-10 levels,
but heightened IFNγ, IL-1β and IL-6 concentrations. Conversely, at timepoints p.i., lean
cells show a robust response to infection as evident by increases in important antiviral
cytokines, including IL-6 and TNFα (Figure 5.8).
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Finally, the increases in oxidative stress, modulations to pro-inflammatory cytokine
production, as well as the increased entry and replication of influenza virus into the obese
cell could be linked by very early signalling processes at the plasma membrane. Interestingly, the protein level of epidermal growth factor receptor (EGFR) trends higher in
obese-derived cells compared to lean (Figure 5.8). Increased EGFR levels have been positively associated with obesity, and have been previously shown to enhance influenza virus
uptake into host cells and contribute to immunopathology during infection (Eierhoff et al.,
2010; Kedzierski et al., 2017; Ito et al., 2015; Giordano et al., 2013).

5.3

Discussion

In three distinct models of obesity—genetically obese, leptin-deficient mice, obese-derived
primary epithelial cells, and the diet-induced obese ferret model—an IFN-deficient state
promotes greater influenza disease severity. Here, it is shown that obese hosts, specifically
the obese respiratory epithelium, are deficient in viral sensing and suffers increased viral
spread, due to a blunted and delayed IFN response, possibly mediated by ROS-induced
increases in EGFR and suppression of antiviral responses. This altered environment has
dire implications for pathogenesis, but also may influence viral life cycle dynamics within
the host. By recognizing how the immune response lacks in the obese host, clinicians are
Figure 5.8: Greater reactive oxygen species production in obese-derived
compared to lean-derived respiratory epithelial cells.
(A) Greater ROS production in obese-derived NHBE cells at the air-liquid
interface at baseline (p=0.0158, t=3.362), upon infection with CA/09 virus
at MOI=0.1 (p=0.0289, t=3.071), or with hydrogen peroxide positive control
(p=0.0101, t=3.573). (B) Treatment of NBHE cells (average titer from n=3
wells with n=3 donors/BMI) with the ROS-scavenger N-acetyl-l-cysteine
reduces CA/09 viral titers in obese, but not lean-, derived NHBE cells
(p=0.0322, t=3.034). (C-D) RNA extracted from obese- and lean-derived
NHBE cells (n=3 wells/timepoint) infected at MOI=10 with CA/09 virus.
Gene expression normalized to GAPDH and average expression of target
gene in lean cells at baseline. Compared to lean cells, obese-derived NHBE
cells have reduced increased expression of (C) SOCS1 at hour 16 p.i.
(p<0.0001, t=9.302), and (D) SOCS3 at hours 0 (p=0.0044, t=4.872), 8
(p<0.0001, t=8.760), and 16 p.i. (p<0.0001, t=9.319). (E-J) Pro-inflammatory
cytokine concentration in apical supernatants collected at indicated
timepoints from obese and lean-derived NHBE cells inoculated with
CA/09 virus at MOI=0.01. (K) Protein levels of EGFR on NHBE cells. Data
analyzed with two-way ANOVA with Sidak’s correction or (K) with t-test.
Data represented as means ± SEM with *p<0.05.
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Figure 5.8: Greater reactive oxygen species production in obese-derived
compared to lean-derived respiratory epithelial cells.

Chapter 5. Blunted Interferon Responses and Amplified Influenza Disease Severity in
79
Obese Hosts
better suited to treat this and other high-risk populations and can inform better vaccine
and antiviral design.
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Chapter 6
Enhanced Genetic Diversification of Obese-Derived
Viral Populations and Consequences for Antiviral
Efficacy1

6.1

Introduction

IAV is a rapidly mutating virus that impacts nearly 15% of the population seasonally, even
more in a pandemic year (V. J. Lee et al., 2018). RNA viruses like IAV replicate using an
RNA-dependent RNA polymerase (RdRp) that lacks proofreading functionality (Domingo
and J. J. Holland, 1997). The resulting high error rate during viral replication ensures the
emergence of minor variants that may affect viral fitness and harm our ability to prevent
infections and mitigate disease severity by rendering antivirals ineffective (J. Holland et al.,
1982; A. J. Te Velthuis and Fodor, 2016; Lauring and Andino, 2010; Giwa, Ogedegbe, and
C. G. Murphy, 2018). Interestingly, host status is implicated in impacting acute, withinhost viral evolution. The acquisition of these novel minor variants has been shown to be
sensitive to host characteristics, such as immunocompromised status, oxidative stress, and
aging (Gay et al., 2006; Levander, 2000; N. Lee and Hurt, 2018; Kiso et al., 2004)
Here, I discuss the impacts of the interferon (IFN)-deficient, obese microenvironment on two aspects of influenza evolution: generation of novel minor variants and the
emergence of phenotypic antiviral resistance. I use three distinct models of obesity—murine,
ferret, and human primary respiratory epithelial cells—in which experimental evolution,
pathogenicity, and drug susceptibility studies were performed. Overall, I conclude that the
unique microenvironment characterized by an impairment in the IFN response in obese
hosts is permissive for the generation of more virulent and possibly oseltamivir-resistant
IAV populations.
1 Portions of chapter from previously published article. Modified: From final submission with open access
permission from American Society for Microbiology. Honce, R., E. A. Karlsson, et al. (Mar. 2020). “ObesityRelated Microenvironment Promotes Emergence of Virulent Influenza Virus Strains”. In: Mbio 11.2. ISSN:
2150-7511 (Electronic). DOI: 10.1128/mBio.03341-19.
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6.2
6.2.1

Results
Experimental evolution of H1N1 influenza virus in obese mice results in
increased disease severity

As previously stated, genetically obese mice (OB) have increased pulmonary viral spread
at day 3 post-infection (p.i., Figure 5.1, Figure 6.1). To determine if this enhanced viral
spread was associated with changes in the viral genome, viral RNA was extracted from
lung homogenates, amplified using universal influenza primers and deep-sequenced. While
no consensus changes were noted, analysis of single nucleotide variants (SNVs) at a frequency of greater than 5% in the viral population showed greater mean within-host diversity in the lungs of obese mice compared to wild-type as measured via Shannon’s entropy
(H) (p=0.0167, Figure 6.1). Although there was a trend for increased diversity in several
genes, only the PB2 gene was significantly increased in obese mice (p=0.0203, Figure 6.1).
This finding led to the question, does the obesogenic microenvironment impact
within-host viral evolution and pathogenicity of IAV? Thus, OB and WT mice were intranasally inoculated with 103 TCID50 units of A/California/04/2009 (CA/09) H1N1 virus.
Lungs were collected day 3 p.i., homogenized and viral titer determined. Naïve OB and
Figure 6.1: Experimental evolution of H1N1 influenza virus in obese
mice results in increased disease severity upon inoculation of wild-type
mice with obese-derived virus.
(A) OB and WT mice inoculated with a bioluminescent reporter
CA/09-nLuc virus (n=5 mice/genotype/timepoint). (B-C) Shannon’s
entropy of viral population is increased in OB-derived viruses at day 3 p.i.
(B) Diversity measures of all genome segments; unpaired t-test OB versus
WT p=0.0167, t=3.959, df=4. (C) Diversity measures by genome segment,
two-way ANOVA, source of variation in diversity for mouse genotype,
p=0.0260; segment PB2 p=0.0203. (D-G) CA/09 virus experimental
evolution through n=3-5 WT mice per passage for 10 passages or OB mice
for 5 passages. (D) CA/09 virus experimental evolution scheme in OB and
WT mice. (E) Percent weight change from baseline at day 3 p.i. in OB and
WT mice. (F) Viral titer recovered at day 3 p.i. in from lungs of n=5 WT or
OB mice. (G) Clinical scores of OB and WT at day 3 p.i. (H-J) Pathogenicity
of indicated viruses (300 TCID50 units) in WT. (H) Percent weight change.
(I) Percent survival. (J) Lung viral titers recovered at day 3 p.i. Data
analyzed in (E-G) with ordinary two-way ANOVA with Sidak’s correction,
in (H) with ordinary two-way ANOVA with Tukey’s multiple comparisons
test up to day 8 p.i., in (I) with Mantel-Cox log rank test, and in (J) with
ordinary one-way ANOVA with Tukey’s multiple comparisons test. Data
represented as means ± SEM with *p<0.05.
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Figure 6.1: Experimental evolution of H1N1 influenza virus in obese
mice results in increased disease severity upon inoculation of wild-type
mice with obese-derived virus.
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WT mice were then intranasally inoculated with 103 TCID50 units of diluted, pooled lung
homogenate for a total of 5 or 10 passages, respectively (Figure 6.1). This scheme was repeated twice, and results reported are representative of the two independent experiments.
Throughout passaging, no difference in weight loss at day 3 p.i. was reported
(Figure 6.1). However, OB mice displayed increased clinical scores and disease severity at viral passage 3 (p=0.0393), 4 (p=0.0015), and 5 (p<0.0001) compared to WT controls
(Figure 6.1). Increasing severity across the passages only occurred in the OB model, forcing an early stop to passaging due to due to high mortality induced by the obese passage
5 (OBp5) virus. Viral titers in lung homogenates did not significantly differ neither across
passaging nor mouse model (Figure 6.1).
The observed increased clinical severity in obese models following passaging may
be an artifact of the poor immunity and heightened disease severity common to obese
hosts, or be due to changes to the viral population propagated in the obese microenvironment. To test, WT mice were inoculated with increasing doses of the original CA/09
viral stock (p0), OBp5 virus, or the virus passaged five or ten times through WT mice
(WTp5 or WTp10, respectively) and monitored for mortality. Mean lethal dose 50 (MLD50 )
was decreased with OBp5 virus (101.92 TCID50 /mL) versus p0 virus (103.92 TCID50 /mL)
and WTp5 virus (103.66 TCID50 /mL) suggesting passage of IAV through an obese mice
enhanced the virulence of the viral population.
To test if increased morbidity was associated with clinical disease severity and viral titer, WT mice were inoculated with 300 TCID50 /mL of p0, OBp5, WTp5, or WTp10
virus and monitored over 14 days. WT mice inoculated with OBp5 virus had significantly
increased weight loss up to day 8 p.i. (vs p0 p<0.001; vs WTp5 p<0.001) and mortality
(p<0.001) compared to WT mice inoculated with p0 or WTp5 virus; however, these differences were mitigated at WTp10 (Ilyushina, Khalenkov, et al., 2010). Increased morbidity
and mortality due to the OBp5 virus was associated with increased lung viral titers at day
3 p.i. (vs p0 p=0.0278; vs WTp5 p=0.0278 (Figure 6.1).

6.2.2

Emergence of a virulent phenotype is not specific to obesity model or viral
strain

The leptin-deficient mouse model of obesity is not a perfect approximation of the etiology of human obesity (Lutz and Woods, 2012). To determine if the observed phenotype
was unique to genetically obese mice, the study was repeated the studies using the dietinduced obese (DIO) model. Similar results were observed in DIO mice, with mice fed a
low-fat diet or regular chow (LN) for a similar time as controls. Weight loss was similar between DIO and LN mice until passage 5, in which DIO mice lost significantly more weight
than LN by day 3 p.i. (p=0.0001, Figure 6.2). Similar to passaging through the OB model
DIO mice displayed increased clinical scores at passage 4 (p=0.0200) and 5 (p=0.0012, Figure 6.2). Viral titers at day 3 p.i. were similar between the DIO and LN models at each
passage except for at passage 2 where modestly increased viral titers were recovered from
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DIO mice (p=0.0403, Figure 6.2). Upon inoculation of WT mice, DIOp5 virus induced increased weight loss (vs p0 p=0.0539; vs LNp5 p=0.1397) and mortality (p=0.0364, Figure 6.2)
in WT mice compared to LNp5 virus inoculated mice. Lung viral titers were 10x higher in
DIOp5 inoculated mice versus p0 (p=0.0001) and LNp5 (p<0.0001) and MLD50 was 102.66
TCID50 /mL for DIOp5, and >103.00 TCID50 /mL for LNp5 (Figure 6.2).
A potential practical application to these findings is the ability to quickly adapt human influenza viruses to mice. Contemporary (post-2010) H3N2 viruses are problematic
to study in laboratory settings due to poor in vitro and in vivo replication. It is difficult to
discern viral titers as it poorly hemagglutinates commonly used turkey and chicken erythrocytes (J. M. Katz, Naeve, and Webster, 1987; Romanova et al., 2003; X. Sun et al., 2018).
Could passage through an OB host rapidly adapt these viruses for use in vivo? To test if
these findings were unique to CA/09 H1N1 virus, OB and WT mice were inoculated with
A/Switzerland/ 9715293/2013 H3N2 virus as described in Chapter 3. Viral titers steadily
and significantly increased over 5 blind passages in OB mice (p=0.0077). Like CA/09 virus,
the OB-derived H3N2 virus induced significantly increased weight loss (p<0.0001) as well
as viral titers (p=0.0028) in WT mice as compared to the parental strain. In contrast, no
Figure 6.2: Emergence of a virulent phenotype is not specific to obesity
model or viral strain.
(A-C) Serial passage of pH1N1 through n=3-5 DIO and LN mice. (A)
Weight changes, (B) clinical disease, and (C) lung viral titers measured at
day 3 p.i. for DIO and LN mice at each passage. (D-F) WT mice (n=5
mice/virus) inoculated with DIOp5 (n=3-5 mice/passage) showed (D)
increased weight loss and (E) reduced survival compared to virus
passaged through LN mice or the parental viral strain p0. (F) Viral titers at
day 3 p.i. are increased in WT mice inoculated with DIOp5 virus compared
to LNp5 and parental viruses (n=3/virus). (G-H) H3N2 virus passaged
blindly through n=3-5 OB mice/passage. (G) Productive infection in only
OB mice as lung viral titers increased at each passage. Viral titers
quantitated via cytopathic effects, with dotted line representing limit of
detection. (H-I) Infection of WT mice with parental H3N2 virus (p0) or
OBp5-H3N2. (H) OB-derived H3N2 virus induced weight loss in WT mice
compared to parental virus. Dotted line represents baseline body weight.
(I) Viral titers recovered from WT mice inoculated with OB-derived H3N2
virus and assayed via hemagglutination of turkey red blood cells
(p<0.0001, t=19). Data analyzed in (A-C, F-G) with ordinary one-way
ANOVA, in (D, H) with ordinary two-way ANOVA with Sidak’s multiple
comparisons test, in (E) Mantel-Cox log-rank and in (I) with unpaired
t-test. Data represented as means ± standard error with *p<0.05. Data
displayed as means ± SEM with *p<0.05.
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infectious virus was recovered from WT mice at day 3 p.i. in the initial infection, so passaging through the WT background could not be completed. These results highlight the
obese mouse supports replication of seasonal H3N2 viruses and can be utilized to rapidly
adapt viruses for in vivo study. Taken together, obesity promotes the evolution of virulent
influenza viruses, even upon inoculation of a WT host (Figure 6.2).

Figure 6.2: Emergence of a virulent phenotype is not specific to obesity
model or viral strain.

Chapter 6. Enhanced Genetic Diversification of Obese-Derived Viral Populations and
86
Consequences for Antiviral Efficacy

6.2.3

Obese-passaged viruses have increased replication kinetics in vitro

The replicative capacity of OB and WT-passaged viruses was further interrogated in vitro.
In reflection of what was observed in vivo, OBp5 virus replicated to significantly higher
titers versus WTp5 (p<0.0001) and p0 (p=0.0011) viruses in single-cycle replication kinetics
in MDCK cells at a multiplicity of infection (MOI) of 1.0 (Figure 6.3). Similarly, in multicycle replication kinetics (MOI of 0.001), OBp5 virus replicated to significantly increased
titers versus WTp5 (p<0.0001), WTp10 (p=0.0238) and p0 (p<0.0001) viruses (Figure 6.3).
Not surprisingly, the OBp5 virus had higher vRNA (p=0.0079), cRNA (p=0.0110) and mRNA
(p=0.0117) levels explaining the enhanced replication. DIOp5 virus showed similar replication kinetics as OBp5. At a high MOI, DIOp5 virus replicated to significantly higher
titers versus p0 (p=0.0044) and LNp5 viruses (p<0.0001) in MDCK cells at a high MOI. At
low MOI, DIOp5 virus had higher viral titers compared to p0 virus (p=0.0117, Figure 6.3).
Since OB-passaged viruses showed increased replication in vitro, the stage in the viral life cycle impacted was determined through immunocytochemistry analysis of MDCK
Figure 6.3: Obese-passaged viruses replicate more quickly and to higher
titers in vitro.
(A) OBp5 virus replicates more quickly in MDCK cells (n=4 wells/virus)
inoculated at multiplicity of infection (MOI) of 1.0 of versus p0 and WTp5
viruses. (B) MDCK cells inoculated with indicated viruses at MOI=0.01
(n=3 wells/virus/timepoint). OBp5 virus replicates to higher titers
compared to the parental p0 virus, WTp5 and WTp10 viruses. (C-E) Mean
fold increase over mock in RNA species production at hour 4 p.i. in MDCK
cells (n=5 wells/virus) inoculated with p0, OBp5, WTp5, or WTp10 virus.
Total RNA was isolated and the levels of vRNA, mRNA, and cRNA were
determined in triplicate using NP strand-specific primers. OBp5 virus
produces greater increases in (C) vRNA species, (D) cRNA species, and (E)
mRNA species compared to WTp5 and WTp10 viruses, and greater than p0
viruses for vRNA and cRNA species. n=1 outlier removed from WTp5 data
for mRNA using the ROUT test for outliers. (F) MDCK cells (n=3
wells/virus) inoculated at multiplicity of infection (MOI) of 1.0 for
single-cycle replication kinetics of p0, DIOp5, and LNp5 viruses. (G)
MDCK cells (n=3 wells/virus/timepoint) inoculated at MOI of 0.01 with
DIOp5 virus shows increased replication kinetics compared to inoculation
with p0 and LNp5 viruses. Data analyzed in (A,B,F,G) with ordinary
two-way ANOVA with Tukey’s multiple comparisons test and in (C-E)
with ordinary one-way ANOVA with Tukey’s multiple comparisons test
and represented as means ± standard error with *p<0.05.
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cells infected with p0, OBp5, WTp5, and WTp10 viruses. The viral M1, NP, and NS1 proteins were probed and visualized using confocal microscopy, with mean fluorescent intensity calculated in ImageJ (Figure 6.4). Increased expression of NP, M1, and NS1 was evident by hour 8 p.i. in OBp5 virus infected MDCK cells as compared to WTp5 (NP p<0.0001;

Figure 6.3: Obese-passaged viruses replicate more quickly and to higher
titers in vitro.
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M1 p=0.0024; NS1 p=0.0009) and p0 (NP p<0.0001; M1 p<0.0001; NS1 p<0.0001) viruses. Increased NP staining at hour 8 p.i. was observed for OBp5 virus infected cells compared
to WTp10 virus (p=0.0102). There was no significant difference in M1 or NS1 expression
between OBp5 and WTp10 viruses. All passaged viruses displayed increased NP, M1, and
NS1 expression compared to p0 at hour 8 p.i., and for NS1 at hour 6 p.i. (Figure 6.4).
Overall, these studies suggest that influenza infection in obese mice results in higher viral
population diversity and the emergence of more virulent viruses with increased replicative
ability. These studies suggest obese-passaged H1N1 virus has increased replication kinetics over lean-passaged virus, supporting the hypothesis that an obesogenic environment
permits evolution of increased pathogenicity in the IAV population.

6.2.4

Higher within-host diversity and mutations associated with virulence in
obese-passaged viruses

As seen in Figure 6.1, obese animals harbor increased genetic diversity in the within-host
influenza virus population at day 3 p.i. Is this diversity maintained upon passage from
host-to-host? Upon experimental evolution, passage 1 retained the highest diversity, but
Figure 6.4: Greater production of viral proteins in MDCK cells
inoculated with obese-derived viruses.
Immunocytochemistry analysis of MDCK cells infected with p0, OBp5,
WTp5, and WTp10 viruses visualized using confocal microscopy with
mean fluorescent intensity calculated in Image J. (A) Representative images
of MDCK cells (n=4 wells/virus) probed for NP, M1, and NS1 viral
proteins. (B-D) Mean fluorescent intensity (MFI) of NP, M1, and NS1
staining in micrographs (n=3 micrographs/fixed Transwell). Ordinary
two-way ANOVA with Tukey’s multiple comparisons test; virus NP
p<0.0001, DF=3, F=9.352; M1 p=0.0006, DF=3, F=6.852; NS1 p<0.0001, DF=3,
F=15.46; HPI NP p<0.0001, DF=2, F=35.59; M1 p<0.0001, DF=2, F=14.27;
NS1 p<0.0001, DF=2, F=42.13; and the interaction NP p<0.0001, DF=6,
F=7.159; M1 p=0.0064, DF=6, F=3.438; NS1 p<0.0001, DF=6, F=7.067.
Increased expression of NP, M1, and NS1 by hour 8 p.i. in OBp5 virus
infected MDCK cells as compared to WTp5 (NP p<0.0001; M1 p=0.0024;
NS1 p=0.0009) and p0 (NP p<0.0001; M1 p<0.0001; NS1 p<0.0001) viruses.
Increased NP staining at hour 8 p.i. was observed for OBp5 virus infected
cells compared to WTp10 virus (p=0.0102). There was no significant
difference in M1 or NS1 expression between OBp5 and WTp10 viruses. All
passaged viruses displayed increased NP, M1, and NS1 expression
compared to p0 at hour 8 p.i., and for NS1 at hour 6 p.i. Data presented as
means ± SEM with *p<0.05.
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Figure 6.4: Greater production of viral proteins in MDCK cells
inoculated with obese-derived viruses.
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obese-derived viruses maintained higher Shannon’s entropy versus WT-derived viruses
(p=0.0498). The bulk of the viral diversity is explained through higher sequence variation in polymerase segments for OB-derived viruses (PB2 p=0.0137; PB1 p=0.1627; PA
p=0.0300). Shannon’s entropy is also higher, albeit non-significantly, for NEP/NS1 (p=0.0556,
Figure 6.5). No significant differences were found in the other four genomic segments.
Investigation of single nucleotide variants (SNVs) reveals amino acid changes, primarily in polymerase proteins as well as NS1 protein (Table 6.1). The PA-X F35L and PB2
K482R mutations are known to be associated with mouse adaptation (E. G. Brown and
Bailly, 1999; B. A. Brown and Pallansch, 1995; Smeenk et al., 1996). PB2 K482R (E. G.
Brown and Bailly, 1999; B. A. Brown and Pallansch, 1995; Smeenk et al., 1996), PB2 E158G
(Zhou et al., 2011), PA-X F35L (Bhoye and Cherian, 2018; Seyer et al., 2012), the PA E349
site (Rolling et al., 2009; Z. Zhang et al., 2011), and NS1 R211K (Engels et al., 2017) are
associated with increased replication. No experimental studies to date have addressed
the virulence properties attributable to PB2 L154I and NA G336D mutations, which were
found at relatively high frequencies in OB-passaged viruses, and the NS1 A202V mutation,
which was found in OB- and at a much lower frequency in WT-passaged viruses. All identified variants have been previously identified in circulating human H1N1 viruses, albeit at
low frequencies, as evidenced by sequences in the Influenza Research Database (Table 6.2,
Y. Zhang et al., 2017). Finally, deep sequencing viruses isolated from WT mice infected
with OBp5 virus showed PB2 L154I, PB2 K482R, PA E349K, and NS1 A202V variants, as
well as PA-X F35L variant associated with mouse adaptation, were maintained in the population. This contrasts with viruses from mice infected with WTp5 and WTp10 viruses
where only PB2 K482R, NS1 A202V and PA-X F35L (WTp5) and PA-X F35L (WTp10) variants were maintained in the population (Table 6.3). All mutations found at 1% or greater
in OB-passaged viruses are displayed in Appendix C.
Within-host diversity was less variable in the DIO versus LN model. However, all
DIO-derived viruses, as with OB-derived viruses, exhibit greater Shannon’s entropy than
those isolated from LN hosts (p=0.0379, Figure 6.5). For DIO passaging, the single SNV
biologically relevant in DIOp5 was PB2 E158G, which has been previously reported in human samples (Table 6.2). All variants found at 1% or greater are in Appendix C. Finally,
obese-derived human bronchial epithelial cells also show a delayed and blunted IFN response that affords increased influenza viral replication ex vivo. NHBE cells differentiated
at the air-liquid interface were inoculated with CA/09 PA-Nluc virus. At hour 48 p.i.,
apical washes were collected for population analysis via deep-sequencing. Viruses grown
in obese epithelial cells showed greater numbers of unique SNVs (p=0.0184) and greater
Shannon’s entropy (p<0.0001, Figure 6.5) across the entire genome compared to viruses
derived from growth in lean epithelial cells. Together, in three laboratory models, including primary respiratory epithelial cells, influenza infection of obese hosts results in the
production of a more genetically diverse viral population.
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Figure 6.5: Obese-derived viruses show increased genetic diversity.
(A) OB-derived viruses over each passage exhibit higher pooled Shannon’s
entropy measurements for all genome segments compared to WT-derived
viruses. (B-E) Mean within-host viral diversity estimated using Shannon’s
entropy (H) for (B) PB2 (p=0.0137), (C) PB1 (p=0.1627). (D) PA (p=0.0300),
and (E) NEP/NS1 (p=0.0556) gene segments. (F) Shannon’s entropy is
increased in DIO-derived viruses (n=6 viruses/genotype from passage 1
and passage 5) compared to LN derived viruses (p=0.0379, t=2.390). (G-H)
CA/09 PA-Nluc virus grown in obese- or lean-derived NBHE cells. (G)
Obese-derived viruses show greater number of (G) mutations (p=0.0184,
U=14) and (H) greater Shannon’s entropy (p<0.0001, U=0) compared to
lean-derived viruses. Data were analyzed in (A) with an unpaired t-test
and in (B-E) for normality using Shapiro-Wilk test, and statistical
comparisons were made between using a Mann-Whitney (B, C, E, G, H) or
unpaired t-test (D, F).
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Table 6.1: Minor viral variants in obese and wild-type derived viral
populations.

SNV calls1
23.5 ± 12.5
43.0 ± 14.5
112.3 ± 15.8
111.3 ± 26.7
133.7 ± 13.5
90.8 ± 19.3
36.4 ± 12.3
78.3 ± 21.8
85.3 ± 4.7

Passage
p0
OBp1
OBp2
OBp3
OBp4
OBp5
WTp1
WTp5
WTp10

PB2
L154I
#4 %5

1
2
3

23%
16%
19%

PB2
K482R
# %

2
3
2
3

6%
52%
13%
50%

PA
E349K
# %

PA-X/PA
F35L2
# %

PA-X/PA
F35L3
# %
28%

7%

68%
5%
14%
22%
21%

2

3

2
1
3
3
5
5

38%

1

6%

3
3
4
1
2
2

21%
23%
11%
25%
35%
8%

NA
G336D
# %

NS1
A202V
# %

NS1
R211K
#
%

3
3

2
2
3
3

14%
14%
28%
21%

1
2%
1%
2%

2

8%

12%
18%

38%
8%
5%
6%

1 Average

± SEM of non-synonymous and synonymous SNVs each passage (n=3-8 lung
homogenates/passage).
2 Nucleotide change of TTT → CTT.
3 Nucleotide change of TTT → TTG.
4 Total number of mice with variant at ≥ 5%.
5 Average relative frequency of mutation in samples with mutation.

Table 6.2: Relative frequencies of obese-derived mutations found in
circulating human H1N1 viruses.
Protein
PB2
PB2
PB2
PA-X
PA
PA
NA
NS1
NS1

Amino acid
position
154
158
482
35
35
349
336
202
211

Consensus
amino acid
Leu
Glu
Lys
Phe
Phe
Glu
Gly
Ala
Arg

Variant
amino acid
Ile
Gly
Arg
Leu
Leu
Lys
Asp
Val
Lys

Sequences
with variant
114
3
15
18
17
7
138
2
21

Total
sequences
11321
11322
11347
14283
13998
11402
20109
11122
11112

Relative frequency
of variant (%)
1.01
0.03
0.13
0.12
0.12
0.06
0.69
0.02
0.19

Data source: Zhang, Y. et al. (Jan. 2017). “Influenza Research Database: An integrated
bioinformatics resource for influenza virus research”. In: Nucleic Acids Res 45.D1, pp.
D466–D474.ISSN: 1362-4962 (Electronic) 0305-1048 (Linking). DOI: 10.1093/nar/gkw857.
Database accessed 22 August 2019.
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Table 6.3: Previously identified viral variants present upon reinfection of
WT mice with indicated viruses.

Passage
OBp5
WTp5
WTp10

PB2
L154I
#3 %4
2
45%

PB2
K482R
# %
5 55%
6 47%

PA
E349K
# %
5 8%

PA-X
F35L1
# %
7 26%
8 44%
2 57%

PA-X
F35L2
# %
5 28%
3 34%
2 13%

NA
G336D
# %

NS1
A202V
# %
3 22%
3 10%

NS1
R211K
# %

1 Nucleotide

change of TTT → CTT
change of TTT → TTG
3 Total number of mice with variant at ≥ 5%.
4 Average relative frequency of mutation in samples with mutation.
2 Nucleotide

6.2.5

Increased pathogenicity occurs at early passages through the obese model

The augmented virulence was not unique to passage 5. Sequencing analysis shows earlypassage viruses contain mutations also present in the OBp5 virus, with NS1 R211K and
NS1 A202V mutations present beginning at OBp2; PB2 L154I mutation arising at OBp3;
and PB2 K482R and NA G336D mutations arising at OBp4. Only PA E349K variant is
unique to OBp5 (Table 1). WT mice were inoculated with 80 TCID50 units of OBp2, OBp3,
and OBp4 viruses, which is close to the MLD50 of the OBp5 virus (101.92 TCID50 units). All
viruses induced significant weight loss and mortality in WT mice and the increased replication phenotype was also observed with early passage viruses (Figure 6.6). Multi-step replication kinetics (MOI of 0.001) in MDCK cells showed replication trended higher in OBp1
versus WTp1 (p=0.0669), was significantly increased for OBp2 versus WTp2 (p=0.0158),
trended higher for OBp3 versus WTp3 (p=0.0548) and was significantly increased for OBp4
versus WTp4 (p=0.0007, Figure 6.6).

6.2.6

Robust interferon responses restrict viral diversity and acquisition of virulent viral phenotypes

Impaired cellular immune responses are characteristic of obese hosts and may translate
to a reduced control of viral spread and clearance of viral infection (McNab et al., 2015).
However, these studies demonstrate increased viral diversity occurs in obese mice by day
3 p.i. At this early timepoint, IFNs are critical for controlling viral replication and spread
and are blunted in obese hosts (Chapter 5, Haller, Kochs, and Weber, 2006). Thus, I questioned if the emergence of a diverse, virulent IAV quasispecies is sensitive to IFN. Indeed,
when WT and OB mice were primed via oral gavage with 1,000 units recombinant murine
IFNα2 protein, 8 hours later infected with CA/09 virus, then intranasally treated with 1,000
units IFNα2 at hour 8 p.i., while there was no reduction in lung viral titers there was a significant decrease in Shannon’s entropy of SNP variants in OB infected mice versus those
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Figure 6.6: Increased virulence and replication emerge early during
obese passaging.
(A-B) Intermediate passages in obese mice during the experimental
evolution scheme were used to inoculate WT mice. (A) Percent weight
changes in WT mice inoculated with indicated viruses. (B) Percent survival
(p<0.0001). (C-F) Early passage OB viruses show increased replication with
(C) OBp1 trending higher, (D) OBp2 significantly replicating higher, (E)
OBp3 trending higher and, (F) OBp4 significantly replicating higher
compared to concordant WT passage viruses. Data analyzed in (A, C-F)
with ordinary one-two ANOVA with Tukey’s multiple comparisons test
and in (B) with Mantel-cox and represented as means ± standard error with
*p<0.05.
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mock treated with PBS at day 3 p.i. (Figure 6.7). No difference in Shannon’s entropy was
determined in WT-treated mice. These studies demonstrate that the blunted IFN response
associated with obesity may support the emergence of viral variants that could impact virulence. The obese environment may permit emergence of IAV virulence due to reduced
immune pressures from the type I IFN response. To test this hypothesis in vivo, I utilized
lean IFN α/β receptor knock out (IFNAR) mice and leptin-deficient, β6 integrin knock-out
mice (OBIFN), a model previously determined to be phenotypically obese with restored
type I IFN levels in the lung epithelium (V. A. Meliopoulos et al., 2016; V. Meliopoulos et
al., 2019) to determine if lack of type I IFN, independent from obesity’s impact on the IFN
response, can restrict IAV virulence. After 5 passages through the respective mouse models, WT mice were inoculated with 103 TCID50 units of OBIFNp5 and IFNARp5 viruses.
The IFNARp5 virus induced reduced survival as compared to WT mice inoculated with
OBIFNp5 virus (p=0.0002) and p0 virus (p=0.0058), as well as higher viral titers at day 3 p.i.
(p=0.0485, Figure 6.7). In conclusion, the virus grown in an IFN-deficient host phenocopies
the obese-derived virus in terms of viral diversity and virulence.

6.2.7

Similar pharmacokinetic dynamics in obese and lean mice treated with
oseltamivir

Epidemiological data suggests antivirals such as OSE are protective in hosts with obesity,
yet empirical studies show obese mice require 10-fold higher doses to achieve complete
survival (O’Brien et al., 2012; Chairat et al., 2016). To determine if pharmacokinetic dynamics of OSE and the metabolite OSE carboxylate vary due to obesity, male, 10-week-old
WT or OB mice were dosed with a single oral gavage of OSE at 10 mg/kg in 100 µL of PBS.
Whole lungs and plasma were collected at 0.5, 1, 4, 8, and 16 hours post treatment and
immediately processed for pharmacokinetic analysis (Figure 6.8). There were no practical
or significant differences in OSE or OSE carboxylate plasma and lung PK between WT and
OB mice (Table 6.4). A similar half-life of OSE (2.12 versus 2.28 hours; and its metabolite
OSE carboxylate (2.30 versus 3.3 hours) was observed in the lungs of obese mice compared
to wild-type mice. However, the maximum concentration of OSE is significantly increased
from an average of 600 ug/L in OB mice lungs to 1500 ug/L in the lungs of WT mice
(p=0.036). Similarly, analysis of plasma showed no difference in OSE (elimination half-life
1.36 versus 1.98 hours, respectively) or OSE carboxylate PK dynamics between WT and OB
mice (elimination half-life 1.87 versus 2.75 hours, respectively); however, there is a trend to
increased maximum concentration of OSE carboxylate in the serum of WT mice compared
to OB (p=0.063; Figure 6.8).

6.2.8

Oseltamivir treatment does not reduce viral titers or improve viral clearance in influenza-infected obese mice

Can OSE treatment reduce viral load or improve viral clearance in obese mice? Beginning
12 hours pre-infection and concluding at day 5 p.i., oral gavage of lean and obese animals
was performed with either 10 mg/kg OSE free-base equivalencies in 100 µL of PBS or PBS
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Figure 6.7: Robust interferon responses restrict viral diversity and
acquisition of virulent viral phenotypes.
(A-B) OB and WT mice were treated with recombinant Ifna2 protein and
inoculated with 103 TCID50 units of CA/09 virus. (A) Ifna2 treatment did
not reduce viral titers at day 3 p.i. (B) Ifna2 treatment reduced viral
population diversity in OB-derived viruses at day 3 p.i. (C-D)
Experimental evolution of CA/09 virus through IFNAR and OBIFN
(n=3-5/passage). WT mice inoculated with IFNAR virus have (F) reduced
survival compared to p0 and OBIFN viruses and (G) increased viral titers
at day 3 p.i. Data analyzed in (A-B) with ordinary one-way ANOVA with
Tukey’s correction, in (C) with Mantel-Cox log-rank test and in (D) with
unpaired t-test. Data represented as means ± standard error with *p<0.05.
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Figure 6.8: Similar pharmacokinetic parameters in lean and obese mice
dosed with oseltamivir.
(A) Naïve male, WT or OB mice were dosed once with 10 mg/kg of
oseltamivir. Plasma and lungs were collected at indicated time points for
bioanalysis. (B-C) After one dose of oseltamivir, bioanalysis of (B)
oseltamivir and (C) oseltamivir carboxylate in lungs of WT and OB mice.
(D) Significantly increased maximum concentration of oseltamivir
(p=0.0364) and trends towards increased oseltamivir carboxylate levels was
observed in the lungs of WT compared to OB mice. (E-F) After one dose of
oseltamivir, bioanalysis of (E) oseltamivir and (F) oseltamivir carboxylate
in plasma of WT and OB mice. (D) Maximum concentration of oseltamivir
and oseltamivir carboxylate in plasma of WT and OB mice. Non-significant
trend towards increased concentration of oseltamivir and oseltamivir
carboxylate in WT compared to OB plasma. Data analyzed in (B, C, E, F)
with ordinary two-way ANOVA and in (D, G) with two-way ANOVA and
Sidak’s post hoc with α=0.05. Data represented as means ± SEM.
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Table 6.4: Pharmacokinetic parameters of oseltamivir and oseltamivir
carboxylate in plasma and lungs of obese and wild-type mice.

Parameter1
Cmax
tmax
AUClast
AUCin f
Kplast
Kpin f
Kel
t1/2
CL/F
Vz /F
Clast
tlast

Unit
µg/L
hr
hr*µg/L
hr*µg /L
1/hr
hr
L/hr/kg
vol/kg
µg /L
hr

Oseltamivir
Obese
Wild-type
Plasma Lung
Plasma Lung
428
839
950
1570
0.5
1
0.5
0.5
1110
3290
1080
3350
1110
3310
1100
3630
0.3374
0.3224
0.3353
0.3030
0.35
0.328
0.509
0.304
1.98
2.12
1.36
2.28
8.99
3.02
9.09
2.75
25.7
9.22
17.9
9.05
1.99
7.02
9.32
69.1
16
16
8
8

Oseltamivir carboxylate
Obese
Wild-type
Plasma Lung
Plasma Lung
1800
162
2960
565
1
0.5
0.5
1
4810
439
6150
637
4860
486
6170
735
10.96
9.655
10.00
8.395
0.252
0.301
0.372
0.208
2.75
2.3
1.87
3.33
2.06
20.6
1.62
13.6
8.16
68.2
4.36
65.2
14.1
15.9
6.8
16.2
16
8
16
8

1 Parameters

measured in units reported in parenthesis with values Cmax =maximum
concentration of analyte; tmax =time to reach maximum concentration of analyte;
AUClast =area under the concentration-time curve from time zero to time of last
measurement concentration; AUCin f =area under the concentration-time curve from time
zero to infinity; Kplast =apparent plasma-to-lung partition coefficient ratio of AUClast in
plasma to lungs; Kpin f =apparent plasma-to-lung partition coefficient ratio of AUCin f in
plasma to lungs; Kel =rate constant; t1/2 =elimination half-life; CL/F=time of apparent
total clearance of the drug; Vz /F=apparent volume of distribution during terminal phase;
Clast =concentration of analyte at last measured time; tlast =time at which concentration of
analyte was above the lower limit of detection.

vehicle control every 12 hours (O’Brien et al., 2012). Mice were infected with CA/09 virus
and lungs excised at 0.5-, 1-, 3-, 5- and 7-days p.i. (Figure 6.9). Significant changes in
weights were observed by days p.i. (p<0.0001), as well as mouse genotype and treatment
group (p<0.0001) according to a mixed-effects model (Figure 6.9). WT mice treated with
OSE displayed significantly increased weight loss compared to OB mice treated with OSE
(p=0.0136) and OB control mice (p=0.0152). No significant differences in viral titers over
time were detected (Figure 6.9), but area under the curve (AUC) analysis suggests significantly accelerated viral clearance upon OSE treatment for WT mice compared to all other
experimental groups (vs WT + PBS p=0.012; vs OB + PBS p=0.0007; vs OB + OSE p=0.0014;
Figure 6.9). No trend in accelerated viral clearance was observed for OSE-treated obese
mice compared to untreated obese mice in AUC analysis.
The exact mechanism by which OSE inhibits viral replications and improves outcomes upon infection is unknown. Mathematical models and empirical studies suggest
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the host immune response is a vital component in OSE efficacy and OSE itself may modulate the host immune response (Z. Li et al., 2014; Boda et al., 2018). IFN also acts synergistically with OSE to aid in viral clearance (Ilyushina and Donnelly, 2014). Further, there is a
demonstrated, critical deficit in type I IFN responses in obese hosts (Chapter 5, Namkoong
et al., 2019). Will OSE treatment further upregulate type I IFN and aids viral clearance in
non-obese mice? Male OB and WT mice were treated with OSE according to the schematic
in Figure 6.9 and infected with influenza A virus at 12 hours post-initial treatment. At the
peak of viral infection (day 3 p.i.), lungs were excised, total RNA extracted and probed
for type I IFN expression. In comparison to mock-treatment, OSE treatment results in
further upregulation of Ifna1 and Ifnab1 expression in the lungs of CA/09 infected mice
(Figure 6.9). The lungs of CA/09-infected, OSE-treated WT mice showed a nearly 4-fold
increase in Ifna1 expression compared to treated (p=0.0292) and untreated (p=0.0203) obese
mice. There was no significant increase in Ifna1 expression in OSE treated versus mocktreated obese mice who were infected with CA/09 virus (Figure 6.9). Similarly, Ifnb1 expression was higher in the lungs of WT mice treated with OSE compared to untreated WT
mice (p=0.0403), untreated OB mice (p=0.0417), and treated OB mice (p=0.0310, Figure 6.9).
Again, no significant increase in Ifnb1 expression was detected in OSE treated OB mice
compared to mock-treated OB mice.
Figure 6.9: Oseltamivir treatment improves viral clearance in wild-type,
but not obese, mice.
(A) Male WT and OB mice were treated with 10 mg/kg oseltamivir or PBS
vehicle control every 12 hours starting 12 hours pre-infection with CA/09
virus. (B) Weight change p.i. is increased for WT mice treated with
oseltamivir compared to OB mice in either the treatment (p=0.0136) or
control group (p=0.0152). (C) Oseltamivir treatment has no impacts on
overall viral load but increased viral clearance is observed in WT mice
treated with oseltamivir. (D) Area-under-the-curve analysis for viral titers
in (C). (E-F) Pulmonary IFN levels at day 3 p.i. in oseltamivir treated mice
standardized to untreated mice. (E) Increased Ifna1 expression in lungs of
WT oseltamivir treated mice compared to OB treated (p=0.0292) and OB
untreated lungs (p=0.0203). (F) Increased Ifnb1 expression in lungs of WT
oseltamivir treated mice compared to OB treated (p=0.0310), OB untreated
lungs (p=0.0417), and WT untreated lungs (p=0.0403). Early = days 1 and 3
p.i., late = days 5 and 7 p.i. Significance was set at α=0.05. Data represented
as means ± SEM. Data in (B-D) represented as means ± SEM and analyzed
via (B,C) repeated measures one-way ANOVA with Tukey’s multiple
comparisons test, in (D) with ordinary one-way ANOVA with Tukey’s
multiple comparisons test and in (E-F) with via two-way ANOVA with
Tukey’s multiple comparisons test with α=0.05. Yellow shading indicates
active treatment. OSE=oseltamivir.
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Figure 6.9: Oseltamivir treatment improves viral clearance in wild-type,
but not obese, mice.

Since there was observed upregulation of IFNs in OSE-treated WT mice but no concordant increase in OSE-treated OB mice, OSE treatment could require IFN for antiviral
activity. To these ends, male and female IFNAR or WT mice were treated with 10 mg/kg
OSE or vehicle control (PBS) and inoculated intranasally with CA/09 H1N1 virus or mock
(PBS) as in Figure 6.9. Over the course of treatment, WT mice lost weight during OSE
treatment (p=0.0165), infection with CA/09 virus (p=0.0157), and in combined CA/09 infection plus OSE treatment (p=0.0425) as compared to mock-infected, vehicle-treated mice
(Figure 6.10). Conversely, IFNAR mice showed no weight loss upon treatment with OSE
(p=0.8260); but CA/09 virus infection (p=0.0193) as well as CA/09 virus plus OSE treatment (p=0.0822) induced weight loss (Figure 6.10). At days 3 and 7 p.i., lungs were excised
and subjected to viral titer determination. No significant differences in viral load were
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Figure 6.10: Interferon-deficient animals are not responsive to
oseltamivir treatment.
(A-C) WT and IFNAR mice treated with OSE or vehicle (PBS) and
inoculated with CA/09 or mock (PBS) were monitored for 7 days. (A) OSE
treatment (p=0.0165), OSE + CA/09 virus infection (p=0.0425), and CA/09
infection alone (p=0.0157) induces weight loss in WT mice. (B) OSE alone
does not induced weight loss in IFNAR mice. (C) Viral load in lungs at
days 3 and 7 p.i. with CA/09 virus. Data in represented as means ± SEM
and analyzed via ordinary one-way ANOVA with Tukey’s multiple
comparisons with α=0.05. OSE=oseltamivir phosphate.

observed between mouse strains or between treatment groups, but WT mice treated with
OSE cleared the virus by day 7 p.i. as compared to all other groups (Figure 6.10). IFNAR
mice, with and without OSE treatment, had detectable pulmonary viral loads at both days
3 and 7 p.i. This suggests that IFN induction is required for robust OSE antiviral activity
and improved viral clearance in mice.

6.2.9

Obese-derived viruses are more resistant to oseltamivir treatment compared to those obtained from lean hosts

Previous studies have shown that infections in OB mice are extended and required greater
doses of OSE to improve survival (O’Brien et al., 2012; Karlsson, V. A. Meliopoulos, Velde,
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et al., 2017). OSE treatment of obese mice had no effect on viral clearance, possibly due
to reduced maximum concentrations at the site of infection. This prolonged infection
and subpar effective levels of the antiviral at the localized site of viral replication could
potentially generate resistance to the drug in immunocompromised obese hosts (39, 40).
To quantitate this difference, lung homogenates from the last timepoint wherein all treatment and genotypes had detectable virus (ie, day 5 p.i.) were titrated on MDCK cells
in the presence of DMSO control or increasing concentrations of OSE carboxylate as indicated. Viruses derived from obese, treated mice trended towards higher viral loads at
all experimental conditions compared to both treated and untreated WT-derived viruses
(Figure 6.11). Strikingly, area under the curve (AUC) analysis showed significantly reduced viral titers across all experimental conditions in treated (WT + OSE, p=0.0316) and
untreated (WT + PBS, p=0.0173; OB + PBS p=0.0425) mice compared to treated obese mice
(OB + OSE). The IC50 for OSE ranges from 0.8 nM to greater than 35 µM (N. Lee and Hurt,
2018; T. C. Li, Chan, and N. Lee, 2015). Within these experimental conditions, the half
maximal inhibitory concentration (IC50 ) values for all obese-derived viruses were shifted
higher compared to wild-type derived viruses, with OSE-treatment further shifting resistance in both groups (Figure 6.11). Mean IC50 values as are follows: OB + OSV, 206.4 ± 86.3
nM; OB + PBS, 52.8 ± 24.4 nM, WT + OSV, 13.7 ± 3.5 nM, WT + PBS 3.8 ± 1.6 nM.

Figure 6.11: Obese-derived viruses are more resistant to oseltamivir
carboxylate compared to those obtained from lean hosts.
Indicated viruses were titrated in the presence of increasing concentrations
of oseltamivir carboxylate, with (A) viral titers determined through
TCID50 , (B) average non-linear curve fits of viral loads compared to
maximum at no treatment, and (C) concentrations of oseltamivir
carboxylate needed to reduce viral load by 50% compared to no treatment.
Data presented as (A) means ± SEM and analyzed in through area-under
the curve analysis via one-way ANOVA with Tukey’s multiple
comparisons test and in (B) with a non-linear fit curve to determine IC50
values reported in (C).
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6.2.10

Oseltamivir treatment largely ablates viral diversity in lean, but not obese,
hosts but does not result in classical markers of resistance.

The observed phenotypic differences in viral susceptibility to OSE in viruses derived from
treated obese versus lean mice suggested the emergnece of OSE-resistant variants in the
viral population. Using the same treatment regimen as in Figure 6.9, the viral RNA recovered from lung homogenates was deep-sequenced to asses total viral diversity and the
potential emergence of mutations associated with OSE resistance in early (days 1 and 3) or
late (days 5 and 7) days p.i.. Overall, OB mice treated with OSE had significantly increased
numbers of unique SNVs compared to WT mice treated with OSE (p=0.0053; Figure 6.12).
This translated to increased overall diversity in treated obese mice, as measures of Shannon’s entropy (H) is reduced in WT treated (p=0.0035) and WT untreated (p=0.0357) compared to OSE treated OB mice (Figure 6.12). OSE ablated viral diversity in lean mice, as
there was a non-significant trend to reduced numbers of SNVs and total Shannon’s entropy
in treated lean mice, compared to no difference in treated obese mice (Figure 6.12).
More SNVs in were detected in obese compared to lean OSE treated mice (HA: 9
and 4, respectively) translating to higher average entropy of 3.27 in OB mice compared
to 1.24 in WT mice. OSE treatment decreased HA entropy in treated WT mice (from 1.98
to 1.24) but not in obese mice, where it increased from 2.30 to 3.27 (Table 6.5). Fewer
SNVs in NA were detected. OSE treatment resulted in 1 variant in obese and 3 variants
in lean, compared to 2 and 1 in obese and lean PBS control mice, respectively (Table 6.5).
While higher genetic diversity and phenotypic resistance was noted in both OSE-treated
and untreated mice, no classical NAI-resistant mutants emerged in mice. However, the
obese-derived viral populations showed greater phenotypic resistance to OSE carboxylate
in vitro (Figure 6.11).

6.3

Discussion

Due to the mutable nature of RNA viruses, I questioned if obesity could also influence influenza virus population diversity. The blunted IFN response promotes greater diversification of the viral quasispecies and upon exogenous drug pressures, increases the resistance
of the population to OSE. These findings further strengthen data demonstrating withinhost evolution of viral pathogens is sensitive to host characteristics (Gay et al., 2006; Beck,
H. K. Nelson, et al., 2001; W. Li, Maeda, and Beck, 2006). Obesity, aside from its impact
on influenza virus pathogenesis, may permit the stochastic accumulation of potentially
pathogenic viral variants raising concerns about its public health impact as the prevalence
of obesity continues to rise. With increasing demands for efficacious IAV antivirals and
vaccines, understanding how the obese host will respond is important; however, even
more important may be discerning the impact the obese population will have on the evolutionary trajectory of influenza virus.
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Figure 6.12: Oseltamivir ablates viral diversity in wild-type, but not
obese, mice.
(A-B) Viral RNA was extracted from lungs of mice treated with oseltamivir
as described in Figure 6.2. Total unique SNVs are significantly higher in
oseltamivir treated OB mice compared to treated WT mice (p=0.0053). (B)
Oseltamivir treated OB mice harbor a more diverse viral population
compared to WT oseltamivir treated (p=0.0035) and PBS-control treated
(p=0.0357) mice. Statistical comparisons made via two-way ANOVA with
Tukey’s multiple comparisons test. Significance was set at α=0.05. Data
represented as means ± SEM.
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Table 6.5: Frequency of detected minor variants in obese and wild-type
mice treated with oseltamivir.
Segment
HA

NA

1 Shannon’s

SNV3
T28C
T333A
A399G
C432A
A515G
A517G
C598T
T853A
T935C
A957T
G1168A
T1187C
C1193T
G1228A
T1298A
C1421T
A1573G
A1579G
T1610C
T1654C
G1688A
A129T
A149G
C377T
T614C
G700A
G1139A
G1197A

Mutation
I10T
D111E
I133M
D144E
E172G
N173D
P200S
S285T
I312T
K319N
D390N
V396A
S398F
V410I
L433Q
A474V
T525A
I527V
V537A
F552L
R563K
Q43H
N50S
P126L
V205A
V234I
W380*
W399*

Obese1
OSE PBS
6.1
30.6

5.3

11.0
8.1
7.1
5.0

Wild-type2
OSE PBS

28.1

5.9
36.4
13.4

5.9
22.3
5.4
7.8
8.2
31.8
16.4
6.0
19.1
10.0
6.7
5.8
43.6
19.2
11.6
5.0
7.5
7.5
5.4
9.7
6.7

Prevalence4
80.8
>0.1
0.7
>0.1
78.2
0.3
67.6
>0.1
>0.1
>0.1
13.7
>0.1
>0.1
>0.1
>0.1
>0.1
>0.1
13.7
4.8
>0.1
0.3
>0.1
0.1
0.1
>0.1
0.4
>0.1
>0.1

entropy (H) of HA of obese non-treated versus treated mice: 2.30 to 3.27, NA:

0.60 to 0.36.
2 Shannon’s entropy (H) of HA in wild-type non-treated versus treated mice: 1.98 vs 1.25,
NA: 0.22 to 0.77.
3 Single nucleotide variant.
4 Prevalence of minor variants in human surveillance samples.
*Indicates unknown amino acid.
Data source: Zhang, Y. et al. (Jan. 2017). “Influenza Research Database: An integrated
bioinformaticsresource for influenza virus research”. In: Nucleic Acids Res 45.D1, pp.
D466–D474.ISSN: 1362-4962 (Electronic) 0305-1048 (Linking). DOI: 10.1093/nar/gkw857.
Database accessed on 23 March 2020.
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7.1

Introduction

Due to their high genetic plasticity and incredible ability to adapt to new host species,
influenza viruses remain a seasonal, zoonotic, and pandemic threat to animal and human
health worldwide. Viral drift and the resulting slow but constant change to viral antigenicity can be contrasted with the other major player in influenza viral evolution: reassortment
(Lowen, 2017). This genetic shift occurs largely within subtypes and is often responsible
for the introduction of novel influenza strains into human circulation. The generation of
reassortant influenza viruses is closely tied with the susceptibility of the host, as it is first
constrained by co-infection of a single cell within a single host by two distinct influenza
viral strains. Not only do obese individuals suffer greater burden upon infection (Kalil
and Thomas, 2019), epidemiological evidence suggests they are more susceptible to infection. In a household transmission study, obese individuals were 2x as likely to have a
symptomatic infection with the 2009 H1N1 pandemic virus compared to lean individuals
(Maier, Kuan, et al., 2020). Increased susceptibility to infection could be due to poor memory responses upon vaccination or natural infection as well as blunted innate responses
during active infection (Namkoong et al., 2019; Milner, Sheridan, et al., 2013; Karlsson
and Beck, 2010). These dampened host defenses and increased susceptibility could also
translate to an increased risk of co-infection with distinct influenza virus strains. Here,
the inherent susceptibility of laboratory models of obesity to influenza infection is interrogated by quantifying the mean lethal dose of infection in mice, the risk of respiratory
transmission in ferrets, and the lower limit of infectivity of various viral strains in NHBE
cells. Finally, the "window of reassortment," the period in which co- or super-infection can
result in the production of reassortant progeny viruses, is defined using high-resolution
melt curve analysis of NL/09 (pH1N1) virus in obese and lean mice (Phipps et al., 2017).
This study and preliminary findings suggest that the greater rate of susceptibility to infection, greater viral spread between and within hosts, plus the blunted interferon responses
can significantly increase the rate of reassortment in obese hosts.
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Results
Increased risk of infection and lower infectious dose in obese mouse and
primary cell models

Obese mouse models, as described in Chapter 5, display increased disease severity upon
infection, including extensive viral spread, reduced antiviral responses, and elevated mortality. However, increased disease severity does not equate with increased susceptibility
to infection. To determine if obese model organisms show increased susceptibility to infection as has been shown for human cohort studies, obese and lean mice were intransally
inoculated with 10-fold serial dilutions, from 102 to 105 TCID50 units, of PR8 and CA/09
viruses to determine the mean lethal dose (MLD50 ). Notably, the MLD50 of both H1N1
strains was significantly reduced on obese mice compared to lean mice. For PR8 virus, a
dose of 102.7 viral particles was sufficient to induce 50% mortality in obese mice compared
to a 103.2 dose in lean mice. For CA/09 virus, a dose of 103.4 viral particles was sufficient
to induce 50% mortality in obese mice compared to a 105.2 dose in lean mice.
To test if a wider range of viruses is able to productively infect obese hosts compared to lean, primary respiratory epithelial cells were utilized. As previously determined, CA/09 virus replicated to higher titers in obese-derived cells compared to lean.
This phenotype was not limited to infection with CA/09 virus. In a panel of various
strains and subtypes of influenza virus, significantly increased viral replication was noted
in obese derived cells inoculated with CA/09 virus (pH1N1), A/canine/Florida/14/2006
(H3N8), A/yellow-billed pintail/Chile/11/2011 (H7N3), and B/Massachusetts/2/2012
(Yamagata-lineage) viruses (Figure 7.1).
Figure 7.1: Wide range of influenza viruses successfully replicate to high
titers in obese-derived primary respiratory epithelial cells.
(A-B) Obese- and lean-derived NHBE cells inoculated with indicated
influenza viruses and apical washes taken to determine viral titer at
specific timepoints. (A) NHBEs inoculated with CA/09 virus at MOI=1. (B)
Panel of CA/09 virus (pH1N1), A/swine/Texas/4119-2/1998 (cH3N2),
A/canine/Florida/14/2006 (H3N8), A/yellow-billed
pintail/Chile/11/2011 (H7N3) and B/Massachusetts/2/2012
(Yamagata-lineage) viruses used to inoculate NHBE cells at MOI=0.1. (C-E)
NHBE cells inoculated with (A) CA/09 (pH1N1) virus, (B)
A/Switzerland/9715293/2013 (H3N2) virus, or (D) B/Brisbane/60/2008
virus at indicated MOIs with apical washes sampled at hour 24 p.i. for
viral titer determination. (F-G) PR8 and ∆NS1 PR8 viruses were used to
inoculated (F) NHBE cells at MOI of 5 or (G) IFN-deficient Vero cells at
MOI of 1 and replication kinetics determined. Data displayed as means ±
standard error with analysis via two-way ANOVA with Tukey’s correction.
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Figure 7.1: Wide range of influenza viruses successfully replicate to high
titers in obese-derived primary respiratory epithelial cells.
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Estimating the susceptibility of the obese population to viral infection could also be
modeled in the laboratory by lowering the infectious dose. Using CA/09 (pH1N1) virus
and A/Switzerland/9715293/2013 (H3N2) virus plus B/Brisbane/60/2008 Victoria-linage
influenza B virus, n=3 NHBE cell donors per BMI were inoculated at MOIs of 5, 1, 0.1, and
0.01 for subtype A viruses and at MOIs of 1, 0.1, and 0.01 for subtype B viruses. Across the
board, higher viral titers were recovered at hour 24 p.i. from obese-derived compared to
lean-derived cells for all viruses tested, with significantly increased titers across all MOIs
for H3N2 (p=0.0454) and IBV (p=0.0171). Strikingly, at the lowest MOI tested, viral titers
were not recovered at this timepoint for H3N2 and IBV infection of lean-derived cells.
Since a wide range of influenza viruses are shown to replicate to higher titers in obese
cells compared to lean, and that obese-derived cells show quicker replication dynamics
and increased polymerase activity, an increase in the production of the IFN-antagonizing
NS1 protein could provide a mechanism. However, NS1-deleted PR8 virus, while slightly
attenuated compared to parent PR8 in IFN-deficient Vero cells, cannot replicate in the IFNblunted environment of obese NHBE cells (Figure 7.1). This suggests the host cellular
environment, and not antagonism by the virus, is mainly responsible for the phenotypes
observed in obese and lean hosts at this timepoint. However, the blunted IFN responses
could provide a foothold which increased production of NS1 protein (Chapter 6) could
exploit.

7.2.2

Enhanced transmission of influenza viruses between obese ferrets

Understanding the dynamics of influenza virus transmission and how an obese index
case or contact may influence these trends is best accomplished using the ferret model.
Here, obese and lean index ferrets were directly inoculated with either a zoonotic A/Hong
Kong/1073/1999 (H9N2) virus which shows limited ability to transmit in studies with
wild-type ferrets, or a seasonal A/Memphis/257/2019 (H3N2) virus (The SJCEIRS H9
Working Group, Schultz-Cherry, and Thomas, 2013, Figure 7.2). First, the ability for the
zoonotic H9N2 virus to transmit via direct contact from either obese or lean index ferrets to
lean or obese direct contact ferrets was assessed. Overall, obese index ferrets shed higher
viral loads early in infection and showed prolonged viral shed, with titers recovered from
nasal washes out to day 12 p.i. ferrets compared to clearance after day 8 p.i. in lean index
ferrets. For contacts, higher viral titers were recovered in nasal washes from lean ferrets
in direct contact with obese index ferrets compared to lean ferrets in direct contact with
lean index ferrets. Obese direct contact ferrets shed higher viral loads in nasal washes
compared to lean direct contact ferrets. Also, obese direct contacts in contact with obese
index ferrets shed virus earlier, day 2 versus day 4 p.i., and shed infectious virus for longer
than those in contact with lean index ferrets. Overall, obese ferrets were more efficient at
direct transmission of H9N2 virus, with obese index ferrets transmitting to 66% of lean
contacts while lean index ferrets only transmitted to 50% of lean contacts. Obese contacts,
regardless of index case BMI, were efficient transmitters of virus (Figure 7.2).
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Figure 7.2: Enhanced transmission of influenza viruses between obese
ferrets.
(A-F) Index obese and lean ferrets were intranasally inoculated with 106
TCID50 units of A/Hong Kong/1073/1999 (H9N2) virus and at day 1 p.i.,
contact ferrets were placed in either the same cage to model direct
transmission or in an adjacent cage to model respiratory transmission. (A)
Viral load in nasal washes recovered from index obese ferrets and direct
contacts. (B) Viral load in nasal washes recovered from index lean ferrets
and direct obese and lean contacts. (C) Transmission efficiency between
obese and lean index ferrets and indicated direct contact ferrets. (D) Viral
titers in nasal washes from obese index ferrets transmitting to obese direct
and obese respiratory contact ferrets. (E) Viral titers in nasal washes from
lean index ferrets transmitting to lean direct and lean respiratory contact
ferrets. (F) Efficiency of viral transmission via the direct or respiratory
route. (G-L) Index obese and lean ferrets were intranasally inoculated with
106 TCID50 units of A/Memphis/257/2019 (H3N2) virus and at day 1 p.i.,
contact ferrets were placed in an adjacent cage to model respiratory
transmission. (G) Viral loads in nasal washes between obese index and
obese respiratory contact ferrets. (H) Viral loads in nasal washes between
obese index and lean respiratory contact ferrets. (I) Viral loads in nasal
washes between lean index and obese respiratory contact ferrets. (J) Viral
loads in nasal washes between lean index and lean respiratory contact
ferrets. (K) Average viral loads in nasal washes of obese and lean index
ferrets. (L) Average viral loads in nasal washes of obese and lean index
ferrets. Data represented as means ± standard error.

For transmission via the respiratory route, again obese index ferrets shed virus earlier and for longer, with lean index ferrets clearing the infection by at least four days earlier
than obese index ferrets (day 6 vs 10 p.i., respectively). All obese and lean index ferrets
were successfully inoculated. For direct contact ferrets, again only 50% of lean ferrets shed
virus compared to 100% of lean ferrets. Finally, no lean ferrets were susceptible to respiratory transmission from a lean index ferret, whereas 100% of obese respiratory contact ferrets were successfully infected via the respiratory route from an obese index ferret. These
findings suggest that obese contact ferrets are not only more susceptible to infection via
direct and respiratory viral transmission, but may also be "super-spreaders" of infection to
more resistant lean contact ferrets (Figure 7.2).
Does infection with a seasonal H3N2 virus also show similar trends? With use of
a contemporary H3N2 viral isolate (A/Memphis/257/2019), obese and lean index ferrets
were intranasally inoculated at 106 TCID50 viral particles. At day 1 p.i., respiratory contact
ferrets were placed in an adjacent cage. Transmission pairs were set up to monitor viral
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Figure 7.2: Enhanced transmission of influenza viruses between obese
ferrets.

111

Chapter 7. Heightened Susceptibility to Infection and Implications for Viral
Reassortment in Obese Hosts

112

transmission from obese index ferrets to both lean and obese respiratory contacts, and the
same for lean index ferrets. Again, overall index obese ferrets shed modestly higher viral
titers in nasal wash compared to lean index ferrets, but also shed virus on average 2 days
longer. Strikingly, obese respiratory contact ferrets, regardless of index ferret BMI, showed
higher viral titers in nasal washes as well as protracted viral shed. Overall, these results
confirm that obese ferrets are highly susceptible to viral transmission, regardless of BMI of
the index ferret, and may be more efficient in transmission as well (Figure 7.2).

7.2.3

Rate of reassortant progeny viruses and the window of reassortment in
mice

Heightened susceptibility to infection in the obese host could lead to a greater chance of
concurrent infection with two or more distinct influenza strains with potential implications
for the generation of reassortant progeny viruses. Compounding this risk are the increases
in viral spread and replication plus blunted immune responses in obese mice (Chapter 5),
as an increase in viral spread over time increases the rate of cellular co-infection and boosts
reassortment frequency in vivo and in vitro (Marshall et al., 2013). Here, OB and WT mice
(n=12/genotype) were intranasally inoculated with a 1:1 mix of phenotypically identical
NL/09 (pH1N1) viruses (WT NL/09 or VAR NL/09) that harbor mutations within each
gene segment, enabling their discrimination at the vRNA level through high-resolution
melt curve analysis (Figure 7.3; Marshall et al., 2013; M. Richard et al., 2018). Since infection with two distinct strains of influenza virus simultaneously is rare, the "window of
reassortment" in which a super-infection event could result in reassortant progeny viruses
Figure 7.3: Increased window of reassortment risk in obese compared to
lean mice.
OB and WT mice inoculated with phenotypically identical NL/09 viruses
capable of discrimination via high-resolution melt curve analysis. (A)
Co-infection or delayed super-infection experimental schematic. Mice
(n=3/genotype/timepoint) were inoculated with a 1:1 mix of WT and VAR
NL/09 at 2 x 104 TCID50 each either concurrently or delayed by 4, 12, or 24
hours after primary infection. (B) Discrimination of WT or VAR genotypes
by each vRNA segment at in WT and OB mice. Each box represents one
unique mouse, with columns representing distinct plaque isolates and
rows each gene segment. Indeterminate wells are identified and plaque
isolates with >3 indeterminate wells excluded from downstream analysis.
(C) Ratio of genotypes in all WT- and OB-derived sampels are similar.
(D-E) Frequency of reassortant progeny viruses in (D) WT or (E) OB mice
either with co-infection or super-infection. Data displayed as ndividual
data points in (B), (C) frequency, (D-F) and means ± SEM and analyzed via
two-way ANOVA with * indicating significant difference at α = 0.05.
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Figure 7.3: Increased window of reassortment risk in obese compared to
lean mice.
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was also tested. Following infection with WT NL/09, super-infection with VAR NL/09
was delayed by 4, 12, or 24 hours (n=3 mice/genotype/timepoint). All mice were sacrificed at hour 48 p.i. with the initial WT NL/09 dose. Lungs were homogenized and the
viral load quantified via plaque assay. From each biological replicate, 12 plaques were
isolated, vRNA extracted, and the 8 gene segments amplified through qPCR to determine
isolate genotype by distinguishing each segment of each plaque as either WT NL/09 or
VAR NL/09 derived (Figure 7.3, Marshall et al., 2013). While previous studies have determined no attenuation of VAR NL/09, there was a bias towards the WT NL/09 genotype
in this study (Marshall et al., 2013).
The frequency of a parental (either WT or VAR) or reassortant (WT and VAR) gene
segments within progeny viral isolates was calculated via melting curve analysis using
the qpcR package and visual discernment of melting curves via the relative fluorescence
units for each curve in comparison to singly inoculated controls. Overall, there was a nonsignificant increase in the number of plaque isolates harboring reassortant genotypes in
OB compared to WT mice (frequencies of 42% and 36%, respectively). However, notably
the window of generating a reassortant virus was prolonged in OB mice. No significant
differences were detected between OB and LN mice in the rate of reassortment upon coinfection (50% veresus 55.6%), super-infection delayed by 4 hours (55.6% versus 52.8%),
and super-infection delayed by 12 hours (27.8% versus 33.3%). In previous studies with
wild-type animals, the generation of reassortant progeny upon co- and super-infection
was dependent on timing of the secondary infection. Delay of the super-infection event
by 18 hours significantly reduces the likelihood of reassortment between the WT and VAR
viruses (Numata et al., 2012). To test if the blunted immunity, increased viral replication,
and enhanced viral spread could extend this window, super-infection was delayed by 24
hours. In WT mice, a delay by 24 hours attenuates the production of reassortant progeny,
with the rate reducing to 2.7% of plaques harboring multiple genotypes in WT mice compared to 36.1% of plaques in OB mice (p=0.0332, Figure 7.3). Over time, WT mice showed a
significant reduction in the production of viral isolates with vRNA derived from both WT
and VAR parental strains (test for linear trend, p=0.0027) while no OB mice maintained
high production of reassortant progeny (p=0.3315).

7.3

Discussion

While the severity of influenza infections in obese hosts has been well-defined in both
epidemiological and experimental studies, the true susceptibility of the obese host is less
known. Recent epidemiological evidence has suggested that obese hosts have heightened
risk of symptoms and risk of symptomatic infection with influenza; this risk may be strainspecific (Maier, Kuan, et al., 2020). Infection of primary respiratory epithelial cells shows
that obese-derived cells show greater susceptibility to infection with a wider range of influenza viral strains and subtypes as well as susceptibility to infection as low infectious
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doses. Obese ferrets, the gold standard for modeling transmission, also may be "superspreaders" of infectious virus to lean and obese contacts as well as "super-susceptible" to
both direct and respiratory-route viral transmission, corresponding to the epidemiological
data in which obese humans show prolonged viral shed and increased vRNA in exhaled
breath (Maier, Lopez, et al., 2018; Yan et al., 2018).
Finally, the inherent susceptibility of the host to infection can constrain the likelihood of co- or super-infection and thus, modulate the risk of reassortment. The increases
in viral spread and replication plus blunted immunity may provide a perfect environment to foster cellular co-infection and generate reassortant virions. The reassortment rate
was similar in obese and lean mice up until a delay in super-infection by 24 hours. This
extended time in which reassortant progeny could be generated may have biological implications, as simulatneous co-infection events are thought to be quite rare. However, in
OB mice, there is an extended window in which a secondary infection could result in reassortant progeny. Together, these data suggest the OB host shows greater susceptibility
to a wide range of influenza viral strains and subtypes which may lead to a greater risk of
reassortment in vivo.
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Chapter 8
Conclusion1

8.1

Discussion

Globally, obesity is a leading cause of morbidity as it underlies many non-communicable
diseases, such as cardiovascular disease and several cancers (Bluher, 2019). As the prevalence of obesity has continued to increase, we have also begun to appreciate its impact on
increasing the susceptibility to and the severity of communicable infectious diseases (Dobner and Kaser, 2018). Epidemiological and empirical studies suggest that obesity increases
the likelihood or severity of bacterial (Langley et al., 2016; Zlotnikov et al., 2017; Ramos
Muniz et al., 2018), viral (Cocoros et al., 2014), fungal (Plotkin et al., 1996), and parasitic
(Wyss et al., 2017; Sarnaglia et al., 2016) infections. Here, I have outlined how the oxidative,
pro-inflammatory obese environment dampens the interferon (IFN)-mediated immune responses and predisposes an obese host to increase viral replication, spread, and disease.
This environment collectively contributes to altering the evolutionary pressures on the viral population and leads to the generation of novel viral variants. Together, this heightened
susceptibility and severity in obese hosts and the predisposition to enhancements in viral
population virulence contribute to poor control of influenza infections through vaccination
or antivirals. Identifying the molecular mechanisms behind the blunted IFN responses will
be crucial to untangling the multiple impacts the obesity epidemic has on public health.
1 Portions

of chapter from previously published articles. Modified: From final submission with permission from Cold Spring Harbor Laboratory Press. Honce, R., N. Wohlgemuth, et al. (Dec. 2019). “Influenza
in High-Risk Hosts-Lessons Learned from Animal Models”. In: Cold Spring Harb Perspect Med. ISSN:
2157-1422 (Electronic) 2157-1422 (Linking). DOI: 10.1101/cshperspect.a038604. Modified: From final submission with open access permission. Honce R, Schultz-Cherry S. They are what you eat: Shaping of viral
populations through nutrition and consequences for virulence. PLoS Pathog. 2020 Aug;16(8):e1008711. DOI:
10.3389/fimmu.2019.01071. Modified: From final submission with with open access permission from American Society for Microbiology. Honce, R., E. A. Karlsson, et al. (Mar. 2020). “Obesity-Related Microenvironment Promotes Emergence of Virulent Influenza Virus Strains”. In: Mbio 11.2. ISSN: 2150-7511 (Electronic).
DOI : 10.1128/mBio.03341-19. Modified: From final submission with open access permission. Honce, R. and
S. Schultz-Cherry (2019a). “Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and
Evolution”. eng. In: Front Immunol 10, p. 1071. ISSN: 1664-3224 (Electronic) 1664-3224 (Linking). DOI:
10.3389/fimmu.2019.01071. Modified: From final submission with permission from Elsevier Inc.. Honce, R.
and S. Schultz-Cherry. (2020). "Recipe for zoonosis: how influenza leaps into human circulation." eng. In: Cell
Host Microbe. DOI: 10.1016/j.chom.2020.09.008.
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Blunted interferon-mediated immunity in the obese host

The intrinsic immune response relies on IFN induction and subsequent signaling in the
epithelium, leading to induction of antiviral IFN stimulated genes, recruitment of innate
lymphocytes, and activation of adaptive immunity. However, these early processes are
delayed in the host with obesity, setting off a cascade of impaired immune responses culminating in heightened immunopathology, morbidity, and mortality upon infection. Delineating the early failures in immunity in the obese host is crucial. Greater viral spread is
evident as early as day 3 p.i. in obese mice and influenza virus replicates to higher viral
titers in NHBE cells from obese donors versus those from lean individuals. Obese mice,
ferrets, and NHBE cells exhibit a reduction in IFN and IFN stimulated gene (ISGs) production after inoculation, potentially reducing the ability to control viral spread and limit
viral replication (Klinkhammer et al., 2018; McNab et al., 2015), undoubtedly having implications for the adaptive immune response (Iwasaki and Pillai, 2014; Phipps-Yonas et al.,
2008), the increased risk of presenting with severe symptoms (Maier, Kuan, et al., 2020),
and ultimately increased risk of mortality (Chapter 5).
The underlying molecular mechanism of increased viral uptake, replication, spread,
and cell death seen in the obese epithelium is unknown. Here, the interactions among
obesity-induced oxidative stress, the antiviral IFN response, and influenza virus have begun to be connected. Specifically, heightened levels of viral uptake may be due to increased
presence of epidermal growth factor receptor (EGFR) on the obese epithelium. EGFR is a
receptor tyrosine kinase present on the surface of the epithelial cells which is heavily involved in orchestrating repair of the damaged epithelium. As a glycoprotein, it can also be
heavily sialidated. Sialic acids are the cognate "receptor" for influenza viruses and EGFR
has been implicated as a necessary entry factor for influenza virus infection of mammalian
cells (Eierhoff et al., 2010). Inhibition of EGFR in vivo reduces viral titers and improves the
immunopathological consequences of influenza infection (Kalinowski et al., 2014; K. Liu
et al., 2008; Ito et al., 2015). Improving the immunopathology that follows infection with
influenza virus can be crucial to maintaining airway integrity, limiting the progression to
acute respriatory distress syndrome (ARDS), and overall, improving morbidity and mortality. Obese mice, as well as the limited case reports outlining influenza infections and
developing of acute lung injury and ARDS in obese humans, note extensive inflammatory
processes especially in the lower lung. This increased pathology could be due to overactivation of the EGFR pathway due to its increased presence on the cells of the obese
epithelium, leading to a suppression of the IFN-based immune defenses as outlined in
Chapter 5 (Ueki et al., 2013).
What is the mechanism behind the baseline alterations to the cellular make-up in
obese hosts? One possible hypothesis is underlying overproduction of reactive oxygen
species. Cellular senescence through the normal aging process increases inflammation
through increased production of ROS and is one of the many links in the “adipaging”
hypothesis, wherein obesity accelerates the aging of the immune system (Perez et al.,
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2016; A. H. Lee and Dixit, 2020). In obesity and diabetes, the senescence and accompanied inflammation leads to insulin and leptin resistance, both huge contributors to the
development of metabolic syndrome (Appendix B, M. Smith, Honce, and Schultz-Cherry,
2020). The continual, positive feedback of heightened inflammatory processes, dampening of negative feedback regulation, and excess ROS production feeds forward at baseline
and is responsible for the meta-inflammation observed in obese hosts. Upon viral infection and the induction of additional antiviral, inflammatory processes can quickly tip the
scales towards immunopathology. Inhibiting ROS production after infection with highpathogenic avian influenza viruses (HPAI) limits cytokine mediated damage through induction of SOCS1 and SOCS3 proteins (Ye, Lowther, and Stambas, 2015), so could be a
potential target in ameliorating disease severity in obese hosts. Further, a highly oxidative
environment has been linked to a reduction in viral sensing and interferon induction, production, and signalling int he context of hepatitis C virus (Di Bona et al., 2006). Dissecting
the mechanisms underlying this obesity-related immunosuppression and the involvement
of EGFR, ROS, and other cytokines such as TGFβ and TNFα and their collective subsequent
effects on TLR-mediated antiviral responses duirnf influenza infections will be the focus of
future research efforts. Notably, these findings will most likely not be unique to influenza
viral infections. Severe COVID-19 patients similarly showed blunted IFN responses and
heightened ROS, suggesting impaired IFN may be a signature of certain high-risk groups
or predictive of disease severity (Hadjadj et al., 2020).

8.1.2

Rapid viral evolution yields increased virulence in obese hosts

The direct effects of population diversity can be easily appreciated with influenza virus as
individual SNVs leading to point mutations, segment swaps leading to novel reassortants,
and incomplete packaging or translation leading to defective particles can impact viral
pathogenesis and transmission. Influenza viruses are uniquely suited as seasonal and pandemic human pathogens as well as zoonotic threats, largely because of this continual flux
of their antigenic properties which can escape previous immunity. In this work, I sought to
determine how the dampened IFN-mediated immune responses could influence the viral
population in obese hosts.
Rapid influenza virus evolution and increased virulence was driven by impaired
IFN responses in obese hosts. The blunted type I IFN response in obese mice, concordant
with the earliest observed enhancement in pulmonary viral spread (Chapter 5), correlated
with heightened viral genetic diversity. This increase in diversity drives a more virulent
infection upon inoculation of wild-type (WT) mice with OB-derived viruses. Importantly,
this increase in genetic entropy is sensitive to host IFN responses, as exogenous treatment of OB mice with IFN reduces viral diversity. Viral growth in a lean, IFN-deficient
host phenocopies viral growth in obese host versus viral growth in an obese, IFN-restored
host. These findings were recapitulated in ex vivo models of the human respiratory system, as virus grown in obese-derived NHBE cells showed greater numbers of SNVs and
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overall greater genetic diversity as computed through Shannon’s entropy. These data suggest the obese-derived epithelial environment permits emergence of multiple minor variants—some of which may have enhanced virulent properties—in the influenza virus quasispecies through relaxed immune pressures from the type I IFN response in vivo and ex
vivo (Chapter 6).
The obesogenic environment mirrors other immunocompromised states, including
undernourished, aged, and immunosuppressed hosts, which have been shown to impact
viral mutation (Gay et al., 2006; Beck, 2001; Beck, Shi, et al., 1995; Beck, Shi, et al., 1996;
Levander, 2000; A. D. Smith, Botero, and Levander, 2008). The relaxed antiviral responses
characterized by blunted type I IFN responses allow viral variants to thrive that may
otherwise be limited due to a timely immune response, increasingly the likelihood for
pathogenic or drug resistance markers to emerge. These obese-derived minor variants are
collectively capable of inducing greater morbidity due to increased replicative potential.
This recalls studies with poliovirus that showed viral populations with a greater scope of
viral variants results in increase virulence in vivo compared to high-fidelity RdRp mutants
which exhibited little pathogenesis (Pfeiffer and Kirkegaard, 2006; Pfeiffer and Kirkegaard,
2005; Vignuzzi et al., 2006). The obese environment may generate a more robust viral population early during infection, providing a key fitness advantage to increase viral spread
before recognition by the host immune response (V. Meliopoulos et al., 2019). Once the
delayed immune response is initiated, the variants selected for in the obese environment
may provide no further advantage, yet this early advantage proves biologically significant as seen in several reports of increased morbidity and mortality in infected obese mice
(Easterbrook et al., 2011; Green and Beck, 2017; A. G. Smith, Sheridan, Harp, et al., 2007).
Unsurprisingly, the delayed induction of an antiviral state due to reduced IFN responses increases the likelihood for infection of the respiratory epithelium. The increased
susceptibility of obese mice, ferrets, and primary cells was modeled in the laboratory by
titrating the amount of virus needed to induce infection or lethality, determining the variety of viral strains and subtypes which could productively infect, and the transmission
efficacy of various viruses through direct and respiratory contact. Here, increased susceptibility to a wide range of viruses, both through direct infection of mice, NHBE cells,
and ferrets, as well as through direct or respiratory transmission, was a feature of obese
hosts. Concordant with this inherent increase in infection susceptibility, an increased rate
of reassortment was also observed (Chapter 7). Due to dampened immune pressures and
increased viral spread, obese mice showed a prolonged window in which they are susceptible to super-infection resulting in reassortant progeny. Further study of this phenomenon
will include defining if the strain-specific and subtype-specific constrains on genetic shift
are weakened in obese hosts, and potentially the incidence of co-infection and reassortment in human cohorts of obese and lean individuals.
Previous studies of within- and between-host influenza evolution in human hosts
has found limited viral diversity and sparse influence of host immune pressures on the
influenza population (Xue, Moncla, et al., 2018; McCrone et al., 2018; Han, Maurer-Stroh,
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and C. A. Russell, 2019). However, other evidence shows that immune pressures can actively shape the genetic and antigenic landscape of influenza viral populations (Plant et
al., 2017; D. Park et al., 2016) and these former studies do not take into account host status, or if they do, neglect obesity as a factor. A plethora of epidemiological data suggests
influenza-infected adults with obesity shed greater amounts of influenza virus for longer
than infected lean adults (Yan et al., 2018; Maier, Lopez, et al., 2018; Maier, Kuan, et al.,
2020). Hosts with obesity show a greater likelihood in generating novel viral variants and
higher susceptibility to co-infection and producing novel reassortant viruses. Since obesity
is linked with a protraction of viral shedding, the effects of the proven blunted immune responses could potentially extend the effects of immune pressures on the within-host evolution. With the shown increased polymerase activity and higher viral loads, this could
yield greater errors through multiple rounds of viral replication over a longer period of
time within the host with obesity. Coupled with increased shed, contingent on this shed
being of truly infectious virus and not just persistant RNA, this could have extreme implications for transmission and control of influenza virus (Figure 8.1).

8.1.3

Antiviral and vaccine efficacy in the obese host

While vaccination remains the most effective preventative measure for influenza infection,
effective antivirals are relied upon to limit disease post-exposure. However, the leading
antivirals and vaccinations can vary in effectiveness due to viral and host characteristics.
Within these studies, I sought to determine if the IFN-deficient obese host would respond
to antiviral treatment to improve disease outcomes. However, even when paired with
oseltamivir treatment, the poor induction of type I IFNs failed to control viral replication.
By day 7 p.i., treated WT mice had no detectable virus yet no change was observed in
treated obese mice. The prolonged infection allowed for the emergence of phenotypic
resistance to OSE emerged by day 5 p.i. Again, this was tied to the initial IFN response, as
IFNAR knockout mice, like obese mice, did not respond to OSE treatment.
Studies in vivo revealed that OSE did not clear faster from the lungs and serum
of obese animals versus wild-type, but the maximum concentration was lower and may
contribute to the generation of phenotypically resistant variants that emerged throughout
the prolonged infection in obese mice. Upon in vitro study, these findings corresponded to
higher effective concentrations of OSE carboxylate needed to control influenza replication
(O’Brien et al., 2012). Population-based pharmacokinetic studies have found that OSE
clearance is accelerated in obese hosts, but not at a biologically significant rate (Chairat
et al., 2016; Jittamala et al., 2014; Pai and Lodise, 2011). Previous studies have determined
that OSE treatment of obese mice can boost survival, yet 10X the dose is needed as what is
commonly used in the literature to ensure survival of WT mice (O’Brien et al., 2012).
OSE shows the highest effectiveness when prescribed early after symptom onset or
even when given as pre- or post-exposure prophylaxis. Treatment delayed as little as 2
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Figure 8.1: Obesity alters within-host viral population dynamics.
Both the amount of viral RNA shed and well as the duration of positive
samples for H1N1 virus, as determined by RT-PCR, are increased in obese
adults (blue, solid line) as compared to average-weight counterparts (gold,
dashed line). Furthermore, I determined through experimental evolution
of H1N1 virus through an obese host results in the emergence of minor
variants that influence pathogenicity and in increased overall viral
population diversity.
Data sources: Yan, J. et al. (Jan. 2018). “Infectious virus in exhaled breath
of symptomatic seasonal influenza cases from a college community”. eng.
In: Proceedings of the National Academy of Sciences of the United States
of America 115.5, pp. 1081–1086. ISSN: 1091-6490 (Electronic) 0027-8424
(Linking). DOI: 10.1073/pnas.1716561115. Maier, H. E., R. Lopez, et al.
(Sept. 2018). “Obesity Increases the Duration of Influenza A Virus
Shedding in Adults”. eng. In: The Journal of Infectious Diseases 218.9, pp.
1378–1382.ISSN: 1537-6613 (Electronic) 0022-1899 (Linking). DOI:
10.1093/infdis/jiy370.

121

Chapter 8. Conclusion

122

days after symptoms onset is ineffective (Sidwell et al., 1999; Lytras et al., 2019). Our findings suggest this biological action may not only be due to the blocking of viral spread via
neuraminidase inhibition, but also the stimulation of IFN responses by OSE. However, in
obese hosts with blunted IFN levels, OSE treated had no effect on viral titers or clearance
(V. Meliopoulos et al., 2019; Green and Beck, 2017; O’Brien et al., 2012). Early and appropriate antiviral responses are crucial to control viral replication, spread and pathology.
Conversely, OSE treatment started too late, akin to delayed immune responses, is ineffective. Highlighted by work with MERS-CoV, delayed IFN responses quickly turns the
action of IFN and IFN-stimulated genes from helpful to hurtful, leading to immunopathology (Channappanavar et al., 2016), which is mirrored in obese mice. IFN is crucial for controlling the emergence of a diverse viral quasispecies that may harbor virulent genotypes.
Type I IFN and OSE may also show synergistic benefit in treating seasonal IAV infection,
and OSE has been shown to modulate immune responses (Ilyushina and Donnelly, 2014;
Jefferson et al., 2014; E. Takahashi et al., 2010). These data posit that IFN is crucial for the
activity of OSE in vivo, and the blunted IFN responses in obese hosts may increase the
likelihood for antiviral resistant variants to emerge leading to the observed phenotypic
resistance.
Antivirals can reduce disease burden post-exposure, but the best defense against
influenza infection is seasonal vaccination. The individuals most at-risk, including the
aged and obese, do not respond to vaccination as well as young, lean adults. The push
for a universal flu vaccine cannot neglect it should work in all people, as well as for all
influenza viral strains or subtypes (Estrada and Schultz-Cherry, 2019). While fine-tuning
the vaccine platforms, just as administration route or adjuvant composition, is one way of
improving immunization efficacy, interventions in the host could also increase efficacy.
However, formerly obese mice that were switched to control chow showed no improvement on vaccine efficacy as measured by mortality after either a 1- or 3-month “diet”
period (Appendix B). Short term caloric restriction or diet changes also failed to improve
or even exacerbate inflammatory processes that may influence infection and vaccination
responses (Messaoudi et al., 2017; Fu et al., 2016). Other “lifestyle” interventions have
been shown to improve vaccine-induced immune responses. Clinical trials have observed
that exercise can boost antibody and cellular-mediated responses upon vaccination, especially in individuals with traditionally “poor” responsiveness such as the elderly and the
obese (T. P. Smith, Kennedy, and Fleshner, 2004; Edwards et al., 2006; Warren et al., 2015;
Kohut et al., 2004). Immunosenescence is a well-known hallmark of the aging process;
obesity has been proposed to hasten this aging of the immune system (Hunsche, Hernandez, and De la Fuente, 2016; H. Yang et al., 2009; Parisi et al., 2017). This feature is
heavily tied to leptin’s effects on B cells (Frasca, Diaz, Romero, and Blomberg, 2020). In
this study, leptin, adiponectin, and insulin levels generally tracked with weight loss and
gain in the varying mouse cohorts. When comparing levels of these metabolically crucial
biomarkers at vaccination, elevated leptin and insulin as well as reduced adiponectin were
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noted during the vaccination period in mice fed a HFD diet. Both always obese and formerly obese mice showed poor responsiveness to vaccination, while formerly lean mice
also showed lower survival post challenge compared to always lean mice. Thus, HFD exposure at the time of vaccination could be predictive of poor vaccine efficacy due to the
immunometabolic consequences of leptin, adiponectin, and insulin on the formation of
robust immune responses. Diet status at the time of challenge also influenced morbidity and mortality, especially the IFN response to viral challenge. The implications of the
obesity-related metabolic environment on the memory responses to vaccination, including
antibody- and cell-mediated correlates of protection, will continue to be defined. Overall,
vaccination efficacy is not improved by weight loss in obese mice; it is unknown if weight
loss prior to vaccination will prove efficacious or if novel platforms, adjuvants, and administration routes will be needed to overcome this roadblock in this high-risk popualation.
By understanding the metabolic profile of obese and lean hosts and how this correlates
with immunity, researchers and clinicians may be able to screen for these biomarkers at
vaccination, predict seroconversion rates, and possibly the response to viral challenge.

8.2

Broad implications of obesity on infectious disease dynamics

Humankind has long faced seasonal and pandemic outbreaks of infectious disease. Concomitantly, pathogens have also evolved to outpace induced immunity. Humans are continually threatened by the ongoing emergence and circulation of potentially zoonotic viruses
in wild and domestic animal populations. Understanding which, if any, of these viruses
pose a threat to human health requires understanding of characteristics of the virus, the
host and the species-specific barriers that must be overcome. The risk of infection from
novel viral species or strains may have never been higher, in part due to climate change
altering the distribution of disease vectors and reservoirs and increases in globalization.
Traditionally, viral spillover has depended on two factors: one, the likelihood of donor
and recipient contact and two, the risk of viral positivity and exposure between the donor
and the contact (Plowright et al., 2017; Jones et al., 2008). Rapid urbanization, deforestation, and climate change are altering the distribution of viral disease vectors (ie mosquitoes
and Zika virus) and bringing humans in closer contact with reservoirs of viruses (ie bats
and Ebolavirus). However, the findings within this dissertation posit if a third factor may
increase the rate of viral spillover into human circulation: increasing population susceptibility (Beck, Handy, and Levander, 2004, Figure 8.2).
Zoonotic transmission and establishment of a novel virus in the human populations is also constrained by three features of the virus and its interactions with a potential
host: the opportunity to spillover from the animal host as discussed above, the capacity to
transmit and replicate in the human population, and the ability to escape human immunity
(Long, Mistry, et al., 2019). Firstly, spillover from the reservoir or intermediate host must
occur through direct or indirect contact between an infected vector and the naïve host.
Secondly, the virus must be able to transmit effectively and replicate in a human host. For
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Figure 8.2: Prevalence of malnutrition may impact global viral
evolutionary patterns.
Worldwide rates of obesity are projected to reach over 50% by 2050.
Additionally, undernutrition of both children and adults continues to be a
global health crisis. (A) In a primarily healthy, lean environment, viral
spread and acquisition of variants is limited due to robust immune
responses. (B) As the incidence of malnourishment has increased, the
resulting diminished immunity can permit the acquisition of minor
variants and a virulent phenotype. In our current environment of
widespread obesity, global viral evolutionary patterns may change due to
increased host susceptibility and decreased host immunity.
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influenza, this is largely constrained by species-specific receptor-mediated entry to cells,
stability of the HA protein in mediating fusion, and the replication competence in that new
host environment (C. J. Russell, Hu, and Okda, 2018). Thirdly, to successfully establish itself in the human population, successful zoonotic influenza viruses must escape human
immunity, including innate defenses and antigenic memory recall responses (Mänz et al.,
2013). Previous studies have determined molecular features of zoonotic influenza viruses
required to successfully infect, replicate and transmit in mammals including humans.
In this work, I have outlined the enhanced evolutionary dynamics of obese-derived
viral populations, including greater genetic diversity and higher rates of genomic reassortment. While few changes were noted in the highly antigenic HA and NA proteins,
a heightened acquisition of diverse minor variants may lead to the selection of specific
markers that could have impacts on receptor binding specificity or avidity, or permit an
antigenic shift in the virus population allowing it to escape host memory responses. The
HA and NA proteins are important determinants of host specificity, but they are not the
only restriction factors. Mutations in NP can generate MxA resistance, an important ISG in
the initial antiviral response, and may permit infections with avian or swine-origin viruses
(Mänz et al., 2013; Dornfeld et al., 2019). With an overall more genetically diverse population, there is potential for evolutionary advantageous mutations to emerge that could have
phenotypic impacts on the virulence properties of the viral population.
Robust replicative and transmission dynamics are required to allow animal-origin
influenza viruses to persist in the human population. High polymerase activity has been
suggested as a as a predictor of aerosol transmission between ferrets and a potential constraint on zoonotic transmission (Long, Giotis, et al., 2016; Linster et al., 2014; Imai et
al., 2012). Here, transfection of obese-derived primary respiratory epithelial cells with a
minireplicon systems on the pH1N1 background reveals higher intrinsic polymerase activity compared to transfection of lean cells. In conjunction with the higher viral loads in
index obese ferrets, lower infectious dose in obese-derived primary respiratory epithelial
cells, and the heightened shed in index and contact ferrets, this suggests the obese host may
be primed for infection with zoonotic viruses of pandemic potential. Due to the increased
window of reassortment in obese mice, a greater risk of super-infection with distinct viral
strains or subtypes exists which could successfully produce reassortant progeny viruses
and lead to the introduction of a novel influenza strain to human circulation.
Emerging infectious disease rates—largely due to zoonotic spillovers—have steadily
climbed since the early twentieth century (Jones et al., 2008). While the HIV/AIDS has
been implicated in causing the spike in emerging diseases in the 1980s, other host characteristics that dampen immunity and increase susceptibility may also play a role (Jones
et al., 2008). The rampant spread of obesity and related metabolic disorders around the
world is rendering a population more susceptible to infection and less robust in the face
of viral disease. Some researchers argue that the increasingly aged, obese population in
the Western world has been a driving factor in the speed and severity with which SARSCoV-2 ravaged the world through the COVID-19 pandemic beginning in December 2019
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(David C. Nieman, 2020). Early reports suggested that the viral induced disease showed
classic age-related mortality. However, as the pandemic spread across the world, many
adults aged 18-50 were succumbing to disease with obesity implicated as a comorbidity
(Dietz and Santos-Burgoa, 2020). It cannot be understated that the Western diet has rendered a globe more susceptible to infection, severe disease, and possibly may increase the
risk of greater zoonotic events. Interrogating not only the viral determinants of spillover,
but also how host characteristics may modulate this, will be increasingly important as the
incidence of malnutrition continues to rise.

8.3

Future Directions

The work within begins to answers some of the epithelial-specific dysregulation of antiviral responses in the host with obesity as well as the implications of this environment on
the viral population. It also provided a plethora of future research questions in which to
continue this line of research:
• Interrogating the susceptibility of obese hosts to zoonotic transmission and defining
the viral transmission bottlenecks.
• Contribution of differing antibody pressures on antigenic evolution of obese-derived
influenza populations.
• Molecular consequences of the obese environment for viral sensing and IFN induction.
The obese ferret model is an ideal experimental system to interrogate many of these
questions, and I propose that future research focus on this more translatable system. First,
I suggest the genetic diversity of viral populations at anatomically distinct regions withinhost as well as between-hosts be quantified for index, direct contact, and respiratory contact ferrets. Understanding the bottlenecks of viral spread from upper to lower respiratory
tract in an index ferret as well as spread between differing forms of contact between ferrets
can aid in understanding the evolutionary pressures within- and between-hosts. Do obese
ferrets actually transmit a more genetically diverse viral population? Are there wider bottlenecks in this transmission chain, potentially allowing for the diverse variants emerging
within an obese host to successfully transmit to a new host? Answering these questions
is vital to modeling how our increasingly obese world will influence the evolutionary dynamics of respiratory viral pathogens.
While this study focused on the innate immune response to viral infections and how
IFN could shape the composition of the viral population, it is important to also consider
how adaptive immune pressures can configure the viral quasispecies. Importantly, the
studies within are all done in influenza-naive animals. The relative absence of pre-existing
immunity, aside from studies done with vaccination, and the lack of original antigenic sin,
limits the conclusions we can draw on how adaptive immunity may be modulated by the
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obese state. However, the higher rates of infection coupled with the dearth of persistent
antibody-mediated immunity in obese hosts could also have implications for the antigenic
evolution of influenza viruses (Neidich et al., 2017; Karlsson, Hertz, et al., 2016). The differing production of influenza-specific antibodies and the subsequent immune pressure on
the viral population could be modeled through serial infection of obese mice and ferrets
with distinct influenza strains. In animals with some semblance of pre-existing immunity,
the antigenic and overall evolutionary trajectory of the viral population may well be altered from the findings in Chapters 6 and 7 and could better estimate obesity’s impact on
viral evolution in humans.
Finally, a detailed understanding of the molecular consequences of obesity, metabolic
syndrome, and related disorders on the initial antiviral response is of utmost importance.
As the initial response orchestrates all downstream antiviral activities, it is crucial to have
a robust yet well-controlled IFN-based response to an infection. However, this response is
clearly dampened and delayed in the host with obesity. By further analysis of the individual and collective contributions of type I and III IFNs, ROS, and other antiviral, metabolic,
and inflammatory cytokines and chemokines, novel targets could be identified that may
help in predicting infection risk, improving vaccine adjuvants and efficacy, and developing
novel pharmacological interventions for high-risk hosts.

8.4

Overall summary

As the obesity epidemic rages on, science and medicine must continue to study how the
obese host environment will contribute to infection risk and severity as well as its implications for pathogen evolution. The findings within this dissertation are most likely not
limited to influenza virus, as previous studies have uncovered similar epidemiological associations between obesity and the pathogenesis of many other microbes. Overall, the
major findings of this work are as follows:
• Obesity results in dampened viral sensing and blunting of the IFN response in mouse,
ferret, and ex vivo human models of the respriatory epithelia.
• The relaxed immune pressures in obeses hosts promotes a more diverse viral populations with implications for viral pathogenicity in wild-type hosts.
• The altered baseline and antiviral responses in obese hosts has long-term implications for the efficacy of vaccines and antivirals.
While this work investigates the viral, immunological, and physiological consequences of the obesity epidemic, it cannot be overlooked that the worldwide obesity epidemic is a complex social issue, intimately tied to socieoeconomic status and geography. While science can recommend healthy food intake and weight loss as a panacea
for improved health, enacting these policies must consider the societal barriers to the
ideal “healthy” lifestyle. Ensuring health equity by taking real steps toward improving
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healthcare access, reducing socioeconomic disparities, and ameliorating food deserts and
swamps can aid in curbing the obesity epidemic and will undoubtedly improve individual
and public health especially upon consideration of the noxious synergy between influenza
virus and obesity.

129

Appendix A
Development and Characterization of an Obese Ferret
Model

A.1

Introduction

Obese individuals are at high risk for severe influenza infection and account for most
influenza-related hospitalizations (Milner and Beck, 2012; W. W. Thompson et al., 2009).
As the number of people living with one or more co-morbidity, such as obesity, continues
to increase, the role of host factors in influenza virus pathogenesis becomes ever more important. Animal models of disease represent a powerful tool to understand and ultimately
prevent severe influenza in vulnerable patient groups; however, few high-risk states can
be accurately modeled in the laboratory (Thangavel and Bouvier, 2014).
To better understand this increased pathogenesis, most influenza obesity studies
to date have been performed in mouse models. While the mouse model is an invaluable tool to understand how obesity impacts the host response to influenza, they do not
readily recapitulate human susceptibility, pathogenesis, or transmission of influenza virus
infection. Ferrets remain the gold-standard for influenza research, as they show similar
susceptibility, respiratory tract anatomy and sialic acid receptor distribution, and transmission dynamics as humans (Albrecht et al., 2018; Robinson et al., 1986; Johnson-Delaney
and Orosz, 2011). However, this model too has limitations including limited reagents to
interrogate immune responses (Albrecht et al., 2018).
To remedy this gap in the literature, I contributed to the development of the dietinduced obese (DIO) ferret model. This robust model allows for improved study of host
responses to influenza virus, susceptibility to infection and transmission studies, and viral
evolutionary dynamics in the host with obesity. Ferrets maintained on the obesogenic protocol for 12 weeks showed increased weight gain and visceral adiposity compared to ageand sex-matched controls. DIO ferrets also displayed elements of metabolic syndrome
(MetS), a common co-occurrence or consequence of obesity in humans that has dire implications for immunity and overall health (Andersen, K. E. Murphy, and Fernandez, 2016).
Overall, the DIO ferret model will be an invaluable addition to the toolbox for virologists
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and immunologists to better understand varied facets of influenza pathogenesis in highrisk states in vivo.

A.2

Results

A.2.1

Development of an obesogenic diet for the ferret model

Neutered male, 6-week-old ferrets were obtained from Triple F Farms (New York). Immediately upon arrival, ferrets were randomly assigned to the diet-induced obesity (DIO)
group or to the lean diet group. Diets were allocated daily per cage of ferrets according
to age and diet group for 12 weeks (Table A.1). All ferrets were provided ad libitum access to water. For lean ferrets, a restricted volume of high-density ferret diet (Lab Supply
cat:5LI4, macronutrient percentage breakdown of: carbohydrates, 17%; protein, 36%; fat,
47%) was fed once daily in the morning. Obese ferrets received a 1:1 mix of high-density
ferret diet plus feline diet (Lab Supply cat:5003, macronutrient percentage breakdown of:
carbohydrates, 40%; protein, 32%; fat, 27%) ad libitum and supplemented with wet kitten
food (Iams, cat:159243 from Chewy.com) once per day starting at 9 weeks of age. Diets
continued for 12 weeks. Throughout the diet period, ferret measurements were recorded
weekly under sedation with isoflurane. Ferret body length was measured from nose to
base of tail and weight circumference just above the iliac crest (Figure A.1). Measures of
skinfold fat were determined using a digital fat caliper on right side of the abdomen above
the iliac crest (Figure A.1). In representative obese and lean ferrets, note gross anatomical
findings including abdominal adiposity (Figure A.1).
To quantify the adiposity of obese ferrets, multiple approaches were taken: Weight
and weight gain over time were calculated from week 0 on diet to week 12, with weight
z-scores calculated for each ferret based upon our sampling of ferret weights each week.
Ferret BMI was calculated by standardizing the product of weight in kilograms and circumference in centimeters by the ferret length in centimeters squared according to Eq.
A.1.
f erretBMI =

weight × circum f erence
length × length

(Eq. A.1)

Lee’s index, a predictor of percent body fat developed in rats, was calculated by
dividing the cubic root of weight by ferret length in centimeters and multiplying by 1000
according to Eq. A.2 (Bernardis, 1970; M. O. Lee, 1929).
0

Lee sIndex =

p
3

weight
× 1000
length

(Eq. A.2)
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Table A.1: Description of ferret diets.
Weeks
of age

Weeks
on diet

Lean

Obese

6

0

135 g ground ferret diet
+ 15 g milk replacer
+ 150 mL distilled water

135 g ferret + feline diet
+ 15 g milk replacer
+ 175 mL distilled water1

7

1

135 g ground ferret diet
+ 150 mL distilled water

35 g ground ferret + feline diet
+ 175 mL distilled water

8

2

90 g ground ferret diet
+ 90 mL distilled water
90 g solid ferret diet

90 g ground ferret + feline diet
+ 100 mL distilled water
135 g solid ferret + feline mix

9

3

135 g solid ferret diet

Ad libitum solid ferret + feline diet

10+

4+

135 g solid ferret diet

Ad libitum solid ferret + feline diet
75 g wet kitten food

1 For

gruel fed from weeks 0-2, additional water was needed due to high carbohydrate content of the obese diet.

Figure A.1: Development of an obese ferret model.
(A) Caging set up with obese ferrets housed 2 per small cage and lean
ferrets house 3 per large cage. (B) Location of a) length from nose to base of
tail, b) waist circumference, and c) skinfold fat measurements taken
weekly. (C) Representative images, top=obese, bottom=lean.
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Diet-induced obese ferrets exhibit increased accumulation of adipose
mass compared to controls

Weekly measurements were taken to assess growth of ferrets and the effectiveness of
the indicated diets in increasing the fat mass of DIO ferrets (Figure A.2). Between diet
groups, significant differences in weight (p=0.0007), weight gain (p=0.0001), weight zscores (p=0.0191), waist circumference (p=0.0001), skinfold fat (p=0.0001), BMI (p=0.0001),
and a trend towards significant difference in Lee’s index (p=0.0848). No difference in length
between diet groups was observed.
Visceral adiposity, assessed by massing total adipose tissue in the abdominal compartment upon necropsy, was increased in DIO ferrets compared to lean, concordant with
the observed increased waist circumference (Table A.2). No other organ had significant
increases in mass, although a slight increase towards greater differential kidney mass was

Figure A.2: Metrics of obesity in ferrets.
Physical measurements were recorded each week. (A) weight, *p=0.0007,
#p=0.0001; (B) weight gain from baseline, *p=0.0001, #p=0.0001; (C) z-score
of weight, *p=0.0191, #p=0.0001; (D) skinfold fat measured at iliac crest,
*p=0.0001, #p=0.0001; (E) waist circumference, *p=0.0001, #p=0.0001; (F)
BMI, *p=0.0001, #p=0.0001; (G) Lee’s obesity index, *p=0.0848, #p=0.0086;
(H) length from nose to base of tail. Data are represented as means ± SEM
with significant differences due to *diet and due to #diet over time.
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Table A.2: Organ mass in lean and obese ferrets.
Target1
Heart (g)
Liver (g)
Spleen (g)
Left Kidney (g)
Right Kidney (g)
Kidney Differential (g)
Abdominal Fat (g)
1

Lean
5.66 ± 0.99
35.31 ± 2.52
11.83 ± 2.32
3.17 ± 0.63
3.11 ± 0.63
0.23 ± 0.21
48.60 ± 12.87

Obese
6.00 ± 0.94
38.23 ± 4.13
13.17 ± 3.37
4.02 ± 1.08
3.83 ± 0.84
0.53 ± 0.58
91.23 ± 13.71*

All values reported as means ± SEM. Comparisons
made using unpaired t-test after assessing for normality using the Shapiro-Wilk test. Significance set
at α=0.5 and indicated by *.

noted. Out of all metrics (aside from length), Lee’s obesity index proved the most conservative in assessing adiposity (Figure A.3). Correlations made between abdominal fat mass
and each of the quantitative metrics show skinfold fat to be the strongest predictor of true
adiposity. As assessed via calculating Pearson correlation coefficients, weight (p=0.0083),
weight gain (p=0.0115), weight z-score (p=0.0083), skinfold fat (p=0.0002), circumference
(p=0.0042), and BMI (p=0.0036) were all positively associated with increased abdominal
fat mass. Lee’s index (p=0.1128) and length (p=0.6148) showed weak positive or no association with abdominal obesity, respectively (Figure A.3). Overall, the plethora of significant
physical differences between ferrets maintained on the obesogenic protocol versus those
on standard ferret chow support the creation of a diet-induced ferret model.

A.2.3

Biomarkers of metabolic syndrome in obese ferrets

Immune dysfunction due to obesity may stem from obesity’s core involvement in triggering MetS (Andersen, K. E. Murphy, and Fernandez, 2016). The chronic low-grade inflammation implicated as the etiology of poor antiviral responses upon infection with influenza
A virus may result from perturbations to cellular metabolism due to MetS (Andersen, K. E.
Murphy, and Fernandez, 2016; Easterbrook et al., 2011; Karlsson, Hertz, et al., 2016). The
National Institutes of Health (NIH) and National Cholesterol Education Program (NCEP)
Adult Treatment Panel III define MetS in adults as the constellation of three of the following five signs: elevated waist circumference, hypertension, fasting hypertriglyceridemia,
fasting hyperglycemia, and low high-density lipoprotein cholesterol (HDL-C) levels (P. L.
Huang, 2009). Increased waist circumference has already been established as a feature
of this DIO ferret model (Figure A.2, A.3). To ascertain the extent of MetS in the obese
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Figure A.3: Correlation between measures of obesity and visceral
adiposity.
(A) Correlation matrix of chosen obesity metrics in n=13 ferrets. (B-J)
Correlation of abdominal fat mass against indicated metrics of obesity. (B)
Weight, R2 =0.48; (C) weight gained, R2 =0.45; (D) weight z-score, R2 =0.48;
(E) skinfold fat, R2 =0.72; (F) waist circumference, R2 =0.54; (G) BMI,
R2 =0.55; are all positively associated with adiposity. (H) Lee’s obesity
index shows a weak positive correlation with abdominal fat mass, R2 =0.21
(I) Length shows no association with abdominal fat mass, R2 =0.02.

ferret model, a diagnostic panel of blood chemistries determined plasma levels of albumin, alkaline phosphatase (ALKP), alanine transaminase (ALT), amylase, blood urea nitrogen (BUN), calcium, creatinine, globulin, glucose, phosphorus, potassium, sodium, total
bilirubin, total protein, and cholesterol (Table A.3). Elevations in fasting glucose (midpoint p=0.0008, final p=0.0132) and reduced high-density lipoprotein cholesterol (HDL-C,
midpoint p=0.0211) are apparent in the DIO ferrets compared to lean controls. Total cholesterol (midpoint p=0.0174) was also elevated in the DIO model compared to lean. Higher
leptin levels were also detected in plasma from DIO ferrets compared to that of lean ferrets. Accurate blood pressure readings in the ferret rely on invasive intraarterial methods
or specialized equipment and were not performed (Oh et al., 2014; Zeeland et al., 2017).
Taken together, the co-occurrence of visceral adiposity, hyperglycemia, and reduced HDLC compared to lean control ferrets suggests the development MetS in the DIO ferret model.
Western diets resulting in obesity can increase risks of non-alcoholic fatty liver disease, renal steatosis, inflammation and oxidative stress. DIO ferrets displayed elevated
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Table A.3: Blood chemistry measurements in lean and obese ferrets.
Lean

Obese

Analyte

Baseline

Midpoint

Final

Baseline

Midpoint

Final

Albumin (g/dL)
ALKP (U/L)
ALT (U/L)
Amylase (U/L)
BUN (mg/dL)
BUN:Creatinine ratio
Calcium (mg/dL)
Cholesterol (mg/dL)
Creatinine (mg/dL)
Globulin (g/dL)
Glucose (mg/dL)
HDL-C (mg/dL)
Potassium (mmol/L)
LDL-C (mg/dL)
Sodium (mmol/L)
NA:K ratio
Phosphorus (mg/dL)
Total Bilirubin (mg/dL)
Protein (g/dL)
TAG (mg/dL)
Leptin (pg/mL)

2.83 ± 0.2
271.0 ± 97.3
165.3 ± 58.9
42.8 ± 7.9
27.5 ± 2.3
98.3 ± 28.7
11.7 ± 1.4
155.5 ± 11.2
0.3 ± 0.1
2.7 ± 0.2
103.0 ± 14.2
122.5 ± 13.2
4.7 ± 0.2
4.8 ± 3.3
144.0 ± 1.8
30.5 ± 1.9
10.5 ± 0.7
1.1 ± 0.5
5.5 ± 0.3
154.8 ± 36.8
-

2.4 ± 0.5
234.7 ± 57.7
256.6 ± 103.3
47.6 ± 18.2
29.1 ± 13.0
77.6 ± 51.5
6.8 ± 1.7
381.3 ± 139.8
0.4 ± 0.2
2.7 ± 0.8
96.0 ± 17.7
237.0 ± 182.5*
5.5 ± 0.6†
30.6 ± 29.3
161.2 ± 19.0†
29.5 ± 1.1†
8.1 ± 1.8
0.5 ± 0.8
5.1 ± 1.2
95.8 ± 42.8
-

3.2 ± 0.2
114.0 ± 22.0
234.3 ± 73.9
25.5 ± 4.8
26.0 ± 3.9
146.8 ± 86.4
10.1 ± 0.7
177.3 ± 8.5
0.2 ± 0.1
2.8 ± 0.3
93.5 ± 6.3‡
189.8 ± 20.1
5.2 ± 0.12
117.0 ± 5.4‡
147.8 ± 0.5
22.9 ± 11.3
8.3 ± 0.9
0.4 ± 0.4
6.0 ± 0.1
46.0 ± 8.9
105.2 ± 11.7

2.6 ± 0.2
203.3 ± 15.7
123.5 ± 29.5
38.3 ± 8.5
30.2 ± 2.8
126.5 ± 45.1
10.8 ± 0.7
172.3 ± 15.1
0.3 ± 0.1
2.5 ± 0.2
112.3 ± 12.8
149.3 ± 13.6
5.0 ± 0.2
5.3 ± 0.3
146.0 ± 0.8
29.5 ± 1.3
9.8 ± 0.8
1.0 ± 0.2
5.1 ± 0.3
152.0 ± 55.0
-

2.7 ± 0.6
299.3 ± 111.2
307.4 ± 108.7
61.1 ± 31.8
44.6 ± 16.7
115.7 ± 50.4
7.9 ± 2.8
539.1 ± 333.0*
0.4 ± 0.1
4.5 ± 1.9*
125.1 ± 37.9*
140.0 ± 101.6
5.5 ± 0.9†
33.8 ± 40.8
157.5 ± 23.1†
28.9 ± 1.1†
10.7 ± 3.0*
0.6 ± 0.7
7.2 ± 2.3*
118.6 ± 68.4
-

3.6 ± 0.4
127.8 ± 23.6
400.8 ± 184.0*
33.8 ± 6.5
26.6 ± 8.
110.9 ± 29.0
11.0 ± 0.9
184.8 ± 19.9
0.2 ± 0.1
2.6 ± 0.2
133.5 ± 24.3*‡
184.3 ± 16.7
5.0 ± 0.1
144.8 ± 4.3‡
149.3 ± 1.3
28.6 ± 0.8*
8.1 ± 0.3
0.3 ± 0.1
6.2 ± 0.3
50.8 ± 17.1
119.7 ± 13.2*

All comparisons made between week 0 (baseline), 6 (midpoint), and 12 (final) blood
chemistries unless otherwise noted. Analyzed via mixed-effects analysis with Sidak’s
multiple comparisons test between lean and DIO groups each week.
All data represented as means ± SD and significance set at α=0.05 and indicated by *.
† Comparisons made between week 4 blood chemistries.
‡ Comparisons made between week 10 blood chemistries.

ALT (final p=0.0304), globulin (midpoint p=0.0001), phosphorus (midpoint p=0.0158), and
total protein levels (midpoint p=0.0001, Table A.3), indicative of early stage liver and kidney disease (P. L. Huang, 2009). Future research can determine the extent of liver and
kidney involvement in the DIO ferret model through histological and lipid analysis.

A.3

Discussion

Obesity poses real risks to human and animal health. Modeling the etiology of obesity
in the laboratory has proved challenging, yet is a needed endeavor as worldwide rates
of obesity continue to skyrocket (Chooi, Ding, and Magkos, 2019). Not only will accurate models of obesity aid metabolic and physiologic research, they will be an invaluable
asset to other fields in which obesity can be considered a “high-risk state,” including infectious diseases. Other models of genetically-acquired and diet-induced obese, including the

Appendix A. Development and Characterization of an Obese Ferret Model

136

mouse and hamster models, have limitations in their use or confounding effects for study
in virology and immunology (Lutz and Woods, 2012; Hintze et al., 2018; Dalboge et al.,
2015). Herein, a novel diet-induced ferret model is shown to robustly mirror the etiology
of human obesity and MetS which can be implemented for susceptibility, transmission,
and viral evolution studies.
As stated above, the ferret model is the gold standard for understanding not only
susceptibility to infection but also the natural transmission dynamics of influenza and
other respiratory viruses (Belser et al., 2020). However, much of this research has been
restricted not only due to the dearth of ferret reagents but also the limited high-risk states
that have been accurately modeled (Albrecht et al., 2018). Ferret models for sex-differences
in host responses as well as pregnancy and aging have been used, yet these represent only
a fraction of those at-risk for severe influenza–and many other respiratory–virus infections
(Yoon, Wong, et al., 2018; Paquette et al., 2015; Sweet, Toms, and H. Smith, 1977). The development of the diet-induced ferret model and the parallel advances in ferret reagents
will enable future research to interrogate the molecular, virologic, and physiologic determinants of virulence, susceptibility, and transmission of influenza viruses in an everimportant high-risk host.
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B.1

Introduction

Systemic metabolic reprogramming due to obesity results in meta-inflammation, alters the
phenotype of immune cell populations, and renders a host more susceptible to infection
and adverse advents (Smallwood et al., 2017). These baseline alterations impair responses
during influenza virus infections. Humans with obesity, as well as obese mouse models
and obese-derived primary cell cultures, display blunted and delayed immune responses
upon infection with influenza virus (Paich et al., 2013; Sheridan, Paich, Handy, Karlsson,
Hudgens, et al., 2012; Easterbrook et al., 2011). Since influenza disease can be so severe
in obese hosts, prevention through vaccination is the best control strategy. However, previous studies in the Schultz-Cherry laboratory and others have determined that obesityrelated systemic metabolic and immune deficiencies weaken immunization efficacy (Sheridan, Paich, Handy, Karlsson, Hudgens, et al., 2012; Y. H. Kim et al., 2012; H. L. Park et al.,
2014; Karlsson, Hertz, et al., 2016). Vaccination, even with adjuvant, does not protect obese
mice from mortality upon viral challenge (Karlsson, Sheridan, and Beck, 2010b; Karlsson,
Hertz, et al., 2016). While the universal influenza vaccine initiative seeks to improve vaccine efficacy through novel platforms, another option is to pursue non-pharmaceutical
interventions to improve vaccination responses.
Can a “lifestyle intervention” reprogram the obesogenic immune environment to
generate an effective response to vaccination through improving the innate interferon and
adaptive responses? To answer the overarching question, vaccinated lean and obese mice
were either maintained on their respective control or high-fat diets (HFD) or were shifted
to the opposing diet, i.e. lean mice changed to HFD or obese mice to the lean diet. This
resulted in four experimental groups (always obese, always lean, formerly obese, and formerly lean) and two treatments (vaccination or mock). Mice were challenged at either 1
or 3-months post-diet switch to determine if weight loss after vaccination could improve
immune responses upon viral challenge and would this translate to better survival.
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Overview of diets, timepoints, and weight loss after diet switch
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At the beginning of the study, 3-week-old mice were randomized to receive either high-fat
purified diet (HFD) or normal chow (Lean) for 16 weeks. At week 16 on diet, cages were
randomized to receive either an inactivated CA/09 virus vaccine via intramuscular injection in the hamstring or vehicle (PBS) control. After a two-week period to generate and
vaccine response, whole cages within each treatment were again randomized to continue
on the same diet protocol or to be switched to the opposing protocol (Figure B.1). Mice
were maintained on this diet until the end of study. Each cohort consisted of n=40 vaccinated and n=40 mock vaccinated mice. Importantly, a day in the life of a mouse does
not equal a day in the life of man. So, to better gauge the relative length mice were maintained on diets, the approximate equivalent time in human years was calculated (Dutta
and Sengupta, 2016; Agoston, 2017).
Weights of mice were recorded biweekly for the duration of the study. At vaccination, significant differences in weight were noted between the HFD and lean, chow-fed
groups. Post-diet switch, weight gain and loss was robust and rapid. Formerly obese mice
fed HFD then switched to chow reached near the lean baseline weight within 4 weeks postdiet switch (Figure B.1). Conversely, formerly lean mice switched to HFD gained weight
but did not reach the same mass as mice maintained on HFD even after 12 weeks of feeding. No differences in growth curves between vaccinated and mock vaccinated mice in all
diet groups were observed (data not shown).

B.2.2

Survival post-infection

Mock vaccinated mice received a 50 µL of PBS in the right hindlimb at 16 weeks on diet,
then 2 weeks later left on their original diet or switched to the opposing diet (Figure B.1).
At the timepoints indicated, mice were challenged at a 10X MLD50 dose with CA/09 virus
in 25 µL PBS, which with this viral stock preparation translated to a dose of 105.43 viral particles. Inoculum was administered intranasally under light anesthesia and over 14 days,
clinical signs, weight, and survival were recorded. As expected, near 100% mortality was
observed in mock vaccinated mice.

B.2.3

Effects of short-term diet switch on vaccine efficacy

To ascertain if weight loss in formerly obese mice could improve immunization efficacy
upon viral challenge, mice were challenged with 10X MLD50 dose of CA/09 virus administered intranasally and monitored for 14 days (Figure B.2). In mice challenged after
short-term diet switch (ie, 4 weeks post-diet switch and 6 weeks post-vaccination), vaccination significantly reduced weight loss in always lean mice (p=0.0458). No significant
improvement in weight loss was detected for other diet groups. These comparisons were
all made up to day 10 p.i., which is the last timepoint in which surviving mock vaccinated
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Figure B.1: Experimental schematic and results of diet protocols.
Overview of diets, timepoints, and weight loss after diet switch. (A)
Timeline of diet administration, vaccination, and challenge in each of
short-term and long-term diet switch studies. (B) Weights of mice on
short-term diet switch protocol up to challenge. (C) Weights of mice on
long-term diet switch protocol up to challenge. Data are represented as
means ± SEM.
Data sources: Dutta, Sulagna and Pallav Sengupta (May 2016). “Men and
mice: Relating their ages”. eng. In: Life Sciences 152, pp. 244–248. ISSN:
1879-0631. DOI: 10.1016/j.lfs.2015.10.025. Agoston, Denes V. (2017). “How
to Translate Time? The Temporal Aspect of Human and Rodent Biology”.
In: Frontiers in Neurology 8. Publisher: Frontiers. ISSN: 1664-2295. DOI:
10.3389/fneur.2017.00092.
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Figure B.2: Effects of short-term diet switch on vaccine efficacy.
Morbidity and mortality in always obese (HFD>HFD), always lean
(Lean>Lean), formerly obese (HFD>Lean), and formerly obese
(Lean>HFD) mice. (A-D) Weight curves post-challenge with statistical
comparisons made with mixed-effects model. (E-H) Clinical scores
post-challenge with statistical comparisons made using a mixed-effects
model. (I-J) Survival post-challenge with statistical comparisons made
using Mantel-Cox long-rank analysis. Data in (A-H) are represented as
means ± SEM and in (I-L) as surviving proportions with * indicating a
significant difference due to diet.
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mice could be observed. Clinical scores showed that vaccination was protective from clinical signs of infection in always obese (p<0.0001), always lean (p<0.0001), formerly obese
(p=0.0462) and formerly lean (p<0.0001) mice. However, this is a perfect representation of
why statistically significant results may be biologically insignificant. In always lean and
formerly lean mice, vaccination completely ameliorated the signs of infection, with littleto-no evidence of influenza disease. However, while vaccination did statistically improve
morbidity as measured by weight loss in always obese and formerly obese mice, analyses
of the data clearly shows that it only delayed the occurrence of severe disease and did not
improve survival outcomes (Figure B.2).
Importantly, weight loss and clinical scores are measures of infectious morbidity
post viral challenge. However, they are not perfect predictors of survival. While morbidity was delayed in always obese and formerly obese mice, survival was not improved by
vaccination in either experimental group. Conversely, mice immunized when lean, regardless of body status at infection, were protected from mortality. Always lean mice showed
100% mortality upon challenge (p=0.0005) and formerly lean mice improved survival from
0% to 75% (p=0.0001). Overall, vaccination resulted in 100% of always lean mice, 0% of always obese mice, 42.9% of formerly obese, and 75% of formerly lean mice surviving viral
challenge, suggesting that body status at vaccination is predictive of vaccine efficacy, but
that weight gain after immunization can attenuate immunization potency (Figure B.2).

B.2.4

Effects of long-term diet switch on vaccine efficacy

Next, secondary diets were continued for a total of 12 weeks post-diet switch to interrogate
if longer-term weight loss would improve survival post challenge. Over 14 days, weight,
clinical score, and survival were monitored upon viral challenge with the same viral stock
and dose as the short-term diet switch challenge (Figure B.3). Here, vaccination significantly reduced weight loss in always lean (p<0.0001), always obese (p=0.0003), formerly
obese (p=0.0036), but not in formerly lean (p=0.7237) mice. These comparisons were all
made up to the last timepoint in which surviving unvaccinated mice could be observed, so
day 10 for always lean and always obese mice and day 11 for formerly obese and formerly
lean mice. Clinical scores followed similar trends, with always lean (p<0.0001), always
obese (p=0.0014). formerly obese (p=0.0028), and formerly lean (p<0.0001) all showing a
significant reduction in signs of infection upon challenge if vaccinated.
Survival post-challenge, the metric by which vaccination efficacy is assessed in this
study, showed that body weight status at the time of immunization was predictive of
immunization efficacy. Compared to mock vaccinated controls, vaccinated always lean
mice were 100% protected from viral challenge (p=0.0001). However, other diet groups
showed differential immunization efficacy as assessed by survival analyses. Vaccination
of always obese mice did not improve survival upon challenge, with 100% mortality in
both groups. For formerly obese mice switched to normal chow, survival was also not
improved (p=0.1823). Increased survival was observed in formerly lean mice switched to
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Figure B.3: Effects of long-term diet switch on vaccine efficacy.
Morbidity and mortality in always obese (HFD>HFD), always lean
(Lean>Lean), formerly obese (HFD>Lean), and formerly obese
(Lean>HFD) mice. (A-D) Weight curves post-challenge with statistical
comparisons made with mixed-effects model. (E-H) Clinical scores
post-challenge with statistical comparisons made using a mixed-effects
model. (I-J) Survival post-challenge with statistical comparisons made
using Mantel-Cox long-rank analysis. Data in (A-H) are represented as
means ± SEM and in (I-L) as surviving proportions with * indicating a
significant difference due to diet.
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HFD post-vaccination (p=0.0641). Overall, vaccination resulted in 100% of always lean
mice, 0% of always obese mice, 40% of formerly obese, and 85.7% of formerly lean mice
surviving viral challenge, suggesting that body status at vaccination is predictive of vaccine efficacy, but that weight gain after immunization can attenuate immunization potency
(Figure B.3).

B.2.5

Viral load and the interferon response is sensitive to diet state

To better understand the differing mortality observed among the diet groups, the innate
immune response and viral loads upon challenge was interrogated in both short-term
and long-term weight loss mice (Figure B.4). First, at day 3 p.i., short-term weight loss
mice were sacrificed and lungs probed for the expression of type I interferons (IFNs). In
mock vaccinated mice, there was a significant increase in the levels of Ifna1, Ifnb1, and
Ifit1 in always lean (p=0.0007, p<0.0001, p=0.0009) and formerly obese (p=0.0075, p=0.0018,
p<0.0001) mice, respectively. In addition, formerly lean mice showed significant upregulation of Ifit1 compared to always obese mice (p=0.0007). There were similar trends in
vaccinated mice. A significant increase in the levels of Ifna1, Ifnb1, and Ifit1 was detected
in always lean (p=0.0004, p=0.0002, p<0.0001) and formerly obese (p=0.0018, p=0.0012,
p<0.0001) mice. In addition, formerly lean mice showed significant upregulation of Ifit1
compared to always obese mice (p=0.0003). At this day 3 p.i. timepoint, there were no
evident differences in viral loads within mock vaccination or vaccinated diet groups, although vaccinated always lean mice did show reductions in overall viral titer comparatively (Figure B.4).
Similar trends were evident in long-term weight loss mice. Compared to always
obese mice, mock vaccinated always lean mice showed significant increases in the levels of Ifna1 (p=0.008), Ifnb1 (p=0.0352), and Ifit1 (p=0.0037). Similarly, vaccinated always
lean mice showed similar increases in Ifna1 (p<0.0001), Ifnb1 (p=0.007), and Ifit1 (p<0.0001).
Again, at this day 3 p.i. timepoint, there were no evident differences in viral loads within
mock vaccination or vaccinated diet groups, although in comparison to other diet groups,
vaccinated always lean mice did show reductions in overall viral titer (Figure B.4).
Overall, these findings suggest that the interferon response at day 3 p.i. is sensitive to diet status. Overall, always obese mice showed dampened expresssion IFN-related
genes. Also, when compared to always lean mice, diet switch obese and lean mice also
trended towards lower levels of Ifna2, Ifnb2, and Ifit1 expression in both mock and vaccinated mice. Together, this dampened interferon state led to no change in viral titers
across vaccination status, but the heightened IFN expression in vaccinated always lean
mice could be correlated with the relative reduction in viral loads observed (Figure B.4).
Future study can also interrogate if vaccination of mice improves viral clearance in the various cohorts post-challenge, or, if like with oseltamivir treatment, obese mice still display
reduced ability to clear the infection (Chapter 6).
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Figure B.4: Interferon responses and viral load are sensitive to diet state.
(A-D) Expression of (A) Ifna1, (B) Ifnb1 (C) Ifit1 and quantification of (D)
viral loads in short-term diet switch mice. (E-H) Expression of (E) Ifna1, (F)
Ifnb1 (G) Ifit1 and quantification of (H) viral loads in long-term diet switch
mice. Data represented as means ± SEM and and compared to levels in
always obese mice through two-way ANOVA with Dunnett’s correction
with * indicating a significant difference.

B.2.6

Diet induced obese mice show poor seroconversion post vaccination and
challenge

While arguably a poor correlate of protection, hemmaglutination inhibition (HAI) titers are
commonly used to estimate immunization efficacy (Reber and J. Katz, 2013). More broadly,
HAI titers are also compared against the circulating H1, H3, and influenza B viruses in
biannual strain selection meetings to provide reasoning for updating the influenza vaccine formulation. Notably, post-vaccination, obese humans show quicker waning of HAI
titers compared to lean, possibly a reason behind their increased susceptibility to infection
even upon vaccination (Neidich et al., 2017). The presence of anti-influenza antibodies
was quantified through HAI prior to vaccination, 2-weeks post-vaccination concordant
with diet switch, and either 1-month or 3 months post-diet switch. Any mouse surviving
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Figure B.5: Reduced seroconversion post-vaccination in HFD mice.
Sera from mice maintained on (A) short term diet switch or (B) long term
diet switch protocols was obtained via retro-orbital bleed and assayed for
the presence of anti-H1N1 virus antibodies through HAI against CA/09
virus at baseline pre-vaccination, 2 weeks post vaccination (diet switch)
immediately prior to challenge at (A) 1 month post-diet switch or (B) 3
months-post diet switch, and for mice that survived challenge, at day 21
p.i. Notably, no mice maintained on HFD at the time of vaccination
seroconverted in this assay. Data displayed as means ± SEM. NS = no
survivors from viral challenge.

challenge was bled at day 21 p.i. (Figure B.5).
Across both cohorts, only lean mice seroconverted prior to challenge. After challenge, there were no surviving obese mice to assess seroconversion, yet previous studies
have demonstrated a reduced breadth and depth of the antibody response in obese mice
(Karlsson, Hertz, et al., 2016). For mice maintained on short-term, 1-month diet switch,
only lean mice showed modest increases in HAI titer. The HAI levels in always lean mice
stayed constant, while a small decrease was noted in formerly lean mice switched to a
HFD. Regardless, after challenge, both always lean and formerly lean mice which survived showed high seroconversion. In long-term diet switch mice, similarly only lean
mice showed any evidence of seroconversion at 2 weeks post-vaccination. After 3 months,
both always lean and formerly lean mice had detectable HAI titers, while always obese
still had no increase from baseline. After challenge, again no always obese mice survived
to compared. However, all other surviving mice except a single formerly lean mouse seroconverted, although mice exposed to HFD at any point showed reductions in the HAI
titers compared to always lean mice. Together, these data suggest obesity impairs the
production of anti-influenza antibodies after vaccination and could possibly attenuate the
strength of the response to true viral challenge.
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Metabolic biomarkers trend with weight loss and gain in diet switch
mice

Obesity has systemic consequences for the human body. Many of these changes have been
tied to the secretion of specific adipokines from the immunolgically-rich adipose tissue as
well as modulation of other signaling hormones (Trim, Turner, and D. Thompson, 2018;
Ferrante, 2007). Since the obesity-induced modulation of several key factors in the immune response has also been observed at the epithelial level (Cheung, K. R. Taylor, and
Jameson, 2012), the levels of obesity-related metabolic biomarkers were assayed through
ELISAs in the various diet cohorts (Figure B.6). After 18 weeks on HFD, the levels of leptin, adiponectin, insulin, and c-peptide were elevated compared to levels in mice fed lean,
control chow.

Figure B.6: Obesity-related metabolic biomarkers in mice flux due to diet
status.
Circulating levels of (A) leptin, (B) adiponectin, (C) insulin, (D) c-peptide,
(E) ghrelin, (F) GLP-1, and (G) PYY were assayed at arrival (week 0), diet
switch (week 18), plus 1-, 2-, and 3-months post-diet switch. Data in are
represented as means ± SEM and analyzed via two-way ANOVA with
tukey’s multiple comparisons test. Significance is indicated by * and
represents significant differences in concentration throughout the study
period compared to always obese (HFD>HFD) mice.
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After diet switch, always obese mice maintained on HFD continued to show increases in their leptin, adiponectin and insulin levels, while c-peptide and ghrelin remained somewhat constant albeit higher than in always lean mice. For formerly obese
mice, leptin levels rapidly dropped after diet switch, and as expected, rapidly rose in
formerly lean mice after being placed on HFD diet. Adiponectin and insulin showed
similar trends. Always lean mice continued to maintain high adiponectin levels, while
levels in formerly obese mice began rising at 2-months post-diet switch. Adiponectin
levels in always obese mice stayed significantly lower than always lean mice, and formerly lean mice also showed rapid reductions in their circulating adiponectin levels by
1-month post-diet switch. For insulin, formerly obese mice rapidly approached the always lean baseline insulin levels within 1-month of diet switch and formerly lean mice
steadily showing increases in insulin levels by 3-months post-diet switch. Ghrelin levels were different between formerly lean and formerly obese mice at 3-months post-diet
switch and both were statistically indistinguishable from levels in always obese and always lean mice, respectively. Glucagon-like protein-1 (GLP-1) and protein tryosine tyrosine (PYY) were modulated less by diet over time. However, at 3-months post-diet
switch, always lean and formerly lean mice showed elevations in GLP-1 levels compared
to always obese and formerly obese mice. Overall, in comparison to always obese mice,
leptin (p<0.0001, p<0.0001, p<0.0001), insulin (p<0.0001, p<0.0001, p<0.0001), adiponectin
(p<0.0001, p=0.0481, p=0.0958), c-peptide (p<0.0001, p<0.0001, p=0.0021) showed significant
different levels in always lean, formerly obese, or formerly lean mice, respectively. Ghrelin
levels throughout the study period were significantly different in always obese mice compared to always lean (p=0.0026) and formerly obese (p=0.0257). No significant difference
in the levels of PYY or GLP-1 in always obese mice compared to other diet groups were
detected during the study period.

B.3

Discussion

The ideal universal flu vaccine is not only effective for all viral strains and subtypes, but
also for all people (Estrada and Schultz-Cherry, 2019). The very young, aged, pregnant,
immunocompromised, and obese are all at high-risk for influenza infection and serious sequelae (Molinari et al., 2007; Van Kerkhove et al., 2011). Yet, there is no guarantee that our
current vaccines or a future universal vaccine will elicit strong enough immune responses
to adequately protect our most vulnerable populations. Altogether, these findings suggest that the immunometabolic consequences of obesity are long-lasting and intractable.
Weight loss after vaccination did not improve survival after challenge in formerly obese
mice, and interestingly, lean mice transferred to an obesogenic diet also showed reductions
in vaccine efficacy.
Always obese mice maintained high leptin and insulin levels as well as low adiponectin levels across the study period, contrasting nicely with the levels in always lean mice.
Formerly obese mice showed similarities in these metabolic biomarkers to always obese
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mice at vaccination, but were more similar to always lean upon challenge. These levels
correlate with the HAI responses to vaccination. High leptin and insulin levels at the
time of vaccination corresponded to low HAI seroconversion, and thus, resulted in high
levels of morbidity and mortality post-vaccination. Conversely, leptin and insulin levels
at the time of challenge are more closely correlated with IFN levels at day 3 p.i.. Together,
this suggests the metabolic profile of the host at vaccination may have implications for
the robustness of vaccine efficacy and memory responses post-challenge, while the innate
response at challenge is more sensitive to the contemporaneous metabolic profile. Future
studies will interrogate the metabolic influence of the indicated diet regimens on innate
and adaptive immune cell subsets. The implications are harrowing, as the rate of obesity
is projected to approach 50% of the global adult population by 2050.
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Appendix C
Supplementary Sequencing Data1

Reported variants for viruses passaged through genetically obese moues model and wildtype model are found in Table C.1. Variants for viruses passaged through the diet-induced
obese and lean model are found in Table C.2.
Table C.1: Total single nucleotide variants in genetically obese- and wild-type
passaged CA/09 virus.
Protein Nucleotide Mutation
PB2
77
A→G
90
A→G
150
G→A
445
C→T
460
C→A
473
A→G
604
A→T
619
C→A
874
G→A
1,306
A→G
1,329
A→C
1,445
A→G
1,763
C→T
1,957
T→C
2,273
T→C
PB1
33
A→C
114
C→G
116
C→G
117
C→G
118
A→C
119
T→C
120
G→T
121
G→A
122
A→T

Amino acid
D26G (GAC→GGC)
I30M (ATA→ATG)
M50I (ATG→ATA)
P149S (CCT→TCT)
L154I (CTC→ATC)
E158G (GAG→GGG)
M202L (ATG→TTG)
L207I (CTA→ATA)
V292I (GTA→ATA)
R436G (AGG→GGG)
K443N (AAA→AAC)
K482R (AAA→AGA)
T588I (ACC→ATC)
S653P (TCT→CCT)
I758T (ATC→ACC)
K11N (AAA→AAC)
Y38* (TAC→TAG)
T39S (ACC→AGC)
T39T (ACC→ACG)
M40L (ATG→CTG)
M40T (ATG→ACG)
M40I (ATG→ATT)
D41N (GAC→AAC)
D41V (GAC→GTC)

OBp1
%1
#2
11% 1
100% 1
17% 1
11% 2
33% 2
15% 1
12% 1
12% 1
11% 1
11% 1
10% 1
10% 1
10% 1
10% 1

OBp5
%
#
8% 1
6% 1
6% 1
19% 3
52% 3
17% 1
-

WTp1
%
#
13% 2
-

WTp5
%
#
18% 3
6%
1
22% 1
50% 3
12% 1
9%
1
-

WTp10
% #
-

1 Appendix from previously published article. Modified: From final submission with open access permission from American Society for Microbiology: Honce, R., E. A. Karlsson, et al. (Mar. 2020). “Obesity-Related
Microenvironment Promotes Emergence of Virulent Influenza Virus Strains”. In: Mbio 11.2. ISSN: 2150-7511
(Electronic). DOI: 10.1128/mBio.03341-19.
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Table C.1 : Continued.
Protein Nucleotide
124
125
128
130
133
135
136
137
139
140
143
170
196
235
1,017
1,335
1,450
1,714
1,729
1,748
1,778
1,828
1,903
1,922
2,023
2,067
2,072
2,074
2,075
2,076
2,083
2,084
2,088
2,095
2,096
2,097
2,099
2,101
2,102
2,107
2,164
2,249
PA
940
1,045
1,154
1,255
1,294
1,358

Mutation
A→T
C→G
T→G
A→C
A→T
A→C
A→C
C→G
C→T
A→T
A→G
C→T
C→T
C→T
G→T
C→T
A→G
A→G
A→G
C→T
A→G
T→C
A→G
A→G
C→A
C→A
A→C
T→C
G→T
C→A
C→G
T→A
C→G
T→C
T→A
T→A
T→A
C→A
C→A
A→G
G→A
T→A
T→C
G→A
A→G
G→T
G→A
G→A

Amino acid
T42S (ACA→TCA)
T42R (ACA→AGA)
V43G (GTA→GGA)
N44H (AAC→CAC)
R45* (AGA→TGA)
R45S (AGA→AGC)
T46P (ACA→CCA)
T46R (ACA→AGA)
H47Y (CAC→TAC)
H47L (CAC→CTC)
Q48R (CAA→CGA)
T57I (ACA→ATA)
L66F (CTC→TTC)
P79S (CCA→TCA)
M339I (ATG→ATT)
D445D (GAC→GAT)
I484V (ATA→GTA)
R572G (AGA→GGA)
K577E (AAG→GAG)
T583I (ACC→ATC)
D593G (GAT→GGT)
C610R (TGC→CGC)
K635E (AAA→GAA)
N641S (AAC→AGC)
L675I (CTC→ATC)
Y689* (TAC→TAA)
K691T (AAG→ACG)
C692R (TGC→CGC)
C692F (TGC→TTC)
C692* (TGC→TGA)
L695V (CTA→GTA)
L695Q (CTA→CAA)
F696L (TTC→TTG)
F699L (TTT→CTT)
F699Y (TTT→TAT)
F699L (TTT→TTA)
F700Y (TTC→TAC)
P701T (CCT→ACT)
P701H (CCT→CAT)
S703G (AGT→GGT)
A722T (GCC→ACC)
I750N (ATT→AAT)
F314L (TTC→CTC)
E349K (GAA→AAA)
K385R (AAA→AGA)
D419Y (GAT→TAT)
V432I (GTT→ATT)
C453Y (TGC→TAC)

OBp1
%1
#2
10% 1
12% 1
9%
1
11% 1
9%
1
9%
1
9%
1
9%
1
9%
1
9%
1
7%
1
10% 1
27% 2
9%
1
-

OBp5
%
#
12% 1
19% 1
6% 1
6% 1
7% 3
8% 1
33% 1
6% 1

WTp1
%
#
7% 1
13% 1
7% 1
35% 1
15% 1
14% 1
15% 1
15% 1
15% 1
15% 1
15% 1
15% 1
15% 1
15% 1
15% 1
15% 1
15% 1
15% 1
14% 1
5% 1
-

WTp5
%
#
19% 1
13% 1
7%
1
8%
1
5%
1
-

WTp10
% #
8% 1
-
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Table C.1 : Continued.
Protein Nucleotide
1,472
1,473
1,496
1,497
1,595
1,874
1,913
2,008
2,045
2,146
PA-X
103
105
121
221
224
227
228
298
HA
122
194
610
717
1,265
1,642
NP
289
342
979
1,136
1,349
1,364
1,456
NA
45
233
248
276
670
1,007
1,323
M1
136
281
427
515
NS1
64
98
106
127
184
208

Mutation
C→T
C→T
A→G
C→A
T→C
C→T
G→A
C→T
A→G
A→G
T→C
T→G
C→T
A→G
G→A
T→C
T→G
G→A
T→C
C→T
G→A
T→C
A→G
G→A
T→G
A→G
C→T
T→C
G→T
A→G
T→G
G→T
A→G
T→G
C→T
T→A
G→A
C→A
C→T
A→G
G→A
T→C
T→C
T→C
C→A
T→C
A→G
A→G

Amino acid
T491I (ACC→ATC)
T491T (ACC→ACT)
N499S (AAC→AGC)
N499K (AAC→AAA)
L532P (CTG→CCG)
P625L (CCC→CTC)
R638K (AGG→AAG)
Q670* (CAG→TAG)
D682G (GAT→GGT)
K716E (AAG→GAG)
F35L (TTT→CTT)
F35L (TTT→TTG)
H41Y (CAT→TAT)
H74R (CAC→CGC)
R75Q (CGA→CAA)
F76S (TTT→TCT)
F76L (TTT→TTG)
V100I (GTA→ATA)
V41A (GTA→GCA)
A65V (GCC→GTC)
D204N (GAC→AAC)
?239? (GNT→GNC)
E422G (GAG→GGG)
G548R (GGG→AGG)
Y97D (TAT→GAT)
?114? (GNA→GNG)
Q327* (CAA→TAA)
L379P (CTG→CCG)
S450I (AGT→ATT)
D455G (GAT→GGT)
S486A (TCT→GCT)
M15I (ATG→ATT)
Q78R (CAG→CGG)
V83G (GTG→GGG)
C92C (TGC→TGT)
L224M (TTG→ATG)
G336D (GGT→GAT)
S441R (AGC→AGA)
L46L (CTA→TTA)
D94G (GAT→GGT)
A143T (GCT→ACT)
L172P (CTA→CCA)
F22L (TTT→CTT)
L33P (CTT→CCT)
L36I (CTC→ATC)
L43L (TTA→CTA)
K62E (AAA→GAA)
K70E (AAA→GAA)

OBp1
%1
#2
8%
1
8%
1
68% 2
28% 2
45% 1
6%
1
6%
1
-

OBp5
%
#
5% 1
5% 1
14% 1
6% 1
21% 5
11% 4
14% 1
14% 1
9% 1
9% 1
13% 1
18% 3
7% 1
-

WTp1
%
#
9% 1
25% 1
12% 1
11% 1
14% 1
9% 1
9% 1
5% 1
7% 1
31% 1
33% 1
19% 1
25% 1
12% 1
45% 1
8% 1
-

WTp5
%
#
7%
1
100% 1
38% 5
35% 2
10% 1
16% 3
100% 1
8%
2
8%
1
5%
2
6%
2
9%
2
7%
1
17% 1
18% 1
9%
1
8%
2

WTp10
% #
6% 1
6% 1
-
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Table C.1 : Continued.
Protein Nucleotide
220
230
232
242
269
316
392
547
605
632
644
655
NEP
721
734
807
809
1 Average

Mutation
A→G
T→C
A→G
T→C
T→C
A→G
A→G
G→A
C→T
G→A
C→A
A→G
G→A
A→G
A→G
A→G

Amino acid
S74G (AGC→GGC)
L77P (CTT→CCT)
R78G (AGA→GGA)
I81T (ATT→ACT)
L90P (CTT→CCT)
M106V (ATG→GTG)
K131R (AAA→AGA)
G183R (GGA→AGA)
A202V (GCT→GTT)
R211K (AGA→AAA)
P215H (CCT→CAT)
K219E (AAA→GAA)
M83I (ATG→ATA)
K88E (AAA→GAA)
E112G (GAG→GGG)
I113V (ATA→GTA)

OBp1
%1
#2
14% 3
29% 3
-

OBp5
%
#
21% 3
6% 2
-

WTp1
%
#
12% 1
9% 1
10% 1
6% 1
13% 1
27% 1
13% 1
-

WTp5
%
#
10% 1
8%
2
6%
1

WTp10
% #
8% 1
5% 1
-

frequency of variant in populations with variant.
viral populations which had detected variant. *Indicates stop codon, ? indicates unknown
amino acid.
2 Mouse-derived
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Table C.2: Total single nucleotide variants in diet-induced obese- and lean passaged
CA/09 virus.
Protein
PB2

PB1

PA

PA-X
HA

NP

NA

M1
M2

NS1

Nucleotide
56
98
473
1419
2000
767
1210
2188
1009
1048
1323
1666
343
975
1298
1505
1507
1510
1514
1516
1519
1523
1527
1528
1602
130
660
733
1183
1252
1394
469
727
754
1018
129
235
897
942
966
122
159
194
208
238
314

Mutation
T→C
A→G
A→G
G→A
T→C
A→G
A→G
T→G
G→T
A→C
G→A
C→A
A→G
A→T
T→C
A→G
T→A
C→T
A→C
T→G
T→A
A→T
A→C
G→A
T→A
T→C
A→C
A→G
A→G
C→T
A→G
A→G
A→G
T→C
T→C
G→A
T→C
A→G
A→G
A→G
A→G
T→G
T→C
A→G
A→G
T→C

Amino acid
I19T (ATA→ACA)
K33R (AAG→AGG)
E158G (GAG→GGG)
M473I (ATG→ATA)
V667A (GTT→GCT)
E256G (GAA→GGA)
S404G (AGT→GGT)
F730V (TTC→GTC)
A337S (GCT→TCT)
N350H (AAT→CAT)
M441I (ATG→ATA)
Q556K (CAA→AAA)
N115D (AAC→GAC)
K325N (AAA→AAT)
L433P (CTG→CCG)
D502G (GAC→GGC)
Y503N (TAC→AAC)
P504S (CCA→TCA)
K505T (AAA→ACA)
Y506D (TAC→GAC)
S507T (TCA→ACA)
E508V (GAG→GTG)
E509D (GAA→GAC)
A510T (GCA→ACA)
Y534* (TAT→TAA)
C44R (TGC→CGC)
E220D (GAA→GAC)
S245G (AGT→GGT)
N395D (AAT→GAT)
L418F (CTC→TTC)
E465G (GAG→GGG)
T157A (ACC→GCC)
T243A (ACC→GCC)
S252P (TCA→CCA)
S340P (TCT→CCT)
M43I (ATG→ATA)
F79L (TTT→CTT)
E70G (GAG→GGG)
D85G (GAT→GGT)
N93S (AAC→AGC)
K41R (AAG→AGG)
D53E (GAT→GAG)
V65A (GTG→GCG)
K70E (AAA→GAA)
T80A (ACA→GCA)
L105P (CTC→CCC)

DIOp1
%1
#2
16% 1
11% 1
11% 1
23% 1
6%
1
6%
1
12% 1
52% 1
7%
1
7%
1
5%
1
6%
1
7%
1
1%
1

LNp1
%
#
9% 1
5% 1
-

DIOp4
%
#
100% 2
10%
1
50%
1
93%
1
23%
1
23%
1
23%
1
23%
1
24%
1
24%
1
25%
1
25%
1
31%
1
6%
1
20%
1
25%
1
32%
1
29%
1
65%
1
9%
1
16%
1
6%
1
6%
1
7%
1
9%
1
5%
1
5%
1
-

LNp4
%
#
11% 1
48% 3
13% 1
-
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Table C.2 : Continued.
Protein

NEP

Nucleotide
326
457
532
635
5
821

1 Average

Mutation
A→G
G→A
G→A
C→T
A→C
T→C

Amino acid
Q109R (CAA→CGA)
E153K (GAG→AAG)
V178I (GTT→ATT)
P212L (CCT→CTT)
D2A (GAC→GCC)
S117P (TCG→CCG)

DIOp1
%
#
6%
1
-

LNp1
%
#
-

DIOp4
%
#
7%
1
6%
1
10%
1

LNp4
%
#
9%
1
37% 3
-

frequency of variant in populations with variant.
viral populations which had detected variant. *Indicates stop codon, ? indicates unknown
amino acid.
2 Mouse-derived
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